angiogenesis modulating agent - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	angiogenesis modulating agent	go back to main search page
Accession:	CHEBI:50926	browse the term
Definition:	An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.

show annotations for term's descendants Sort by:
Rat (1788) Mouse (1824) Human (1860) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (9) Green Monkey (0) Naked Mole-rat (0) All
Genes (1788)

(20S)-ginsenoside Rg3

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression

XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of ABCG2 mRNA]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acid phosphatase 5, tartrate resistant

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929

G

androgen receptor

increases degradation
multiple interactions

ginsenoside Rg3 results in increased degradation of AR protein
ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of AR protein]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

decreases expression

ginsenoside Rg3 results in decreased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

BCL2 associated X, apoptosis regulator

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

multiple interactions

[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bone gamma-carboxyglutamate protein

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein]

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

baculoviral IAP repeat-containing 5

decreases expression

ginsenoside Rg3 results in decreased expression of BIRC5 mRNA; ginsenoside Rg3 results in decreased expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 2

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein receptor type 1A

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]

NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616

G

caspase 1

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases cleavage
multiple interactions

ginsenoside Rg3 results in increased cleavage of CASP3 protein
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP3 protein]

PMID:22101440 PMID:26427350 PMID:31916386

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cellular communication network factor 1

decreases expression

ginsenoside Rg3 results in decreased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

decreases expression

ginsenoside Rg3 results in decreased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cadherin 1

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

dipeptidylpeptidase 4

multiple interactions

[Xiao-Ke-An results in increased abundance of ginsenoside Rg3] which results in decreased activity of DPP4 protein

NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901

G

epidermal growth factor

multiple interactions

EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
affects phosphorylation

EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

epithelial cell adhesion molecule

decreases expression

ginsenoside Rg3 results in decreased expression of EPCAM mRNA

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

fucosyltransferase 4

multiple interactions
decreases expression

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of FUT4 protein]
ginsenoside Rg3 results in decreased expression of FUT4 protein

NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682

G

heat shock transcription factor 1

multiple interactions
decreases expression

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of HSF1 protein]
ginsenoside Rg3 results in decreased expression of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

interleukin 1 beta

increases expression
multiple interactions

ginsenoside Rg3 results in increased expression of IL1B protein
ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of IL1B protein]

PMID:14534150 PMID:33050067 PMID:34423507

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

ginsenoside Rg3 results in decreased expression of KIT mRNA

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KLF transcription factor 4

decreases expression

ginsenoside Rg3 results in decreased expression of KLF4 mRNA

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

kallikrein 1-related peptidase C10

multiple interactions

ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 mRNA]; ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 protein]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

large tumor suppressor kinase 1

increases expression

ginsenoside Rg3 results in increased expression of LATS1 mRNA

NCBI chr 1:2,160,411...2,193,640
Ensembl chr 1:2,160,411...2,193,640

G

large tumor suppressor kinase 2

increases expression

ginsenoside Rg3 results in increased expression of LATS2 mRNA

NCBI chr15:31,825,068...31,877,193
Ensembl chr15:31,825,092...31,877,220

G

microtubule-associated protein 2

increases expression

ginsenoside Rg3 results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

marker of proliferation Ki-67

multiple interactions

[ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 2

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

ginsenoside Rg3 results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

Nanog homeobox

decreases expression

ginsenoside Rg3 results in decreased expression of NANOG mRNA

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

G

nuclear factor kappa B subunit 1

multiple interactions
increases activity

[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein
ginsenoside Rg3 results in increased activity of NFKB1 protein

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein; [ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 3

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

noggin

multiple interactions

NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

nitric oxide synthase 2

multiple interactions
increases expression

Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]
ginsenoside Rg3 results in increased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of NTRK2 protein modified form]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

ginsenoside Rg3 results in increased cleavage of PARP1 protein
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of PARP1 protein]

PMID:22101440 PMID:24793912 PMID:26427350 PMID:31916386

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

increases expression

ginsenoside Rg3 results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

POU class 5 homeobox 1

decreases expression

ginsenoside Rg3 results in decreased expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

PPARG coactivator 1 alpha

increases expression

ginsenoside Rg3 results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prominin 1

decreases expression
multiple interactions

ginsenoside Rg3 results in decreased expression of PROM1 mRNA
XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of PROM1 mRNA]

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

PYD and CARD domain containing

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein; ginsenoside Rg3 affects the localization of and results in increased activity of RELA protein
ginsenoside Rg3 results in decreased expression of and results in decreased phosphorylation of RELA protein

PMID:14534150 PMID:33050067

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RUNX family transcription factor 2

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

spalt-like transcription factor 4

decreases expression

ginsenoside Rg3 results in decreased expression of SALL4 mRNA

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

sirtuin 1

increases activity

ginsenoside Rg3 results in increased activity of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 6 member 2

multiple interactions

[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions

[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A3 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

SMAD family member 2

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

snail family transcriptional repressor 1

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

SRY-box transcription factor 2

decreases expression

ginsenoside Rg3 results in decreased expression of SOX2 mRNA

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

Sp1 transcription factor

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

sequestosome 1

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein]
3-methyladenine affects the reaction [ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]]; ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

serine/threonine kinase 3

increases expression

ginsenoside Rg3 results in increased expression of STK3 mRNA

NCBI chr 7:66,053,209...66,323,292
Ensembl chr 7:66,052,345...66,323,233

G

serine/threonine kinase 4

increases expression

ginsenoside Rg3 results in increased expression of STK4 mRNA

NCBI chr 3:152,745,958...152,827,747
Ensembl chr 3:152,745,681...152,827,744

G

transforming growth factor, beta 1

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

Thy-1 cell surface antigen

decreases expression

ginsenoside Rg3 results in decreased expression of THY1 mRNA

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

tumor necrosis factor

increases expression
multiple interactions

ginsenoside Rg3 results in increased expression of TNF protein
ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]

PMID:14534150 PMID:33050067

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF superfamily member 11

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

vimentin

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

WW domain containing transcription regulator 1

decreases expression

ginsenoside Rg3 results in decreased expression of WWTR1 mRNA

NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968

G

Yes1 associated transcriptional regulator

decreases expression

ginsenoside Rg3 results in decreased expression of YAP1 mRNA

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

2-methoxy-17beta-estradiol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

2-Methoxyestradiol inhibits the reaction [Quercetin results in decreased phosphorylation of AKT1 protein]; [Quercetin co-treated with 2-Methoxyestradiol] results in decreased phosphorylation of AKT1 protein; Quercetin inhibits the reaction [2-Methoxyestradiol results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aquaporin 1

affects expression

2-Methoxyestradiol affects the expression of AQP1 protein

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

aquaporin 4

affects expression

2-Methoxyestradiol affects the expression of AQP4 protein

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

BCL2-associated agonist of cell death

decreases phosphorylation

2-Methoxyestradiol results in decreased phosphorylation of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2-antagonist/killer 1

increases expression

2-Methoxyestradiol results in increased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in decreased expression of BAX mRNA]
2-Methoxyestradiol results in increased expression of BAX protein

PMID:30154949 PMID:36414027

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases phosphorylation

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of BCL2 mRNA]
2-Methoxyestradiol results in decreased expression of BCL2 protein
2-Methoxyestradiol results in increased phosphorylation of BCL2 protein

PMID:17418156 PMID:30154949 PMID:36414027

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

2-Methoxyestradiol results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 3

increases cleavage
multiple interactions
increases expression

2-Methoxyestradiol results in increased cleavage of CASP3 protein
2-Methoxyestradiol promotes the reaction [Quercetin results in increased cleavage of CASP3 protein]; Arsenic Trioxide promotes the reaction [2-Methoxyestradiol results in increased expression of CASP3 protein modified form]; Quercetin promotes the reaction [2-Methoxyestradiol results in increased cleavage of CASP3 protein]

PMID:23967052 PMID:26011145

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases expression
multiple interactions

2-Methoxyestradiol results in increased expression of CASP7 protein modified form
Arsenic Trioxide promotes the reaction [2-Methoxyestradiol results in increased expression of CASP7 protein modified form]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases expression

2-Methoxyestradiol results in increased expression of CASP8 protein modified form

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases expression

2-Methoxyestradiol results in increased expression of CASP9 protein modified form

PMID:23967052 PMID:36414027

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin A2

decreases expression

2-Methoxyestradiol results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

multiple interactions
increases expression

2-Methoxyestradiol results in increased expression of and results in increased activity of CCNB1 protein
2-Methoxyestradiol results in increased expression of CCNB1 protein

PMID:16356831 PMID:23967052

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression

2-Methoxyestradiol results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

decreases expression

2-Methoxyestradiol results in decreased expression of CCND3 protein

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin E2

decreases expression

2-Methoxyestradiol results in decreased expression of CCNE2 protein

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cell division cycle 25C

multiple interactions

2-Methoxyestradiol results in decreased expression of and affects the phosphorylation of CDC25C protein

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cyclin-dependent kinase 1

decreases phosphorylation

2-Methoxyestradiol results in decreased phosphorylation of CDK1 protein

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

decreases expression

2-Methoxyestradiol results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

2-Methoxyestradiol results in decreased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1B

increases expression

2-Methoxyestradiol results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

catechol-O-methyltransferase

affects chemical synthesis

COMT protein affects the chemical synthesis of 2-Methoxyestradiol

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cardiotrophin 1

multiple interactions

2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of CTF1 protein]; 2-Methoxyestradiol inhibits the reaction [Vitamin K 3 results in increased expression of CTF1 protein]

NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335

G

catenin beta 1

multiple interactions
decreases expression

2-Methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]
2-Methoxyestradiol results in decreased expression of CTNNB1 mRNA; 2-Methoxyestradiol results in decreased expression of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases abundance

Tetrachlorodibenzodioxin promotes the reaction [CYP1A1 protein results in increased abundance of 2-Methoxyestradiol]; Tetradecanoylphorbol Acetate inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CYP1A1 protein results in increased abundance of 2-Methoxyestradiol]]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

dynamin 1-like

increases expression

2-Methoxyestradiol results in increased expression of DNM1L protein

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

epidermal growth factor

decreases expression

2-Methoxyestradiol results in decreased expression of EGF mRNA; 2-Methoxyestradiol results in decreased expression of EGF protein

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

decreases expression

2-Methoxyestradiol results in decreased expression of EGFR mRNA; 2-Methoxyestradiol results in decreased expression of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

erythropoietin

decreases expression
multiple interactions

2-Methoxyestradiol results in decreased expression of EPO protein
2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of EPO protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of EPO protein]

PMID:31850806 PMID:32461003

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

H2A.X variant histone

increases expression

2-Methoxyestradiol results in increased expression of H2AX protein modified form

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
decreases expression

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of HIF1A protein]; 2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of HIF1A protein]
2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein]
2-Methoxyestradiol results in decreased expression of HIF1A protein
2-Methoxyestradiol inhibits the reaction [Glucose results in increased expression of HIF1A protein]

PMID:21617913 PMID:28624453 PMID:30154949 PMID:31850806 PMID:32461003

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hydroxysteroid (17-beta) dehydrogenase 2

decreases response to substance
multiple interactions

HSD17B2 protein results in decreased susceptibility to 2-Methoxyestradiol
[HSD17B2 protein results in increased metabolism of and results in decreased activity of 2-Methoxyestradiol] which results in increased chemical synthesis of 2-methoxyestrone

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

interleukin 1 alpha

multiple interactions

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of IL1A protein]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

mitofusin 1

increases expression

2-Methoxyestradiol results in increased expression of MFN1 protein

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

Nanog homeobox

multiple interactions

2-Methoxyestradiol inhibits the reaction [Curcumin results in increased expression of NANOG mRNA]

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

G

OPA1, mitochondrial dynamin like GTPase

decreases expression

2-Methoxyestradiol results in decreased expression of OPA1 protein

NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109

G

poly (ADP-ribose) polymerase 1

increases expression

2-Methoxyestradiol results in increased expression of PARP1 protein modified form

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

POU class 5 homeobox 1

multiple interactions

2-Methoxyestradiol inhibits the reaction [Curcumin results in increased expression of POU5F1 mRNA]

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxiredoxin 4

increases expression

2-Methoxyestradiol results in increased expression of PRDX4 protein

NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066

G

prostaglandin-endoperoxide synthase 2

multiple interactions

2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of PTGS2 mRNA]; 2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 2 member 1

decreases expression
multiple interactions

2-Methoxyestradiol results in decreased expression of SLC2A1 protein
2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of SLC2A1 protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of SLC2A1 protein]

PMID:31850806 PMID:32461003

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

SMAD family member 2

multiple interactions

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased phosphorylation of SMAD2 protein]

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

superoxide dismutase 2

increases response to substance
affects response to substance
multiple interactions

SOD2 protein results in increased susceptibility to 2-Methoxyestradiol
SOD2 protein affects the susceptibility to 2-Methoxyestradiol
2-Methoxyestradiol inhibits the reaction [Curcumin results in increased expression of SOD2 mRNA]

PMID:17895890 PMID:22547077 PMID:25822711

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sulfotransferase family 1A member 1

increases sulfation
affects sulfation

SULT1A1 protein results in increased sulfation of 2-Methoxyestradiol
SULT1A1 gene polymorphism affects the sulfation of 2-Methoxyestradiol

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

transforming growth factor, beta 1

multiple interactions

2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tight junction protein 1

multiple interactions

2-Methoxyestradiol inhibits the reaction [Glucose results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tubulin, beta 4A class IVa

decreases expression

2-Methoxyestradiol results in decreased expression of TUBB4A mRNA alternative form; 2-Methoxyestradiol results in decreased expression of TUBB4A protein alternative form

NCBI chr 9:1,917,841...1,925,286
Ensembl chr 9:1,917,845...1,925,291

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

UGT1A1 protein results in increased glucuronidation of 2-Methoxyestradiol

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

UGT1A3 protein results in increased glucuronidation of 2-Methoxyestradiol

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

UGT1A9 protein results in increased glucuronidation of 2-Methoxyestradiol

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

vascular endothelial growth factor A

affects expression
decreases expression
multiple interactions

2-Methoxyestradiol affects the expression of VEGFA protein
2-Methoxyestradiol results in decreased expression of VEGFA protein
2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of VEGFA protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of VEGFA protein]
2-Methoxyestradiol results in decreased expression of VEGFA mRNA; 2-Methoxyestradiol results in decreased expression of VEGFA protein
2-Methoxyestradiol inhibits the reaction [Glucose results in increased expression of VEGFA protein]
2-Methoxyestradiol promotes the reaction [Quercetin results in decreased expression of VEGFA mRNA]; 2-Methoxyestradiol promotes the reaction [Quercetin results in decreased expression of VEGFA protein]; Quercetin promotes the reaction [2-Methoxyestradiol results in decreased expression of VEGFA mRNA]; Quercetin promotes the reaction [2-Methoxyestradiol results in decreased expression of VEGFA protein]

PMID:21092735 PMID:21617913 PMID:26011145 PMID:31850806 PMID:32461003

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

X-linked inhibitor of apoptosis

decreases expression

2-Methoxyestradiol results in decreased expression of XIAP protein

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

7,8-diacetoxy-4-methylcoumarin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl2-like 1

decreases expression

7,8-diacetoxy-4-methylcoumarin results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

calreticulin

increases activity
multiple interactions

7,8-diacetoxy-4-methylcoumarin results in increased activity of CALR protein
7,8-diacetoxy-4-methylcoumarin promotes the reaction [CALR protein results in increased acetylation of NOS1 protein]

PMID:20188080 PMID:24103856

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

caspase 3

increases activity

7,8-diacetoxy-4-methylcoumarin results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

7,8-diacetoxy-4-methylcoumarin results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cytochrome c, somatic

affects localization

7,8-diacetoxy-4-methylcoumarin affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

nitric oxide synthase 1

multiple interactions

7,8-diacetoxy-4-methylcoumarin promotes the reaction [CALR protein results in increased acetylation of NOS1 protein]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

increases expression

7,8-diacetoxy-4-methylcoumarin results in increased expression of NOS2

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression

7,8-diacetoxy-4-methylcoumarin results in increased expression of NOS3

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

prostaglandin-endoperoxide synthase 2

decreases expression

7,8-diacetoxy-4-methylcoumarin results in decreased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

Rac family small GTPase 1

decreases expression

DAMTC decreases expression of RAC1 protein in non-small cell lung cancer cells

RGD

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

7,8-diacetoxy-4-methylcoumarin inhibits the reaction [TNF protein affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

multiple interactions

7,8-diacetoxy-4-methylcoumarin inhibits the reaction [TNF protein affects the localization of RELA protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression

7,8-diacetoxy-4-methylcoumarin results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin 1

increases activity
increases expression

7,8-diacetoxy-4-methylcoumarin results in increased activity of TXN protein
7,8-diacetoxy-4-methylcoumarin results in increased expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin interacting protein

decreases expression

7,8-diacetoxy-4-methylcoumarin results in decreased expression of TXNIP mRNA

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

thioredoxin reductase 1

increases expression

7,8-diacetoxy-4-methylcoumarin results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

vascular endothelial growth factor A

increases expression

7,8-diacetoxy-4-methylcoumarin results in increased expression of VEGFA mRNA; 7,8-diacetoxy-4-methylcoumarin results in increased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

asiatic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of BAX protein]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased expression of BAX mRNA]; asiatic acid inhibits the reaction [Glucose results in increased expression of BAX mRNA]

PMID:29108773 PMID:30802477

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of BCL2 protein]
asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]

PMID:29108773 PMID:30802477

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP3 protein]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased activity of CASP3 protein]; asiatic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]

PMID:29108773 PMID:30802477

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin D1

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of CYP2E1 protein]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

DNA methyltransferase 3 alpha

multiple interactions

asiatic acid inhibits the reaction [cypermethrin results in decreased expression of DNMT3A protein]

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

DNA methyltransferase 3 beta

multiple interactions

asiatic acid inhibits the reaction [cypermethrin results in decreased expression of DNMT3B protein]

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

glutathione peroxidase 1

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of and results in decreased secretion of GPX1 protein]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of and results in decreased secretion of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

interleukin 1 beta

multiple interactions

asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL1B protein]]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL1B protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL6 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL6 protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; asiatic acid inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

mitogen-activated protein kinase 8

multiple interactions

[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]; asiatic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of NQO1 protein]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

proliferating cell nuclear antigen

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

cytochrome p450 oxidoreductase

multiple interactions

asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of POR protein]

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

PPARG coactivator 1 alpha

multiple interactions

[Glutamic Acid co-treated with asiatic acid] results in increased expression of PPARGC1A protein

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prostaglandin-endoperoxide synthase 2

multiple interactions

asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

Sp1 transcription factor

multiple interactions

asiatic acid inhibits the reaction [cypermethrin results in decreased phosphorylation of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

tumor necrosis factor

multiple interactions

asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]]
asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

voltage-dependent anion channel 1

multiple interactions

asiatic acid inhibits the reaction [Hydrogen Peroxide results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 protein]

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

astragaloside IV

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aquaporin 9

increases expression

astragaloside A results in increased expression of AQP9 mRNA; astragaloside A results in increased expression of AQP9 protein

NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions

astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA]

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

BCL2 associated X, apoptosis regulator

multiple interactions

astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]

PMID:22278385 PMID:33285147 PMID:36322813

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]

PMID:33285147 PMID:36322813

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone

multiple interactions

astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCS1L protein]

NCBI chr 9:76,164,925...76,168,940
Ensembl chr 9:76,164,932...76,168,938

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

caspase 3

multiple interactions

astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CASP3 protein modified form]
astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]

PMID:22278385 PMID:30842369 PMID:33285147 PMID:36322813

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin D1

increases expression

astragaloside A results in increased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

dual specificity phosphatase 5

decreases expression
multiple interactions

astragaloside IV decreases expression Dusp5 mRNA and protein in thoracic aorta
astragaloside IV inhibits the reaction [beta-Glycerophosphate increases expression of DUSP5 mRNA and protein in Vascular smooth muscle cells]

RGD

PMID:30529164 PMID:30529164

RGD:243048424, RGD:243048424

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

epidermal growth factor receptor

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

ferritin heavy chain 1

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

gap junction protein, alpha 4

multiple interactions

astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of GJA4 protein]

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

glutamate-ammonia ligase

multiple interactions

astragaloside A inhibits the reaction [bisphenol A results in decreased activity of GLUL protein]

NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108

G

glutamic--pyruvic transaminase

multiple interactions

astragaloside A inhibits the reaction [Cisplatin results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutamate ionotropic receptor NMDA type subunit 2A

multiple interactions

astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2A mRNA]

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2B mRNA]

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

H19 imprinted maternally expressed transcript

increases expression
multiple interactions

astragaloside IV increases expression H19 RNA in thoracic aorta
astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases expression of H19 RNA in Vascular smooth muscle cells]

RGD

PMID:30529164 PMID:30529164

RGD:243048424, RGD:243048424

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

histone deacetylase 9

multiple interactions

astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of HDAC9 protein]

NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333

G

heme oxygenase 1

multiple interactions
increases expression

[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein
astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 1 beta

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]

PMID:25604657 PMID:30842369 PMID:32344236

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]

PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

KH RNA binding domain containing, signal transduction associated 1

decreases expression
multiple interactions

astragaloside IV decreases expression of Khdrbs1 protein in thoracic aorta
astragaloside IV inhibits the reaction [beta-Glycerophosphate astragaloside IV increases expression of KHDRBS1 protein in Vascular smooth muscle cells]

RGD

PMID:30529164 PMID:30529164

RGD:243048424, RGD:243048424

NCBI chr 5:142,051,844...142,089,175
Ensembl chr 5:142,063,570...142,089,180

G

mitogen activated protein kinase 1

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mechanistic target of rapamycin kinase

multiple interactions
increases phosphorylation

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA
astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases phoshorylation of MTOR protein in Vascular smooth muscle cells]
astragaloside IV increases phosphorylation Mtor protein in thoracic aorta

CTD
RGD

PMID:32344236 PMID:30529164 PMID:30529164

RGD:243048424, RGD:243048424

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

mucin 5B, oligomeric mucus/gel-forming

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA

NCBI chr 1:196,916,861...196,948,830
Ensembl chr 1:196,916,825...196,949,250

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects localization

[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein
astragaloside A affects the localization of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions

astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]

PMID:25604657 PMID:33285147 PMID:36322813

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor beta

multiple interactions

astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]

NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862

G

NLR family, pyrin domain containing 3

multiple interactions

astragaloside A inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

proliferating cell nuclear antigen

increases expression

astragaloside A results in increased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

phospholamban

multiple interactions

astragaloside A inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein]

NCBI chr20:32,629,537...32,639,559

G

protein tyrosine phosphatase, non-receptor type 1

increases expression

Astragaloside IV increases expression of Ptpn1 protein in the hypothalamus

RGD

NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]

PMID:25604657 PMID:33285147 PMID:36322813

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

rhodopsin

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]

NCBI chr 4:148,975,597...148,988,693
Ensembl chr 4:148,980,611...148,985,773

G

retinoid isomerohydrolase RPE65

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]

NCBI chr 2:248,766,497...248,798,403
Ensembl chr 2:248,766,612...248,798,403

G

solute carrier family 11 member 2

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]

NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145

G

superoxide dismutase 1

multiple interactions

astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sequestosome 1

multiple interactions

astragaloside A inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

transferrin receptor

multiple interactions

astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions

[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]

PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

carnosic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

salvin results in decreased expression of A2M protein

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

acetoacetyl-CoA synthetase

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of AACS mRNA]

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

4-aminobutyrate aminotransferase

increases expression

salvin results in increased expression of ABAT protein

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily A member 6

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of ABCA6 mRNA]

NCBI chr10:95,142,805...95,212,087
Ensembl chr10:95,142,966...95,211,530

G

abhydrolase domain containing 11

increases expression

salvin results in increased expression of ABHD11 protein

NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398

G

abl-interactor 1

increases expression

salvin results in increased expression of ABI1 protein

NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792

G

ATP citrate lyase

increases expression

salvin results in increased expression of ACLY protein

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA synthetase short-chain family member 2

increases expression

salvin results in increased expression of ACSS2 protein

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

actinin, alpha 1

increases expression

salvin results in increased expression of ACTN1 protein

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

adenylate cyclase 9

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of ADCY9 mRNA]

NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066

G

adhesion G protein-coupled receptor E1

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of ADGRE1 mRNA]

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

adhesion G protein-coupled receptor E4

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of ADGRE4 mRNA]

NCBI chr 9:9,758,106...9,901,908
Ensembl chr 9:9,760,355...9,900,760

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

increases expression

salvin results in increased expression of ADH1 protein

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

AE binding protein 1

decreases expression

salvin results in decreased expression of AEBP1 protein

NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877

G

alkylglycerone phosphate synthase

decreases expression

salvin results in decreased expression of AGPS protein

NCBI chr 3:60,747,323...60,845,831
Ensembl chr 3:60,747,323...60,845,830

G

alpha-2-HS-glycoprotein

decreases expression

salvin results in decreased expression of AHSG protein

NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999

G

AKT serine/threonine kinase 1

increases phosphorylation
decreases phosphorylation

salvin results in increased phosphorylation of AKT1 protein
salvin results in decreased phosphorylation of AKT1 protein

PMID:25178877 PMID:25271104

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

decreases expression

salvin results in decreased expression of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member A3

decreases expression

salvin results in decreased expression of ALDH1A3 protein

NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436

G

apoptotic peptidase activating factor 1

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of APAF1 protein]

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

apolipoprotein A1

decreases expression

salvin results in decreased expression of APOA1 protein

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A4

decreases expression

salvin results in decreased expression of APOA4 protein

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein E

decreases expression

salvin results in decreased expression of APOE protein

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein H

decreases expression

salvin results in decreased expression of APOH protein

NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

salvin results in decreased expression of ASNS protein

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

aspartoacylase

decreases expression

salvin results in decreased expression of ASPA protein

NCBI chr10:57,891,704...57,945,267
Ensembl chr10:57,892,104...57,945,272

G

asporin

increases expression

salvin results in increased expression of ASPN protein

NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

increases expression

salvin results in increased expression of ATP12A protein

NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229

G

beta-2 microglobulin

increases expression

salvin results in increased expression of B2M protein

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

BCL2-associated agonist of cell death

multiple interactions
increases expression
decreases phosphorylation

salvin promotes the reaction [arsenic trioxide results in decreased phosphorylation of BAD protein]
salvin results in increased expression of BAD protein
salvin results in decreased phosphorylation of BAD protein

PMID:23239002 PMID:28918123

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

brain abundant, membrane attached signal protein 1

decreases expression

salvin results in decreased expression of BASP1 protein

NCBI chr 2:75,816,130...75,863,801
Ensembl chr 2:75,816,122...75,864,043

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

salvin inhibits the reaction [Paraquat results in increased expression of BAX protein]; salvin inhibits the reaction [Pyruvaldehyde results in increased expression of BAX protein]
salvin inhibits the reaction [sodium arsenite results in increased expression of BAX protein]
salvin results in increased expression of BAX protein

PMID:26577515 PMID:26686574 PMID:28918123 PMID:29854073

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCAS2, pre-mRNA processing factor

decreases expression

salvin results in decreased expression of BCAS2 protein

NCBI chr 2:190,692,503...190,700,386
Ensembl chr 2:190,692,461...190,700,389

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]
salvin inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]
salvin results in decreased expression of BCL2 protein
Acetylcysteine inhibits the reaction [salvin results in decreased expression of BCL2 protein]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Pyruvaldehyde results in decreased expression of BCL2 protein]

PMID:25446857 PMID:26577515 PMID:26686574 PMID:28918123 PMID:29854073 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 2

multiple interactions

salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of BCL2L2 protein]

NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624

G

bone morphogenetic protein 5

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of BMP5 mRNA]

NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925

G

basic leucine zipper and W2 domains 2

decreases expression

salvin results in decreased expression of BZW2 protein

NCBI chr 6:52,828,069...52,888,599
Ensembl chr 6:52,827,661...52,888,628

G

complement C3

decreases expression

salvin results in decreased expression of C3 protein

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

complement C4B

decreases expression

salvin results in decreased expression of C4B protein

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

cathelicidin antimicrobial peptide

decreases expression

salvin results in decreased expression of CAMP protein

NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543

G

carbonic anhydrase 2

increases expression

salvin results in increased expression of CA2 protein

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

caspase 14

increases expression

salvin results in increased expression of CASP14 protein

NCBI chr 7:10,929,759...10,932,591
Ensembl chr 7:10,926,725...10,933,405

G

caspase 3

multiple interactions
increases cleavage

salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]
salvin inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein]
salvin results in increased cleavage of CASP3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]]; Acetylcysteine inhibits the reaction [salvin results in increased cleavage of CASP3 protein]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of CASP3 protein]; salvin inhibits the reaction [Acrylamide results in increased expression of CASP3 mRNA]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; salvin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; salvin inhibits the reaction [Pyruvaldehyde results in increased expression of CASP3 protein]

PMID:24557422 PMID:25271104 PMID:25446857 PMID:26577515 PMID:26686574 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

decreases expression

salvin results in decreased expression of CASP6 protein

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 8

multiple interactions
increases cleavage

Acetylcysteine inhibits the reaction [salvin results in increased cleavage of CASP8 protein]
salvin inhibits the reaction [sodium arsenite results in increased cleavage of CASP8 protein]

PMID:28918123 PMID:29854073

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity
multiple interactions
increases cleavage

salvin results in increased activity of CASP9 protein
salvin inhibits the reaction [sodium arsenite results in increased cleavage of CASP9 protein]
salvin results in increased cleavage of CASP9 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Pyruvaldehyde results in increased expression of CASP9 protein]]; Acetylcysteine inhibits the reaction [salvin results in increased cleavage of CASP9 protein]; salvin inhibits the reaction [Acrylamide results in increased expression of CASP9 mRNA]; salvin inhibits the reaction [Paraquat results in increased activity of CASP9 protein]; salvin inhibits the reaction [Pyruvaldehyde results in increased expression of CASP9 protein]; salvin promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]

PMID:23239002 PMID:26577515 PMID:26686574 PMID:28159594 PMID:28918123 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

salvin inhibits the reaction [Acrylamide results in decreased activity of CAT protein]; salvin inhibits the reaction [Acrylamide results in decreased expression of CAT mRNA]
salvin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]

PMID:28159594 PMID:29854073

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

CD14 molecule

multiple interactions

[salvin co-treated with Tretinoin] results in increased expression of CD14 protein; salvin promotes the reaction [Calcitriol results in increased expression of CD14 protein]

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD177 molecule

decreases expression

salvin results in decreased expression of CD177 protein

NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621

G

cyclin-dependent kinase inhibitor 1B

increases expression
multiple interactions

salvin results in increased expression of CDKN1B protein
salvin promotes the reaction [arsenic trioxide results in increased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

chymotrypsin like elastase 1

decreases expression

salvin results in decreased expression of CELA1 protein

NCBI chr 7:131,773,161...131,786,300
Ensembl chr 7:131,742,002...131,786,285

G

chymotrypsin like elastase 3B

decreases expression

salvin results in decreased expression of CELA3B protein

NCBI chr 5:149,628,773...149,636,937
Ensembl chr 5:149,628,773...149,636,937

G

calcineurin-like EF hand protein 2

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of CHP2 mRNA]

NCBI chr 1:176,757,945...176,772,443
Ensembl chr 1:176,757,876...176,772,139

G

creatine kinase, mitochondrial 1

increases expression

salvin results in increased expression of CKMT1 protein

NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758

G

chloride channel accessory 1

increases expression

salvin results in increased expression of CLCA1 protein

NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369

G

chloride channel accessory 4

decreases expression

salvin results in decreased expression of CLCA4A protein

NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089

G

C-type lectin domain containing 14A

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of CLEC14A mRNA]

NCBI chr 6:75,881,470...75,884,612
Ensembl chr 6:75,881,473...75,884,612

G

chloride intracellular channel 5

increases expression

salvin results in increased expression of CLIC5 protein

NCBI chr 9:16,710,980...16,813,502
Ensembl chr 9:16,710,980...16,813,427

G

chloride nucleotide-sensitive channel 1A

increases expression

salvin results in increased expression of CLNS1A protein

NCBI chr 1:152,019,369...152,039,670
Ensembl chr 1:152,019,378...152,039,661

G

clusterin

decreases expression

salvin results in decreased expression of CLU protein

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

collagen type XVIII alpha 1 chain

decreases expression

salvin results in decreased expression of COL18A1 protein

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593

G

collagen type VI alpha 3 chain

decreases expression

salvin results in decreased expression of COL6A3 protein

NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471

G

cytochrome c oxidase subunit 6A1

increases expression

salvin results in increased expression of COX6A1 protein

NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041

G

ceruloplasmin

decreases expression

salvin results in decreased expression of CP protein

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

carboxypeptidase B1

decreases expression

salvin results in decreased expression of CPB1 protein

NCBI chr 2:102,755,241...102,785,628
Ensembl chr 2:102,755,241...102,785,628

G

coproporphyrinogen oxidase

increases expression

salvin results in increased expression of CPOX protein

NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746

G

cleavage and polyadenylation specific factor 7

decreases expression

salvin results in decreased expression of CPSF7 protein

NCBI chr 1:207,167,690...207,191,938
Ensembl chr 1:207,167,859...207,191,905

G

crooked neck pre-mRNA splicing factor 1

decreases expression

salvin results in decreased expression of CRNKL1 protein

NCBI chr 3:133,338,593...133,354,329
Ensembl chr 3:133,337,039...133,354,302
Ensembl chr 6:133,337,039...133,354,302

G

chymotrypsin-like

decreases expression

salvin results in decreased expression of CTRB1 protein

NCBI chr19:33,827,279...33,829,129
Ensembl chr19:33,827,229...33,833,626

G

cytochrome b-245 beta chain

decreases expression

salvin results in decreased expression of CYBB protein

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 20, subfamily a, polypeptide 1

decreases expression

salvin results in decreased expression of CYP20A1 protein

NCBI chr 9:61,755,804...61,805,123
Ensembl chr 9:61,755,790...61,805,123

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of CYP2B10 mRNA]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 66

decreases expression

salvin results in decreased expression of CYP2C66 protein

NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650

G

cytochrome P450, family 51

decreases expression

salvin results in decreased expression of CYP51A1 protein

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of CYP7A1 mRNA]

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

deleted in malignant brain tumors 1

decreases expression

salvin results in decreased expression of DMBT1 protein

NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478

G

DnaJ heat shock protein family (Hsp40) member C10

decreases expression

salvin results in decreased expression of DNAJC10 protein

NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719

G

DOP1 leucine zipper like protein B

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of DOP1B mRNA]

NCBI chr11:33,024,376...33,125,931
Ensembl chr11:33,024,411...33,125,931

G

dipeptidase 1

decreases expression

salvin results in decreased expression of DPEP1 protein

NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of EHHADH mRNA]

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

elastase, neutrophil expressed

decreases expression

salvin results in decreased expression of ELANE protein

NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100

G

enolase 3

increases expression

salvin results in increased expression of ENO3 protein

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

fatty acid binding protein 1

decreases expression

salvin results in decreased expression of FABP1 protein

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 5

decreases expression

salvin results in decreased expression of FABP5 protein

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

Fas cell surface death receptor

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fibulin 2

decreases expression

salvin results in decreased expression of FBLN2 protein

NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948

G

flap structure-specific endonuclease 1

decreases expression

salvin results in decreased expression of FEN1 protein

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

fibrinogen alpha chain

decreases expression

salvin results in decreased expression of FGA protein

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

fibrinogen beta chain

decreases expression

salvin results in decreased expression of FGB protein

NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979

G

fibroblast growth factor 21

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of FGF21 mRNA]

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

fibrinogen gamma chain

decreases expression

salvin results in decreased expression of FGG protein

NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322

G

fission, mitochondrial 1

multiple interactions

salvin inhibits the reaction [Oxidopamine results in increased expression of FIS1 protein]

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

flavin containing dimethylaniline monoxygenase 2

increases expression

salvin results in increased expression of FMO2 protein

NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308

G

fascin actin-bundling protein 1

decreases expression

salvin results in decreased expression of FSCN1 protein

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

polypeptide N-acetylgalactosaminyltransferase 12

decreases expression

salvin results in decreased expression of GALNT12 protein

NCBI chr 5:61,384,575...61,413,346
Ensembl chr 5:61,384,571...61,413,354

G

polypeptide N-acetylgalactosaminyltransferase 3

decreases expression

salvin results in decreased expression of GALNT3 protein

NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268

G

granule associated Rac and RHOG effector 1

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of GARRE1 mRNA]

NCBI chr 1:86,862,121...86,939,725
Ensembl chr 1:86,862,121...86,939,687

G

GC, vitamin D binding protein

decreases expression

salvin results in decreased expression of GC protein

NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

salvin results in increased expression of GCLC mRNA
salvin results in increased expression of GCLC protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLC protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLC protein]

PMID:18329808 PMID:25446857 PMID:26577515 PMID:26686574

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions
increases expression

salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein]
salvin results in increased expression of GCLM protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLM protein]; salvin inhibits the reaction [Acrylamide results in decreased expression of GCLM mRNA]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein]

PMID:25446857 PMID:26577515 PMID:26686574 PMID:28159594

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glucosaminyl (N-acetyl) transferase 3, mucin type

decreases expression

salvin results in decreased expression of GCNT3 protein

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562

G

growth factor, augmenter of liver regeneration

increases expression

salvin results in increased expression of GFER protein

NCBI chr10:13,718,489...13,721,782
Ensembl chr10:13,718,489...13,720,869

G

gamma-glutamyl hydrolase

increases expression

salvin results in increased expression of GGH protein

NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787

G

glyoxalase domain containing 5

increases expression

salvin results in increased expression of GLOD5 protein

NCBI chr X:14,473,994...14,488,797
Ensembl chr X:14,473,994...14,488,683

G

G protein nucleolar 3

decreases expression

salvin results in decreased expression of GNL3 protein

NCBI chr16:6,207,402...6,213,491
Ensembl chr16:6,207,402...6,213,392

G

glutamic--pyruvic transaminase

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of GPT protein]

PMID:29854073 PMID:35202923

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

salvin inhibits the reaction [Acrylamide results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

granulin precursor

decreases expression

salvin results in decreased expression of GRN protein

NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775

G

gasdermin E

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of GSDME mRNA]

NCBI chr 4:79,258,799...79,321,129
Ensembl chr 4:79,257,804...79,320,806

G

glutathione-disulfide reductase

multiple interactions
increases expression

salvin inhibits the reaction [Oxidopamine results in decreased expression of GSR protein]
salvin inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]
salvin results in increased expression of GSR protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GSR protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSR protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GSR protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GSR protein]

PMID:25446857 PMID:26577515 PMID:26686574 PMID:29854073

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase pi 1

multiple interactions
increases expression

salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]
salvin results in increased expression of GSTP1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GSTP1 protein]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSTP1 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]; salvin results in increased expression of and results in increased activity of GSTP1 protein

PMID:25271104 PMID:26577515

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

general transcription factor IIF subunit 1

decreases expression

salvin results in decreased expression of GTF2F1 protein

NCBI chr 9:1,844,027...1,853,455
Ensembl chr 9:1,843,901...1,853,423

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

decreases expression

salvin results in decreased expression of HMGCS2 protein

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression
multiple interactions

salvin results in increased expression of HMOX1 mRNA; salvin results in increased expression of HMOX1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of HMOX1 protein]

PMID:18329808 PMID:23942037 PMID:26686574

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A3

decreases expression

salvin results in decreased expression of HNRNPA3 protein

NCBI chr 3:60,578,574...60,588,755
Ensembl chr 3:60,578,673...60,588,306

G

haptoglobin

decreases expression

salvin results in decreased expression of HP protein

NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523

G

hemopexin

decreases expression

salvin results in decreased expression of HPX protein

NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328

G

hydroxysteroid (17-beta) dehydrogenase 6

decreases expression

salvin results in decreased expression of HSD17B6 protein

NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425

G

inhibitor of DNA binding 3

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of ID3 mRNA]

NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349

G

interferon gamma

multiple interactions

salvin inhibits the reaction [IFNG protein results in increased abundance of Nitrites]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor binding protein 7

decreases expression

salvin results in decreased expression of IGFBP7 protein

NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314

G

immunoglobulin kappa variable like, pseudogene 13

decreases expression

salvin results in decreased expression of IGKV1-133 protein

NCBI chr 4:96,968,574...96,969,477

G

inhibitor of nuclear factor kappa B kinase regulatory subunit gamma

multiple interactions
increases ubiquitination

PRKN protein affects the reaction [salvin results in increased ubiquitination of IKBKG protein]

NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499

G

inhibin subunit beta E

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of INHBE mRNA]

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

indolethylamine N-methyltransferase

increases expression

salvin results in increased expression of INMT protein

NCBI chr 4:84,318,197...84,322,493
Ensembl chr 4:84,318,197...84,322,493

G

integrator complex subunit 3

decreases expression

salvin results in decreased expression of INTS3 protein

NCBI chr 2:175,859,421...175,911,683
Ensembl chr 2:175,859,440...175,911,709

G

integrin subunit alpha 2

decreases expression

salvin results in decreased expression of ITGA2 protein

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha M

multiple interactions
decreases expression

[salvin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of ITGAM protein; salvin promotes the reaction [Calcitriol results in increased expression of ITGAM protein]; salvin promotes the reaction [Tretinoin results in increased expression of ITGAM protein]
salvin results in decreased expression of ITGAM protein

PMID:11504768 PMID:35926579

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 2

decreases expression

salvin results in decreased expression of ITGB2 protein

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

KLF transcription factor 12

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of KLF12 mRNA]

NCBI chr15:76,628,778...77,062,000
Ensembl chr15:76,637,654...77,062,056

G

kininogen 1

decreases expression

salvin results in decreased expression of KNG1 protein

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

lysosomal-associated membrane protein 2

decreases expression

salvin results in decreased expression of LAMP2 protein

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

lipocalin 2

decreases expression

salvin results in decreased expression of LCN2 protein

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

galectin 2

decreases expression

salvin results in decreased expression of LGALS2 protein

NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802

G

galectin 3 binding protein

decreases expression

salvin results in decreased expression of LGALS3BP protein

NCBI chr10:103,619,912...103,629,251
Ensembl chr10:103,619,908...103,629,256

G

galectin 9

decreases expression

salvin results in decreased expression of LGALS9 protein

NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045

G

legumain

decreases expression

salvin results in decreased expression of LGMN protein

NCBI chr 6:121,544,048...121,582,495
Ensembl chr 6:121,544,053...121,582,480

G

lactotransferrin

decreases expression

salvin results in decreased expression of LTF protein

NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795

G

leucine zipper protein 1

decreases expression

salvin results in decreased expression of LUZP1 protein

NCBI chr 5:148,706,094...148,781,616
Ensembl chr 5:148,706,138...148,781,609

G

lymphatic vessel endothelial hyaluronan receptor 1

increases expression

salvin results in increased expression of LYVE1 protein

NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309

G

lysozyme 2

decreases expression

salvin results in decreased expression of LYZ2 protein

NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106

G

mitogen-activated protein kinase 8

multiple interactions

salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]
salvin inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK8 protein]

PMID:25446857 PMID:29854073

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions

salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MARCKS-like 1

decreases expression

salvin results in decreased expression of MARCKSL1 protein

NCBI chr 5:141,851,491...141,853,814
Ensembl chr 5:141,850,110...141,853,817

G

minichromosome maintenance complex component 7

decreases expression

salvin results in decreased expression of MCM7 protein

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

mitofusin 2

multiple interactions

salvin inhibits the reaction [Oxidopamine results in decreased expression of MFN2 protein]

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

Mov10 RNA helicase

decreases expression

salvin results in decreased expression of MOV10 protein

NCBI chr 2:192,292,041...192,315,142
Ensembl chr 2:192,293,470...192,315,083

G

myeloperoxidase

decreases expression

salvin results in decreased expression of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

myelin protein zero-like 2

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of MPZL2 mRNA]

NCBI chr 8:45,348,285...45,359,298
Ensembl chr 8:45,348,285...45,359,298

G

mitochondrial ribosomal protein S31

decreases expression

salvin results in decreased expression of MRPS31 protein

NCBI chr16:69,601,349...69,621,609
Ensembl chr16:69,601,349...69,630,654

G

mechanistic target of rapamycin kinase

decreases phosphorylation

salvin results in decreased phosphorylation of MTOR protein

PMID:25178877 PMID:28918123

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

murinoglobulin 1

decreases expression

salvin results in decreased expression of MUG1 protein

NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051

G

murinoglobulin 2

decreases expression

salvin results in decreased expression of MUG2 protein

NCBI chr 4:155,164,061...155,236,894
Ensembl chr 4:155,164,011...155,236,475

G

myosin regulatory light chain interacting protein

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of MYLIP mRNA]

NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295

G

myosin Ib

decreases expression

salvin results in decreased expression of MYO1B protein

NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798

G

N-deacetylase and N-sulfotransferase 1

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of NDST1 mRNA]

NCBI chr18:54,136,887...54,199,545
Ensembl chr18:54,140,779...54,178,191

G

NADH:ubiquinone oxidoreductase subunit A12

increases expression

salvin results in increased expression of NDUFA12 protein

NCBI chr 7:28,771,330...28,798,316
Ensembl chr 7:28,771,330...28,798,315

G

negative elongation factor complex member B

decreases expression

salvin results in decreased expression of NELFB protein

NCBI chr 3:8,010,883...8,027,403
Ensembl chr 3:8,010,888...8,027,403

G

NFE2 like bZIP transcription factor 2

increases activity
multiple interactions

salvin results in increased activity of NFE2L2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased activity of NFE2L2 protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSR protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSTP1 protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of SOD2 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GSR protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of NQO1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of SOD2 protein]; salvin affects the localization of and results in increased activity of NFE2L2 protein; salvin inhibits the reaction [Acrylamide results in decreased expression of NFE2L2 mRNA]; salvin inhibits the reaction [Acrylamide results in decreased expression of NFE2L2 protein]

PMID:26577515 PMID:26686574 PMID:28159594

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions

salvin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; salvin inhibits the reaction [sodium arsenite results in increased phosphorylation of NFKBIA protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased phosphorylation of NFKBIA protein]; salvin results in increased phosphorylation of and results in increased degradation of NFKBIA protein

PMID:21375325 PMID:25271104 PMID:29854073

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 12

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of NLRP12 mRNA]

NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934

G

nitric oxide synthase 2

multiple interactions

salvin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NADPH oxidase 1

decreases expression

salvin results in decreased expression of NOX1 protein

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

salvin results in increased expression of NQO1 mRNA
salvin results in increased expression of NQO1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of NQO1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of NQO1 protein]; salvin inhibits the reaction [Acrylamide results in decreased expression of NQO1 mRNA]

PMID:18329808 PMID:26686574 PMID:28159594

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 3, group C, member 2

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of NR3C2 mRNA]

NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885

G

nardilysin convertase

decreases expression

salvin results in decreased expression of NRDC protein

NCBI chr 5:123,755,807...123,818,910
Ensembl chr 5:123,755,806...123,818,595

G

2'-5' oligoadenylate synthetase 1A

increases expression

salvin results in increased expression of OAS1G protein

NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517

G

OPA1, mitochondrial dynamin like GTPase

multiple interactions
increases expression

OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; PRKN protein affects the reaction [salvin results in increased expression of OPA1 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 protein]

NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109

G

orosomucoid 1

decreases expression

salvin results in decreased expression of ORM1 protein

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases expression
increases cleavage

Acetylcysteine inhibits the reaction [salvin results in increased cleavage of PARP1 protein]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
salvin results in decreased expression of PARP1 protein

PMID:25446857 PMID:28918123 PMID:30707903 PMID:31705926

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

pterin-4 alpha-carbinolamine dehydratase 2

increases expression

salvin results in increased expression of PCBD2 protein

NCBI chr17:8,845,161...8,896,343
Ensembl chr17:8,845,084...8,910,539

G

phosphodiesterase 5A

increases expression

salvin results in increased expression of PDE5A protein

NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701

G

pyridoxal kinase

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of PDXK mRNA]

NCBI chr20:10,210,276...10,232,314
Ensembl chr20:10,210,289...10,232,110

G

period circadian regulator 2

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of PER2 mRNA]

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

PGAM family member 5, mitochondrial serine/threonine protein phosphatase

decreases expression

salvin results in decreased expression of PGAM5 protein

NCBI chr12:46,409,324...46,416,410
Ensembl chr12:46,409,369...46,416,420

G

peptidoglycan recognition protein 1

decreases expression

salvin results in decreased expression of PGLYRP1 protein

NCBI chr 1:78,531,815...78,537,001
Ensembl chr 1:78,531,815...78,537,001

G

phosphoglycerate dehydrogenase

decreases expression

salvin results in decreased expression of PHGDH protein

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

PTEN induced kinase 1

multiple interactions

PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PINK1 protein]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

plasminogen

decreases expression

salvin results in decreased expression of PLG protein

NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786

G

perilipin 2

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of PLIN2 mRNA]

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

perilipin 4

increases expression

salvin results in increased expression of PLIN4 protein

NCBI chr 9:929,168...938,062
Ensembl chr 9:929,176...938,056

G

phospholipid phosphatase 1

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of PLPP1 mRNA]

NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268

G

pancreatic lipase

decreases expression

salvin results in decreased expression of PNLIP protein

NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654

G

pancreatic lipase-related protein 1

decreases expression

salvin results in decreased expression of PNLIPRP1 protein

NCBI chr 1:257,867,885...257,883,514
Ensembl chr 1:257,867,885...257,883,514

G

peroxisome proliferator-activated receptor gamma

increases activity

salvin results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

peroxiredoxin 6

increases expression

salvin results in increased expression of PRDX6 protein

NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions
increases expression

PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; PRKN protein affects the reaction [salvin results in increased expression of OPA1 protein]; PRKN protein affects the reaction [salvin results in increased expression of RELA protein]; PRKN protein affects the reaction [salvin results in increased ubiquitination of IKBKG protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]
salvin results in increased expression of PRKN protein

PMID:30707903 PMID:31705926

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

prominin 1

decreases expression

salvin results in decreased expression of PROM1 protein

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

phosphatase and tensin homolog

multiple interactions
increases expression

salvin promotes the reaction [arsenic trioxide results in increased expression of PTEN mRNA]
salvin results in increased expression of PTEN mRNA

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin D2 synthase

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of PTGDS mRNA]

NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833

G

prostaglandin-endoperoxide synthase 2

multiple interactions

salvin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

parvalbumin

decreases expression

salvin results in decreased expression of PVALB protein

NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561

G

peroxidasin

decreases expression

salvin results in decreased expression of PXDN protein

NCBI chr 6:46,580,749...46,658,345
Ensembl chr 6:46,580,761...46,658,345

G

quiescin sulfhydryl oxidase 1

decreases expression

salvin results in decreased expression of QSOX1 protein

NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459

G

RAB11 family interacting protein 2

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of RAB11FIP2 mRNA]

NCBI chr 1:258,950,535...259,094,555
Ensembl chr 1:258,923,873...259,093,752

G

Rap guanine nucleotide exchange factor 5

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of RAPGEF5 mRNA]

NCBI chr 6:138,445,184...138,679,943
Ensembl chr 6:138,437,991...138,679,936

G

retinoic acid receptor, alpha

multiple interactions

[Tetradecanoylphorbol Acetate co-treated with salvin] results in increased expression of RARA protein

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

RNA binding protein, mRNA processing factor

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of RBPMS mRNA]

NCBI chr16:58,239,370...58,395,424
Ensembl chr16:58,239,474...58,395,426

G

retinol dehydrogenase 9

decreases expression

salvin results in decreased expression of RDH9 protein

NCBI chr 7:63,642,305...63,645,149

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression
affects localization

salvin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; salvin inhibits the reaction [sodium arsenite results in increased phosphorylation of and affects the localization of RELA protein]
salvin results in increased expression of RELA protein
salvin affects the localization of RELA protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin affects the localization of RELA protein]; PRKN protein affects the reaction [salvin results in increased expression of RELA protein]; salvin results in increased expression of and results in increased activity of RELA protein

PMID:21375325 PMID:25271104 PMID:29854073 PMID:31705926

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

retention in endoplasmic reticulum sorting receptor 1

increases expression

salvin results in increased expression of RER1 protein

NCBI chr 5:165,634,567...165,646,643
Ensembl chr 5:165,634,300...165,646,750

G

Ras homolog, mTORC1 binding

decreases expression

salvin results in decreased expression of RHEB protein

NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160

G

ribonuclease A family member 4

decreases expression

salvin results in decreased expression of RNASE4 protein

NCBI chr15:24,312,765...24,330,112
Ensembl chr15:24,312,464...24,330,117

G

replication protein A1

decreases expression

salvin results in decreased expression of RPA1 protein

NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949

G

ribosomal protein S21, pseudogene 1

increases expression

salvin results in increased expression of RPS21 protein

NCBI chr 5:153,387,133...153,387,476
Ensembl chr 5:153,387,176...153,387,427

G

retinoid X receptor alpha

increases expression
multiple interactions

salvin results in increased expression of RXRA protein
Calcitriol promotes the reaction [salvin results in increased expression of RXRA protein]; Tretinoin promotes the reaction [salvin results in increased expression of RXRA protein]

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

S100 calcium binding protein A11

decreases expression

salvin results in decreased expression of S100A11 protein

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

S100 calcium binding protein A8

decreases expression

salvin results in decreased expression of S100A8 protein

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

decreases expression

salvin results in decreased expression of S100A9 protein

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

S100 calcium binding protein G

increases expression

salvin results in increased expression of S100G protein

NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433

G

syndecan 3

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of SDC3 mRNA]

NCBI chr 5:142,965,659...142,998,390
Ensembl chr 5:142,965,591...142,996,480

G

serine (or cysteine) peptidase inhibitor, clade A, member 3N

decreases expression

salvin results in decreased expression of SERPINA3N protein

NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433

G

small G protein signaling modulator 3

decreases expression

salvin results in decreased expression of SGSM3 protein

NCBI chr 7:112,514,453...112,544,109
Ensembl chr 7:112,514,630...112,544,108

G

SHC adaptor protein 1

multiple interactions
increases expression
decreases expression

salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]; SIRT1 mutant form inhibits the reaction [salvin results in decreased expression of SHC1 protein]
salvin results in increased expression of SHC1 mRNA

NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536

G

serine hydroxymethyltransferase 2

decreases expression

salvin results in decreased expression of SHMT2 protein

NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236

G

salt-inducible kinase 2

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of SIK2 mRNA]

NCBI chr 8:51,225,543...51,325,343
Ensembl chr 8:51,225,543...51,325,415

G

sirtuin 1

multiple interactions
increases expression

Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; SIRT1 mutant form inhibits the reaction [salvin results in decreased expression of SHC1 protein]
salvin results in increased expression of SIRT1 mRNA; salvin results in increased expression of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 26 member 3

increases expression

salvin results in increased expression of SLC26A3 protein

NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772

G

solute carrier family 35 member A2

increases expression

salvin results in increased expression of SLC35A2 protein

NCBI chr X:14,608,145...14,616,937
Ensembl chr X:14,608,055...14,616,678

G

SAFB-like, transcription modulator

decreases expression

salvin results in decreased expression of SLTM protein

NCBI chr 8:71,215,995...71,261,821
Ensembl chr 8:71,216,612...71,261,825

G

SNW domain containing 1

decreases expression

salvin results in decreased expression of SNW1 protein

NCBI chr 6:107,095,450...107,119,536
Ensembl chr 6:107,095,457...107,119,536

G

sorting nexin 4

decreases expression

salvin results in decreased expression of SNX4 protein

NCBI chr11:67,460,872...67,518,143
Ensembl chr11:67,460,870...67,518,174

G

superoxide dismutase 1

multiple interactions

salvin inhibits the reaction [Acrylamide results in decreased expression of SOD1 mRNA]; salvin inhibits the reaction [Oxidopamine results in decreased expression of SOD1 protein]

PMID:25446857 PMID:28159594

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of SOD2 protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of SOD2 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of SOD2 protein]; salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SOD2 protein]

PMID:24557422 PMID:26577515 PMID:26686574

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sorbin and SH3 domain containing 1

multiple interactions

salvin inhibits the reaction [sodium arsenite results in decreased expression of SORBS1 mRNA]

NCBI chr 1:239,107,882...239,330,276
Ensembl chr 1:239,108,777...239,330,169

G

secreted protein acidic and cysteine rich

decreases expression

salvin results in decreased expression of SPARC protein

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

small proline rich protein 2A

decreases expression

salvin results in decreased expression of SPRR2A protein

NCBI chr 2:177,815,964...177,816,236
Ensembl chr 2:177,815,964...177,816,236

G

STIP1 homology and U-box containing protein 1

decreases expression

salvin results in decreased expression of STUB1 protein

NCBI chr10:14,850,765...14,853,046
Ensembl chr10:14,850,765...14,853,046

G

T-box transcription factor 3

multiple interactions

salvin inhibits the reaction [sodium arsenite results in increased expression of TBX3 mRNA]

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

telomerase associated protein 1

decreases expression

salvin results in decreased expression of TEP1 protein

NCBI chr15:24,045,876...24,093,526
Ensembl chr15:24,045,878...24,093,526

G

transferrin

decreases expression

salvin results in decreased expression of TF protein

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transglutaminase 3

increases expression

salvin results in increased expression of TGM3 protein

NCBI chr 3:117,228,661...117,264,078
Ensembl chr 3:117,228,661...117,264,075

G

tyrosine hydroxylase

multiple interactions

salvin inhibits the reaction [Oxidopamine results in decreased expression of TH protein]

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

tubulointerstitial nephritis antigen-like 1

increases expression

salvin results in increased expression of TINAGL1 protein

NCBI chr 5:142,513,710...142,523,730
Ensembl chr 5:142,513,714...142,523,720

G

transmembrane p24 trafficking protein 5

decreases expression

salvin results in decreased expression of TMED5 protein

NCBI chr14:1,607,895...1,619,028
Ensembl chr14:1,607,819...1,628,426

G

thymosin beta 4, X-linked

decreases expression

salvin results in decreased expression of TMSB4X protein

NCBI chr X:27,144,666...27,146,667
Ensembl chr X:27,128,610...27,146,667

G

tumor necrosis factor

multiple interactions

salvin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tenascin XB

increases expression

salvin results in increased expression of TNXB protein

G

tumor susceptibility 101

decreases expression

salvin results in decreased expression of TSG101 protein

NCBI chr 1:97,412,689...97,442,589
Ensembl chr 1:97,410,848...97,442,554

G

tetraspanin 15

increases expression

salvin results in increased expression of TSPAN15 protein

NCBI chr20:30,130,528...30,174,912
Ensembl chr20:30,130,530...30,174,930

G

taxilin alpha

decreases expression

salvin results in decreased expression of TXLNA protein

NCBI chr 5:141,969,337...141,985,054
Ensembl chr 5:141,969,346...141,984,583

G

tyrosinase

decreases expression

salvin results in decreased expression of TYR mRNA

NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207

G

ubiquitin-like 4A

decreases expression

salvin results in decreased expression of UBL4A protein

NCBI chr X:152,151,242...152,154,094
Ensembl chr X:152,151,460...152,154,069

G

voltage-dependent anion channel 1

multiple interactions

PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein]

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

vitamin D receptor

multiple interactions
increases expression

Calcitriol promotes the reaction [salvin results in increased expression of VDR protein]; Tetradecanoylphorbol Acetate promotes the reaction [salvin results in increased expression of VDR protein]; Tretinoin promotes the reaction [salvin results in increased expression of VDR protein]

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

villin-like

decreases expression

salvin results in decreased expression of VILL protein

NCBI chr 8:118,776,718...118,794,983
Ensembl chr 8:118,776,742...118,794,983

G

WD repeat domain 5

decreases expression

salvin results in decreased expression of WDR5 protein

NCBI chr 3:10,836,964...10,856,682
Ensembl chr 3:10,837,025...10,856,671

G

Wnt inhibitory factor 1

decreases expression

salvin results in decreased expression of WIF1 protein

NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:56,548,053...56,618,360

G

zinc finger protein 207

decreases expression

salvin results in decreased expression of ZFP207 protein; salvin results in decreased expression of ZNF207 protein

NCBI chr10:65,385,807...65,398,086
Ensembl chr10:65,385,740...65,397,386

ginsenoside Rb1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

ATPase H+ transporting V1 subunit A

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1A mRNA]

NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694

G

ATPase H+ transporting V1 subunit B2

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1B2 mRNA]

NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745

G

bone morphogenetic protein 2

multiple interactions
increases expression

ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA]
ginsenoside Rb1 results in increased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

caspase 3

multiple interactions

ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

chloride voltage-gated channel 7

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CLCN7 mRNA]

NCBI chr10:14,151,758...14,177,130
Ensembl chr10:14,151,758...14,177,130

G

cathepsin B

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSB mRNA]

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSD mRNA]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

heme oxygenase 1

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein

PMID:19781563 PMID:25422538

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

insulin-like growth factor 1

multiple interactions
increases expression

ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA]
ginsenoside Rb1 results in increased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 6

multiple interactions

ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha M

multiple interactions

ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 2

multiple interactions

ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein]

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

potassium voltage-gated channel subfamily E regulatory subunit 1

increases expression

ginsenoside Rb1 results in increased expression of KCNE1

NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901

G

potassium voltage-gated channel subfamily H member 2

affects activity

ginsenoside Rb1 affects the activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

lysosomal-associated membrane protein 1

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of LAMP1 mRNA]

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

microtubule-associated protein 2

increases expression

ginsenoside Rb1 results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

nuclear factor of activated T-cells 1

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects localization
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]
ginsenoside Rb1 affects the localization of NFE2L2 protein
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein
ginsenoside Rb1 results in increased expression of NFE2L2 mRNA

PMID:19781563 PMID:22780686 PMID:25422538

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

purinergic receptor P2X 4

multiple interactions

ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]

NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253

G

progesterone receptor

increases expression

ginsenoside Rb1 results in increased expression of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RUNX family transcription factor 2

increases expression
multiple interactions

ginsenoside Rb1 results in increased expression of RUNX2 mRNA
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ginsenoside Rb1 binds to and results in decreased activity of SLCO1B3 protein

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

sequestosome 1

multiple interactions
decreases expression

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]
ginsenoside Rb1 results in decreased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

transcription factor EB

multiple interactions

[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA]

NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714

G

transforming growth factor, beta 1

multiple interactions
increases expression

ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA]
ginsenoside Rb1 results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 11

multiple interactions
decreases response to substance

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA]
ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

ginsenoside Rd

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

ginsenoside Rd results in increased phosphorylation of and results in increased activity of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

increases expression

ginsenoside Rd results in increased expression of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

ginsenoside Rd results in increased expression of CDKN1A mRNA
staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

choline O-acetyltransferase

increases expression
multiple interactions

ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein
staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein]

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

cytochrome c, somatic

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

lipoprotein lipase

decreases secretion

ginsenoside Rd results in decreased secretion of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

microtubule-associated protein 2

increases expression

ginsenoside Rd results in increased expression of MAP2 mRNA; ginsenoside Rd results in increased expression of MAP2 protein

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase 1

multiple interactions

ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nerve growth factor

increases expression

ginsenoside Rd results in increased expression of NGF mRNA

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nerve growth factor receptor

increases expression

ginsenoside Rd results in increased expression of NGFR mRNA; ginsenoside Rd results in increased expression of NGFR protein

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

purinergic receptor P2X 4

multiple interactions

ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]

NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253

G

purinergic receptor P2X 7

decreases response to substance

P2RX7 gene mutant form results in decreased susceptibility to ginsenoside Rd

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

solute carrier family 18 member A3

increases expression

ginsenoside Rd results in increased expression of SLC18A3 mRNA

NCBI chr16:7,713,630...7,716,491

G

solute carrier family 5 member 7

increases expression

ginsenoside Rd results in increased expression of SLC5A7 mRNA

NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ginsenoside Rd binds to and results in decreased activity of SLCO1B3 protein

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

ginsenoside Rg1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases transport
multiple interactions

ABCB11 protein results in increased transport of ginsenoside Rg1
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein]
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein]

PMID:25297453 PMID:29964319 PMID:32198087

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 1

increases transport

ABCC1 protein results in increased transport of ginsenoside Rg1

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases transport
multiple interactions
increases expression

ABCC2 protein results in increased transport of ginsenoside Rg1
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein]
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]]
ginsenoside Rg1 results in increased expression of ABCC2 protein

PMID:25297453 PMID:29964319 PMID:32198087

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of ABCC3 protein
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]]

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of ABCC4 protein
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein]

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

increases transport

ABCG2 protein results in increased transport of ginsenoside Rg1

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acetylcholinesterase

decreases activity

ginsenoside Rg1 results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

ADAM metallopeptidase domain 10

multiple interactions

ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]

NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889

G

AKT serine/threonine kinase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]
ginsenoside Rg1 inhibits the reaction [Doxorubicin results in increased expression of AKT1 mRNA]

PMID:33331133 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apoptotic peptidase activating factor 1

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of APAF1 mRNA]

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

amyloid beta precursor protein

multiple interactions

ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

activating transcription factor 6

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein]

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATM serine/threonine kinase

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of ATM mRNA]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

beta-secretase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

BCL2-associated agonist of cell death

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of BAX protein
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of BAX protein]
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of BAX mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]

PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

ginsenoside Rg1 results in decreased expression of BCL2 protein
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein]

PMID:26593335 PMID:28371286 PMID:34859534 PMID:36811218

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases activity

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP3 mRNA]
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]
ginsenoside Rg1 results in increased activity of CASP3 protein

PMID:24386346 PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity
multiple interactions

ginsenoside Rg1 results in increased activity of CASP9 protein
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP9 protein]
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP9 mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]

PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of CAT protein]

PMID:29964319 PMID:37923178

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin E1

multiple interactions

ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cadherin 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin dependent kinase 2

multiple interactions

ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein]

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]

PMID:15606011 PMID:34783124

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cAMP responsive element binding protein 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of CYP2E1 mRNA]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage inducible transcript 3

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ERN1 protein]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ginsenoside Rg1 results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

follicle stimulating hormone receptor

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of FSHR protein]

NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of GCLC mRNA
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of GCLM protein
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gap junction protein, alpha 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glutamate dehydrogenase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of GLUD1 protein]

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

glutamic--pyruvic transaminase

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glycogen synthase kinase 3 beta

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

H2A.X variant histone

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of H2AX mRNA]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

heme oxygenase 1

multiple interactions
increases expression

[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]
ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein

PMID:25422538 PMID:29964319

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interferon gamma

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein]

PMID:22214447 PMID:29964319 PMID:32198087 PMID:36811218

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of IL6 protein]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

PMID:17655881 PMID:29964319 PMID:30918470 PMID:36811218 PMID:37923178

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of INHA protein]

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

potassium voltage-gated channel subfamily H member 2

affects activity

ginsenoside Rg1 affects the activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

Kelch-like ECH-associated protein 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

luteinizing hormone subunit beta

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipoprotein lipase

increases secretion

ginsenoside Rg1 results in increased secretion of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

microtubule-associated protein 2

increases expression

ginsenoside Rg1 results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase 1

multiple interactions
affects phosphorylation

PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

affects phosphorylation
multiple interactions

ginsenoside Rg1 affects the phosphorylation of MAPK3 protein
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions
increases expression

Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

mitofusin 2

multiple interactions

ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

microRNA 23a

decreases expression
multiple interactions

ginsenoside Rg1 results in decreased expression of MIR23A mRNA
Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]

NCBI chr19:23,954,997...23,955,071
Ensembl chr19:23,954,997...23,955,071

G

matrix metallopeptidase 2

increases expression

ginsenoside Rg1 results in increased expression of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression

ginsenoside Rg1 results in increased expression of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein]

PMID:24386346 PMID:33331133

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects localization
increases expression

[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein
ginsenoside Rg1 affects the localization of NFE2L2 protein
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]]
ginsenoside Rg1 results in increased expression of NFE2L2 mRNA

PMID:22780686 PMID:25422538 PMID:29964319

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

affects phosphorylation
multiple interactions

ginsenoside Rg1 affects the phosphorylation of NFKBIA protein
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]

PMID:22214447 PMID:29964319

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

progesterone receptor

increases expression

ginsenoside Rg1 results in increased expression of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of PIK3CA mRNA]

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

phospholipase C, gamma 1

multiple interactions

PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of PRKAA1 protein]

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

phosphatase and tensin homolog

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of PTEN protein]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]

PMID:22214447 PMID:29964319

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RAD51 recombinase

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of RAD51 mRNA]

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

ribosomal protein S6

increases phosphorylation

ginsenoside Rg1 results in increased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

regulatory associated protein of MTOR, complex 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein]

NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983

G

sirtuin 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 10 member 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier organic anion transporter family member 1B2

multiple interactions

SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1
SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

superoxide dismutase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

sulfotransferase family 2A member 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein]

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

trefoil factor 1

increases expression

ginsenoside Rg1 results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

tumor necrosis factor

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]

PMID:22214447 PMID:29964319 PMID:30918470 PMID:32198087 PMID:36811218 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein]

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

X-ray repair cross complementing 1

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of XRCC1 mRNA]

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

goralatide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

increases expression
decreases expression
multiple interactions

goralatide results in increased expression of ACE mRNA
goralatide results in decreased expression of ACE mRNA
[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]

PMID:20096676 PMID:33007385

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

actin alpha 2, smooth muscle

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]

PMID:31181250 PMID:33007385

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

angiotensinogen

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]

PMID:31181250 PMID:33007385

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

bradykinin receptor B1

affects abundance
multiple interactions

BDKRB1 protein affects the abundance of goralatide
[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

cadherin 1

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

collagen type III alpha 1 chain

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

GLI family zinc finger 1

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI family zinc finger 2

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]

NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574

G

GLI family zinc finger 3

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]

NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein]

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

patched 1

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]

NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333

G

sonic hedgehog signaling molecule

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]

NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170

G

smoothened, frizzled class receptor

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]

NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829

G

vimentin

multiple interactions

goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

JTE-013

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

multiple interactions

[Colchicine co-treated with JTE 013] inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

AKT serine/threonine kinase 1

multiple interactions

JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

autophagy related 5

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of ATG5 protein]

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

collagen type I alpha 1 chain

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of COL1A1 protein]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

cAMP responsive element binding protein 1

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

epidermal growth factor receptor

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of EGFR protein]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

fibronectin 1

multiple interactions

[JTE 013 binds to and results in decreased activity of S1PR2 protein] inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; [JTE 013 binds to and results in decreased activity of S1PR2 protein] inhibits the reaction [sphingosine 1-phosphate results in increased expression of FN1 protein]; JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of FN1 protein]

PMID:22406263 PMID:37169277

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

interleukin 18

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of IL18 protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 6

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of IL6 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of and results in increased lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK1 protein]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]

PMID:18612546 PMID:26518876

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK3 protein]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]

PMID:18612546 PMID:26518876

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 2

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP2 protein]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP9 protein]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

NLR family, pyrin domain containing 3

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

prostaglandin-endoperoxide synthase 2

multiple interactions

JTE 013 inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 protein]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; JTE 013 promotes the reaction [Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin promotes the reaction [JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]

PMID:18612546 PMID:26518876

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate affects the localization of RELA protein modified form]; JTE 013 inhibits the reaction [Taurocholic Acid affects the localization of RELA protein modified form]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

sphingosine-1-phosphate receptor 2

multiple interactions

[JTE 013 binds to and results in decreased activity of S1PR2 protein] inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; [JTE 013 binds to and results in decreased activity of S1PR2 protein] inhibits the reaction [sphingosine 1-phosphate results in increased expression of FN1 protein]; [JTE 013 binds to and results in decreased activity of S1PR2 protein] results in decreased susceptibility to [sphingosine 1-phosphate co-treated with Glucose]; [JTE 013 binds to and results in decreased activity of S1PR2 protein] which results in decreased susceptibility to sphingosine 1-phosphate; JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of S1PR2 protein]

PMID:22406263 PMID:37169277

NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574

G

tumor necrosis factor

multiple interactions

JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of TNF mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

morin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

morin results in decreased activity of ABCB11 protein
morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases activity
multiple interactions

morin results in increased activity of ABCB1 protein
morin promotes the reaction [Quercetin results in increased activity of ABCB1 protein]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

decreases activity

morin results in decreased activity of ABCC1 protein

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

acetylcholinesterase

multiple interactions

morin inhibits the reaction [Ifosfamide results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

actin alpha 2, smooth muscle

multiple interactions

morin inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; morin inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adiponectin, C1Q and collagen domain containing

multiple interactions

morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of ADIPOQ protein]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

aryl hydrocarbon receptor

multiple interactions

AHR gene mutant form inhibits the reaction [morin results in increased expression of CYP1A1 mRNA]; AHR gene mutant form inhibits the reaction [morin results in increased expression of UGT1A1 mRNA]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

morin inhibits the reaction [Excitatory Amino Acid Agonists affects the localization of AIFM1 protein]

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

multiple interactions
increases expression

morin inhibits the reaction [Acetaminophen results in decreased phosphorylation of AKT1 protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists results in decreased phosphorylation of AKT1 protein]; morin inhibits the reaction [Streptozocin results in increased expression of AKT1 mRNA]
morin results in increased expression of AKT1 mRNA

PMID:19201465 PMID:26767949 PMID:28689916 PMID:35414346

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apoptotic peptidase activating factor 1

increases expression

morin results in increased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

amyloid beta precursor protein

multiple interactions

morin affects the reaction [APP protein binds to APP protein]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 2

multiple interactions

morin inhibits the reaction [Doxorubicin affects the expression of AQP2 protein]

NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468

G

androgen receptor

decreases expression
multiple interactions

morin results in decreased expression of AR mRNA
morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in increased expression of AR mRNA]

PMID:24726691 PMID:35900689

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in increased expression of BAX mRNA]; morin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; morin inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX protein]; morin inhibits the reaction [Doxorubicin affects the expression of BAX protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; morin inhibits the reaction [Streptozocin results in increased expression of BAX mRNA]; morin inhibits the reaction [titanium dioxide results in increased expression of BAX mRNA]
morin results in increased expression of BAX mRNA

PMID:19201465 PMID:19931519 PMID:26767949 PMID:28689916 PMID:28844848 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

multiple interactions

morin inhibits the reaction [Ifosfamide results in increased activity of BCHE protein]

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

morin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein]; morin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; morin inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; morin inhibits the reaction [Streptozocin results in increased expression of BCL2 mRNA]; morin inhibits the reaction [titanium dioxide results in decreased expression of BCL2 mRNA]
morin results in decreased expression of BCL2 mRNA

PMID:19931519 PMID:26767949 PMID:28689916 PMID:28844848 PMID:31100273 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression
multiple interactions

morin results in decreased expression of BCL2L1 mRNA
morin inhibits the reaction [Streptozocin results in increased expression of BCL2L1 mRNA]

PMID:28689916 PMID:35414346

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

brain-derived neurotrophic factor

multiple interactions

morin inhibits the reaction [Ifosfamide results in increased expression of BDNF mRNA]; morin inhibits the reaction [Streptozocin results in increased expression of BDNF mRNA]

PMID:31722249 PMID:35414346

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 2

decreases expression

morin results in decreased expression of BIRC2 mRNA

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

decreases expression

morin results in decreased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

decreases expression

morin results in decreased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

multiple interactions
increases activity

morin inhibits the reaction [Acetaminophen results in increased activity of CASP3 protein]; morin inhibits the reaction [Acetaminophen results in increased cleavage of CASP3 protein]; morin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 protein]; morin inhibits the reaction [Ifosfamide results in increased activity of CASP3 protein]; morin inhibits the reaction [Streptozocin results in increased expression of CASP3 mRNA]; morin inhibits the reaction [titanium dioxide results in increased expression of CASP3 mRNA]
morin results in increased activity of CASP3 protein

PMID:19931519 PMID:24726691 PMID:26767949 PMID:28844848 PMID:31722249 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity

morin results in increased activity of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 9

multiple interactions

morin inhibits the reaction [Acetaminophen results in increased activity of CASP9 protein]; morin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP9 protein]

PMID:19931519 PMID:26767949

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in decreased activity of CAT protein]]; morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased activity of CAT protein]; morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in decreased activity of CAT protein]; morin inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]; morin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists results in decreased activity of CAT protein]; morin inhibits the reaction [Freund's Adjuvant results in decreased activity of CAT protein]; morin inhibits the reaction [Ifosfamide results in decreased activity of CAT protein]; morin inhibits the reaction [Streptozocin results in decreased activity of CAT protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in decreased activity of CAT protein]]

PMID:19201465 PMID:24854284 PMID:25698669 PMID:26767949 PMID:31100273 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions

[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 protein]]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 protein]]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin B1

decreases expression

morin results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cell division cycle 25C

decreases expression

morin results in decreased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cyclin-dependent kinase 1

decreases expression

morin results in decreased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase inhibitor 1A

increases expression

morin results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

checkpoint kinase 2

decreases expression

morin results in decreased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

collagen type II alpha 1 chain

multiple interactions

2-chloro-5-nitrobenzanilide inhibits the reaction [morin inhibits the reaction [COL2A1 protein results in increased expression of FASN mRNA]]; morin inhibits the reaction [COL2A1 protein results in increased expression of FASN mRNA]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

ceruloplasmin

multiple interactions

[Indomethacin co-treated with morin] inhibits the reaction [Freund's Adjuvant results in increased expression of CP protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of CP protein]

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cathepsin D

multiple interactions

[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased activity of CTSD protein]; morin inhibits the reaction [Freund's Adjuvant results in increased activity of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cytochrome c, somatic

multiple interactions

morin inhibits the reaction [Diethylnitrosamine results in decreased expression of CYCS protein]; morin inhibits the reaction [Streptozocin results in increased expression of CYCS mRNA]

PMID:19931519 PMID:35414346

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

morin affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]
morin results in increased expression of CYP1A1 mRNA; morin results in increased expression of CYP1A1 protein
AHR gene mutant form inhibits the reaction [morin results in increased expression of CYP1A1 mRNA]

PMID:20930378 PMID:29584932

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

diablo, IAP-binding mitochondrial protein

increases expression

morin results in increased expression of DIABLO mRNA

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

iodothyronine deiodinase 1

decreases activity

morin results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 3

decreases activity

morin results in decreased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

eukaryotic translation initiation factor 2A

multiple interactions

[morin co-treated with 1,2-Dimethylhydrazine] results in increased phosphorylation of EIF2A protein

NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
increases phosphorylation

[1,2-Dimethylhydrazine co-treated with morin] results in increased expression of EIF2AK3 protein
morin results in increased phosphorylation of EIF2AK3 protein

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

Fas associated via death domain

increases expression

morin results in increased expression of FADD mRNA

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

Fas cell surface death receptor

multiple interactions

morin inhibits the reaction [titanium dioxide results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

increases expression

morin results in increased expression of FASLG mRNA

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

multiple interactions

2-chloro-5-nitrobenzanilide inhibits the reaction [morin inhibits the reaction [COL2A1 protein results in increased expression of FASN mRNA]]; morin inhibits the reaction [COL2A1 protein results in increased expression of FASN mRNA]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

morin inhibits the reaction [Ifosfamide results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

multiple interactions

morin inhibits the reaction [titanium dioxide results in increased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

glial fibrillary acidic protein

multiple interactions

morin inhibits the reaction [Ifosfamide results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutamic--pyruvic transaminase

multiple interactions

morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased activity of GPT protein]; morin inhibits the reaction [Doxorubicin results in increased activity of GPT protein]

PMID:24854284 PMID:31100273

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in decreased activity of GPX1 protein]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

multiple interactions

[1,2-Dimethylhydrazine co-treated with morin] results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glycogen synthase kinase 3 beta

multiple interactions

morin inhibits the reaction [Acetaminophen results in decreased phosphorylation of GSK3B protein]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of GSK3B protein modified form]

PMID:19931519 PMID:26767949

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions

morin inhibits the reaction [Streptozocin results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

heme oxygenase 1

multiple interactions

[1,2-Dimethylhydrazine co-treated with morin] results in increased expression of HMOX1 mRNA; morin inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 protein]

PMID:26767949 PMID:32028820

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interferon gamma

multiple interactions

morin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in decreased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 17A

multiple interactions

[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA]

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

multiple interactions

morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of IL1B mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]]; morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in increased expression of IL1B mRNA]; morin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]]

PMID:22698256 PMID:25698669 PMID:31100273 PMID:35900689

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of IL6 mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 mRNA]

PMID:22698256 PMID:25698669

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of INS1 protein]; morin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]

PMID:24854284 PMID:35414346

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

iodotyrosine deiodinase

multiple interactions

morin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of JUN mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of JUN mRNA]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions

morin inhibits the reaction [titanium dioxide results in decreased expression of KIT mRNA]

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

keratin 1

multiple interactions

morin inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]

NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844

G

leptin

multiple interactions

morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of LEP protein]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

luteinizing hormone subunit beta

multiple interactions

morin inhibits the reaction [titanium dioxide results in increased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

mitogen activated protein kinase 1

multiple interactions

morin inhibits the reaction [Excitatory Amino Acid Agonists results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

morin inhibits the reaction [Excitatory Amino Acid Agonists results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

morin inhibits the reaction [Ifosfamide results in increased activity of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

microsomal glutathione S-transferase 1

multiple interactions

[1,2-Dimethylhydrazine co-treated with morin] results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

matrix metallopeptidase 2

multiple interactions

morin inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions
decreases expression

morin inhibits the reaction [Diethylnitrosamine results in increased expression of MMP9 protein]
morin results in decreased expression of MMP9 mRNA

PMID:16304905 PMID:19539802

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

increases expression

morin results in increased expression of MTOR mRNA

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFE2 like bZIP transcription factor 2

multiple interactions

[1,2-Dimethylhydrazine co-treated with morin] affects the localization of NFE2L2 protein; morin inhibits the reaction [Acetaminophen results in decreased expression of and affects the localization of NFE2L2 protein]; morin inhibits the reaction [Acetaminophen results in increased ubiquitination of and results in decreased expression of NFE2L2 protein]; morin inhibits the reaction [Ifosfamide results in decreased expression of NFE2L2 protein]

PMID:26767949 PMID:31722249 PMID:32028820

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 1

multiple interactions

morin inhibits the reaction [Ifosfamide results in increased activity of NOS1 protein]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

multiple interactions

morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of NOS2 mRNA]
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of NOS2 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of NOS2 mRNA]

PMID:22698256 PMID:25698669

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPHS1 adhesion molecule, nephrin

multiple interactions

morin inhibits the reaction [Doxorubicin affects the expression of NPHS1 protein]

NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

morin inhibits the reaction [Acetaminophen results in decreased activity of NQO1 protein]; morin inhibits the reaction [Acetaminophen results in decreased expression of NQO1 protein]
Morin enhances the reaction [Carbon tetrachloride increases expression of Nqo1 mRNA in liver]

CTD
RGD

PMID:26767949 PMID:29307993

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

morin inhibits the reaction [Streptozocin results in increased expression of NTRK2 mRNA]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

poly (ADP-ribose) polymerase 1

increases expression

morin results in increased expression of PARP1 mRNA

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphodiesterase 5A

multiple interactions

morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in increased activity of PDE5A protein]

NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701

G

pyruvate dehydrogenase kinase 1

multiple interactions

morin inhibits the reaction [Diethylnitrosamine results in increased expression of PDK1 protein modified form]

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

PH domain and leucine rich repeat protein phosphatase 2

multiple interactions

morin inhibits the reaction [Acetaminophen results in increased expression of PHLPP2 protein]

NCBI chr19:37,835,125...37,901,804
Ensembl chr19:37,835,125...37,905,513

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta

increases expression

morin results in increased expression of PIK3CB mRNA

NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663

G

peroxisome proliferator-activated receptor gamma

affects localization
affects binding
multiple interactions

morin affects the localization of PPARG protein
morin binds to PPARG protein
2-chloro-5-nitrobenzanilide inhibits the reaction [morin promotes the reaction [PPARG protein binds to SP1 protein]]; morin promotes the reaction [PPARG protein binds to SP1 protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein kinase AMP-activated non-catalytic subunit beta 1

decreases expression

morin results in decreased expression of PRKAB1 mRNA

NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661

G

protein kinase C, epsilon

decreases expression

morin results in decreased expression of PRKCE mRNA

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

phosphatase and tensin homolog

multiple interactions

morin inhibits the reaction [Diethylnitrosamine results in decreased expression of PTEN protein modified form]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein]]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 mRNA]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein]]

PMID:19539802 PMID:25698669

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, non-receptor type 1

decreases activity

morin results in decreased activity of PTPN1 protein

NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of RELA mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA protein]]; morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in increased expression of RELA protein]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of RELA mRNA]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of RELA protein]; morin inhibits the reaction [Diethylnitrosamine results in increased localization of RELA protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists affects the localization of and results in increased activity of RELA protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA protein]]

PMID:19201465 PMID:19539802 PMID:25698669 PMID:35900689

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S6 kinase B1

increases expression

morin results in increased expression of RPS6KB1 mRNA

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

solute carrier family 16 member 1

multiple interactions

morin inhibits the reaction [SLC16A1 protein results in increased uptake of Benzoic Acid]
[morin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate

PMID:17108059 PMID:17976262

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

superoxide dismutase 1

multiple interactions

morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

Sp1 transcription factor

multiple interactions

2-chloro-5-nitrobenzanilide inhibits the reaction [morin promotes the reaction [PPARG protein binds to SP1 protein]]; morin promotes the reaction [PPARG protein binds to SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

steroidogenic acute regulatory protein

multiple interactions

morin inhibits the reaction [titanium dioxide results in decreased expression of STAR mRNA]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

transforming growth factor, beta 1

multiple interactions

morin inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; morin inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of TNF mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
[Indomethacin co-treated with morin] inhibits the reaction [Freund's Adjuvant results in increased expression of TNF mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein]]; morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in increased expression of TNF mRNA]; morin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein]; morin inhibits the reaction [Ifosfamide results in increased expression of TNF protein]; morin inhibits the reaction [titanium dioxide results in increased expression of TNF protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein]]

PMID:22698256 PMID:24854284 PMID:25698669 PMID:28844848 PMID:31100273 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 25

increases expression

morin results in increased expression of TNFRSF25 mRNA

NCBI chr 5:162,621,669...162,626,341
Ensembl chr 5:162,622,075...162,626,341

G

TNF superfamily member 11

multiple interactions

[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of TNFSF11 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNFSF11 mRNA]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

tumor protein p53

increases expression
multiple interactions

morin results in increased expression of TP53 mRNA
morin inhibits the reaction [Ifosfamide results in increased expression of TP53 protein]

PMID:28689916 PMID:31722249

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin reductase 1

multiple interactions

[1,2-Dimethylhydrazine co-treated with morin] results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation
decreases activity
multiple interactions

UGT1A1 protein results in increased glucuronidation of morin
morin results in decreased activity of UGT1A1 protein
AHR gene mutant form inhibits the reaction [morin results in increased expression of UGT1A1 mRNA]

PMID:14557274 PMID:29584932 PMID:35063619

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

decreases activity

morin results in decreased activity of UGT1A3 protein

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glycosyltransferase 1 family, polypeptide A3

multiple interactions

[1,2-Dimethylhydrazine co-treated with morin] results in increased expression of UGT1A5 mRNA

NCBI chr 9:88,780,328...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

decreases activity

morin results in decreased activity of UGT1A6 protein

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation
decreases activity

UGT1A9 protein results in increased glucuronidation of morin
morin results in decreased activity of UGT1A9 protein

PMID:14557274 PMID:35063619

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

decreases activity

morin results in decreased activity of UGT2B7 protein

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

G

vascular endothelial growth factor A

multiple interactions

Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of VEGFA protein]]; morin inhibits the reaction [[bisphenol S co-treated with diethyl phthalate] results in increased expression of VEGFA mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of VEGFA protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of VEGFA protein]]

PMID:25698669 PMID:35900689

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

WEE1 G2 checkpoint kinase

increases expression

morin results in increased expression of WEE1 mRNA

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

oltipraz

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

oltipraz results in decreased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases expression

oltipraz results in increased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

multiple interactions

[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC1 protein

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions
increases expression

[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC2 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA
oltipraz results in increased expression of ABCC2 mRNA; oltipraz results in increased expression of ABCC2 protein

PMID:12920174 PMID:15833929 PMID:16837569 PMID:18032408 PMID:25752797 More...

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression
multiple interactions

oltipraz results in increased expression of ABCC3 mRNA
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA]
[oltipraz results in increased expression of ABCC3 protein] which affects the export of Acetaminophen metabolite
oltipraz results in increased expression of ABCC3 mRNA; oltipraz results in increased expression of ABCC3 protein

PMID:12920174 PMID:15833929 PMID:16837569 PMID:22496397 PMID:30114225

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

multiple interactions
increases expression

[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC4 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA]
oltipraz results in increased expression of ABCC4 mRNA; oltipraz results in increased expression of ABCC4 protein
oltipraz promotes the reaction [ABCC4 protein results in increased transport of Arsenic]

PMID:15833929 PMID:18032408 PMID:20395535 PMID:22496397 PMID:25752797

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily C member 5

multiple interactions
increases expression

[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC5 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA
oltipraz results in increased expression of ABCC5 mRNA

PMID:15833929 PMID:18032408

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 6

multiple interactions
increases expression

[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA
oltipraz results in increased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily G member 2

multiple interactions
increases expression
increases activity

oltipraz promotes the reaction [ABCG2 protein results in increased transport of Benzo(a)pyrene metabolite]
oltipraz results in increased expression of ABCG2 mRNA
oltipraz results in increased activity of ABCG2 protein

PMID:15917307 PMID:16837569

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

multiple interactions

[oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

angiotensin I converting enzyme

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

angiotensinogen

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

multiple interactions
increases activity

[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA]
oltipraz results in increased activity of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldo-keto reductase family 7 member A3

increases activity

oltipraz results in increased activity of AKR7A3 protein

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

albumin

decreases expression

oltipraz results in decreased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions
increases expression

[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA]

PMID:17998271 PMID:22496397

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Lithocholic Acid co-treated with oltipraz] results in increased expression of BAX mRNA
oltipraz inhibits the reaction [Acetaminophen results in increased expression of BAX protein]

PMID:19433268 PMID:33959992

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl2-like 1

multiple interactions

[Lithocholic Acid co-treated with oltipraz] results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 3

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CCAAT/enhancer binding protein beta

multiple interactions

[Dexamethasone co-treated with oltipraz] results in increased activity of CEBPB protein; N-acetylsphingosine inhibits the reaction [oltipraz results in increased localization of CEBPB protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter]; oltipraz results in increased localization of and results in increased activity of CEBPB protein

PMID:12509401 PMID:15319326 PMID:15870285

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

carboxylesterase 1D

increases expression
multiple interactions

oltipraz results in increased expression of CES1 mRNA
NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA]

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2C

increases expression
multiple interactions

oltipraz results in increased expression of CES2C mRNA
NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA]

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
affects metabolic processing
decreases activity
affects activity

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA]; 2-aminoethoxydiphenyl borate inhibits the reaction [[oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA]; [oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; [oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; oltipraz results in increased expression of and results in increased activity of CYP1A1 protein; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA]
CYP1A1 protein affects the metabolism of oltipraz
oltipraz results in increased expression of CYP1A1 mRNA; oltipraz results in increased expression of CYP1A1 protein
oltipraz metabolite results in decreased activity of CYP1A1 protein
oltipraz affects the activity of CYP1A1 protein

PMID:10775323 PMID:11959854 PMID:15831204 PMID:15890477 PMID:15920769

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity
increases expression
multiple interactions
increases activity
affects metabolic processing

oltipraz metabolite results in decreased activity of CYP1A2 protein; oltipraz results in decreased activity of CYP1A2 protein
oltipraz results in increased expression of CYP1A2 mRNA
NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA]
oltipraz results in increased activity of CYP1A2 protein
oltipraz inhibits the reaction [CYP1A2 results in increased activity of 2-amino-3,4-dimethylimidazo(4,5-f)quinoline]
CYP1A2 protein affects the metabolism of oltipraz

PMID:8625305 PMID:10775323 PMID:15831204 PMID:15920769 PMID:22496397

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity
affects activity
increases expression

oltipraz metabolite results in decreased activity of CYP1B1 protein
oltipraz affects the activity of CYP1B1 protein
oltipraz results in increased expression of CYP1B1 mRNA

PMID:10775323 PMID:15890477

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 1

affects metabolic processing

CYP2B1 protein affects the metabolism of oltipraz

PMID:15831204 PMID:15920769

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

affects metabolic processing

CYP2B2 protein affects the metabolism of oltipraz

PMID:15831204 PMID:15920769

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity
increases expression

oltipraz results in decreased activity of CYP2B6 protein
oltipraz results in increased expression of CYP2B10 mRNA
oltipraz results in increased expression of CYP2B6 mRNA; oltipraz results in increased expression of CYP2B6 protein

PMID:17627975 PMID:19833192

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

affects metabolic processing

CYP2C11 protein affects the metabolism of oltipraz

PMID:15831204 PMID:15920769

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily d, polypeptide 1

affects metabolic processing

CYP2D1 protein affects the metabolism of oltipraz

PMID:15831204 PMID:15920769

NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084

G

cytochrome P450, family 2, subfamily e, polypeptide 1

affects activity

oltipraz affects the activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects metabolic processing
decreases activity
affects activity

CYP3A2 protein affects the metabolism of oltipraz
oltipraz metabolite results in decreased activity of CYP3A4 protein; oltipraz results in decreased activity of CYP3A4 protein
oltipraz affects the activity of CYP3A4 protein

PMID:10775323 PMID:15831204 PMID:15920769 PMID:19833192

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

affects metabolic processing

CYP3A23-3A1 protein affects the metabolism of oltipraz

PMID:15831204 PMID:15920769

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

glutamic-oxaloacetic transaminase 1

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in increased activity of GOT1 protein]

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 3

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in decreased activity of GPX3 protein]

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

glutathione S-transferase alpha 1

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in decreased expression of and results in increased secretion of GSTA1 protein]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 mRNA]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 protein]

PMID:31385618 PMID:33959992

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 2

increases expression
multiple interactions

oltipraz results in increased expression of GSTA2 mRNA; oltipraz results in increased expression of GSTA2 protein
2-tert-butylhydroquinone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; N-acetylsphingosine inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter]

PMID:9203627 PMID:12242683 PMID:12509401 PMID:15155840 PMID:15319326 More...

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 3

increases expression

oltipraz results in increased expression of GSTA3 mRNA; oltipraz results in increased expression of GSTA3 protein

PMID:9203627 PMID:9794803

NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240

G

glutathione S-transferase alpha 5

increases activity
increases expression

oltipraz results in increased activity of GSTA5 protein
oltipraz results in increased expression of GSTA5 mRNA; oltipraz results in increased expression of GSTA5 protein

PMID:8051171 PMID:8625305 PMID:9203627 PMID:9328168

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase mu 1

multiple interactions
increases expression

[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA]

PMID:9203627 PMID:18723825 PMID:22496397

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

multiple interactions
increases expression

[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA]

PMID:18723825 PMID:22496397

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase mu 4

multiple interactions
increases expression

[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA]

PMID:18723825 PMID:22496397

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

glutathione S-transferase, mu 5

multiple interactions
increases expression

[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA]
oltipraz results in increased expression of GSTM3 protein

PMID:9794803 PMID:18723825 PMID:22496397

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase pi 1

increases expression
multiple interactions

oltipraz results in increased expression of GSTP1 mRNA
oltipraz results in increased expression of GSTP1 protein
oltipraz results in increased expression of and results in increased activity of GSTP1 protein

PMID:9794803 PMID:15374950 PMID:16950796

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

affects localization
increases expression

oltipraz affects the localization of GSTT1 protein
oltipraz results in increased expression of GSTT1 protein

PMID:9794803 PMID:9855024 PMID:10413528

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

HNF1 homeobox A

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in decreased expression of HNF1A mRNA]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of HNF1A protein]

PMID:31385618 PMID:33959992

NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104

G

insulin 2

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

involucrin

decreases expression

oltipraz results in decreased expression of IVL protein

NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in increased phosphorylation of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

mitogen-activated protein kinase 8

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions

[Lithocholic Acid co-treated with oltipraz] results in increased expression of MCL1 mRNA

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

O-6-methylguanine-DNA methyltransferase

increases expression
multiple interactions

oltipraz results in increased expression of MGMT mRNA
oltipraz results in increased expression of and results in increased activity of MGMT protein

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

microsomal glutathione S-transferase 3

multiple interactions
increases expression

[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA
oltipraz results in increased expression of MGST3 mRNA

PMID:18723825 PMID:22496397

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411

G

NFE2 like bZIP transcription factor 2

affects activity
multiple interactions
increases activity
affects response to substance

oltipraz affects the activity of NFE2L2 protein
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]
oltipraz results in increased activity of NFE2L2 protein
[oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B35 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES1G mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of SULT3A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT1A6A mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B36 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz binds to and results in increased activity of NFE2L2 protein; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]
NFE2L2 protein affects the susceptibility to oltipraz

PMID:11309284 PMID:15833929 PMID:15919853 PMID:19150646 PMID:20086057 More...

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

increases activity
multiple interactions
increases expression

oltipraz results in increased activity of NQO1 protein
oltipraz promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA]
oltipraz metabolite results in increased expression of NQO1 protein; oltipraz results in increased expression of NQO1 mRNA; oltipraz results in increased expression of NQO1 protein
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NQO1 mRNA]

PMID:11309284 PMID:12407167 PMID:15919853 PMID:17627975 PMID:18488193 More...

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

oltipraz inhibits the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein]

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

solute carrier family 10 member 1

decreases expression

oltipraz results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 22 member 7

decreases expression

oltipraz results in decreased expression of SLC22A7 mRNA

NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921

G

solute carrier organic anion transporter family member 1B2

decreases expression

oltipraz results in decreased expression of SLCO1B3 mRNA

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 2b1

increases expression

oltipraz results in increased expression of SLCO2B1 mRNA

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

superoxide dismutase 1

multiple interactions

oltipraz inhibits the reaction [Acetaminophen results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

increases expression

oltipraz results in increased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

thioredoxin reductase 1

increases expression

oltipraz results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

uncoupling protein 2

multiple interactions

oltipraz inhibits the reaction [Doxorubicin results in decreased expression of UCP2 protein]

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

UDP glucuronosyltransferase family 1 member A1

increases expression

oltipraz results in increased expression of UGT1A1 mRNA

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A5

increases expression

oltipraz results in increased expression of UGT1A5 mRNA

NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions
increases expression

oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A6 mRNA]
oltipraz results in increased expression of UGT1A6 mRNA

PMID:15374950 PMID:19144771

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

multiple interactions

oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A7 mRNA]

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member A3

decreases expression

oltipraz results in decreased expression of UGT2A3 mRNA

NCBI chr14:20,572,793...20,590,795
Ensembl chr14:20,572,808...20,590,729

G

UDP glucuronosyltransferase 2 family, polypeptide B1

decreases expression
multiple interactions

oltipraz results in decreased expression of UGT2B1 mRNA
[oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA

PMID:19144771 PMID:22496397

NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986

G

UDP glucuronosyltransferase family 2 member B7

increases expression
multiple interactions

oltipraz results in increased expression of UGT2B34 mRNA
NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA]

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

panobinostat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin-like 1

decreases expression

Panobinostat results in decreased expression of OVOS2 mRNA

NCBI chr 4:161,815,111...161,857,286
Ensembl chr 4:161,814,708...161,857,343

G

4-aminobutyrate aminotransferase

increases expression
multiple interactions

panobinostat results in increased expression of ABAT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA

PMID:26272509 PMID:27188386

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily A member 5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA
panobinostat results in decreased expression of ABCA5 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976

G

ATP binding cassette subfamily G member 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

abhydrolase domain containing 14A

decreases expression
multiple interactions

panobinostat results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:107,079,139...107,089,004
Ensembl chr 8:107,079,144...107,086,985

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA

NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065

G

acyl-CoA dehydrogenase family, member 11

increases expression

panobinostat results in increased expression of ACAD11 mRNA

NCBI chr 8:104,681,346...104,746,559
Ensembl chr 8:104,681,396...104,746,560

G

atypical chemokine receptor 3

increases expression
multiple interactions

panobinostat results in increased expression of ACKR3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237

G

acid phosphatase 3

increases expression
multiple interactions

Panobinostat results in increased expression of ACP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236

G

acyl-CoA synthetase long-chain family member 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA
panobinostat results in increased expression of ACSL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

acyl-CoA synthetase medium-chain family member 3

increases expression

panobinostat results in increased expression of ACSM3 mRNA

NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184

G

actin alpha 2, smooth muscle

decreases expression

Panobinostat results in decreased expression of ACTA2 mRNA

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adenosine deaminase

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA
panobinostat results in decreased expression of ADA mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

ADAM metallopeptidase domain 12

decreases expression
multiple interactions

panobinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667

G

ADAM metallopeptidase domain 22

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA
panobinostat results in decreased expression of ADAM22 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962

G

ADAM metallopeptidase domain 28

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA
panobinostat results in increased expression of ADAM28 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:43,774,463...43,840,726
Ensembl chr15:42,944,467...43,840,672

G

ADAM metallopeptidase with thrombospondin type 1 motif, 15

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA
panobinostat results in increased expression of ADAMTS15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249

G

ADAM metallopeptidase with thrombospondin type 1 motif, 17

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA

NCBI chr 1:120,445,800...120,768,204
Ensembl chr 1:120,445,749...120,768,202

G

ADAM metallopeptidase with thrombospondin type 1 motif, 19

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA
panobinostat results in increased expression of ADAMTS19 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:52,346,448...52,531,245
Ensembl chr18:52,347,428...52,530,509

G

adenylate cyclase activating polypeptide 1

increases expression
multiple interactions

panobinostat results in increased expression of ADCYAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773

G

ADCYAP receptor type I

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA
panobinostat results in increased expression of ADCYAP1R1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700

G

adhesion G protein-coupled receptor G1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA
panobinostat results in decreased expression of ADGRG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

adhesion G protein-coupled receptor G6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA

NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123

G

adhesion G protein-coupled receptor L3

decreases expression
multiple interactions

panobinostat results in decreased expression of ADGRL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860

G

adhesion G protein-coupled receptor V1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA
panobinostat results in decreased expression of ADGRV1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:11,331,434...11,911,713
Ensembl chr 2:11,331,442...11,911,688

G

adrenoceptor alpha 2A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

actin filament associated protein 1-like 1

increases expression
multiple interactions

panobinostat results in increased expression of AFAP1L1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:55,183,786...55,244,174
Ensembl chr18:55,183,786...55,244,146

G

AHNAK nucleoprotein

increases expression
multiple interactions

panobinostat results in increased expression of AHNAK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

adherens junctions associated protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA
panobinostat results in increased expression of AJAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317

G

A-kinase anchoring protein 12

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA
panobinostat results in decreased expression of AKAP12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

AKT serine/threonine kinase 1

multiple interactions

[Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

activated leukocyte cell adhesion molecule

increases expression
multiple interactions

panobinostat results in increased expression of ALCAM mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA

PMID:26272509 PMID:27188386

NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954

G

aldehyde dehydrogenase 1 family, member A2

decreases expression
multiple interactions

panobinostat results in decreased expression of ALDH1A2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107

G

aldehyde dehydrogenase 1 family, member A3

increases expression
multiple interactions

panobinostat results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436

G

aldehyde dehydrogenase 1 family, member L2

increases expression
multiple interactions

panobinostat results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776

G

ALK and LTK ligand 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA
panobinostat results in increased expression of ALKAL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:47,495,645...47,505,235
Ensembl chr 6:47,495,782...47,505,234

G

ALX homeobox 1

increases expression
multiple interactions

panobinostat results in increased expression of ALX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:38,157,626...38,177,220
Ensembl chr 7:38,147,117...38,177,220

G

APC membrane recruitment protein 2

increases expression
multiple interactions

panobinostat results in increased expression of AMER2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:34,525,352...34,535,660
Ensembl chr15:34,524,542...34,528,455

G

adhesion molecule with Ig like domain 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA
panobinostat results in increased expression of AMIGO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695

G

angiogenin

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA

NCBI chr15:24,312,711...24,323,361

G

angiopoietin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA
panobinostat results in increased expression of ANGPT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA
panobinostat results in increased expression of ANGPT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

ANKH inorganic pyrophosphate transport regulator

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA
panobinostat results in increased expression of ANKH mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:78,153,027...78,280,181
Ensembl chr 2:78,153,026...78,280,187

G

ankyrin repeat domain 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA
panobinostat results in increased expression of ANKRD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919

G

ankyrin repeat domain 22

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA

NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381

G

ankyrin repeat and sterile alpha motif domain containing 1B

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

anoctamin 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA

NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154

G

anosmin 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA
panobinostat results in decreased expression of KAL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:68,561,954...68,562,801
Ensembl chr10:68,561,954...68,562,801

G

annexin A1

increases expression

panobinostat results in increased expression of ANXA1 mRNA

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A2

increases expression
multiple interactions

panobinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

annexin A3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA
panobinostat results in increased expression of ANXA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

annexin A9

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA

NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374

G

aldehyde oxidase 1

decreases expression
multiple interactions

panobinostat results in decreased expression of AOX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770

G

adaptor related protein complex 1 subunit mu 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA
panobinostat results in increased expression of AP1M2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:19,838,579...19,856,560
Ensembl chr 8:19,838,580...19,856,482

G

adaptor related protein complex 5 subunit sigma 1

decreases expression

Panobinostat results in decreased expression of AP5S1 mRNA

NCBI chr 3:118,429,618...118,432,929
Ensembl chr 3:118,429,637...118,432,926

G

apelin receptor early endogenous ligand

increases expression

Panobinostat results in increased expression of APELA mRNA

NCBI chr16:24,694,356...24,703,466
Ensembl chr16:24,694,324...24,703,465

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2

increases expression
multiple interactions

panobinostat results in increased expression of ARAP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154

G

ARFGEF family member 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA
panobinostat results in decreased expression of ARFGEF3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084

G

Rho GTPase activating protein 15

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA
panobinostat results in decreased expression of ARHGAP15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265

G

Rho GTPase activating protein 18

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA
panobinostat results in increased expression of ARHGAP18 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256

G

Rho GTPase activating protein 24

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA

NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823

G

Rho GTPase activating protein 31

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA]

NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564

G

Rho GTPase activating protein 5

decreases expression
multiple interactions

panobinostat results in decreased expression of ARHGAP5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660

G

Rho GTPase activating protein 6

increases expression
multiple interactions

panobinostat results in increased expression of ARHGAP6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:24,953,464...25,490,003
Ensembl chr X:24,953,464...25,488,663

G

AT-rich interaction domain 2

affects expression
multiple interactions

panobinostat affects the expression of ARID2 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARID2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA]

NCBI chr 7:127,447,192...127,565,987
Ensembl chr 7:127,447,278...127,563,512

G

AT-rich interaction domain 5B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA
panobinostat results in increased expression of ARID5B mRNA

PMID:26272509 PMID:27188386

NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433

G

armadillo-like helical domain containing 4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA
panobinostat results in decreased expression of ARMH4 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:22,975,895...23,076,986
Ensembl chr15:22,975,895...23,076,949

G

aryl hydrocarbon receptor nuclear translocator 2

decreases expression
multiple interactions

panobinostat results in decreased expression of ARNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153

G

arrestin, beta 1

increases expression
multiple interactions

panobinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

aristaless related homeobox

decreases expression
multiple interactions

panobinostat results in decreased expression of ARX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA

PMID:26272509 PMID:27188386

NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142

G

arsenite methyltransferase

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA

NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872

G

ankyrin repeat and SOCS box-containing 9

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA

NCBI chr X:29,956,576...30,001,436
Ensembl chr X:29,956,576...30,001,105

G

achaete-scute family bHLH transcription factor 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA

NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993

G

acid sensing ion channel subunit 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA

NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression
multiple interactions

panobinostat results in increased expression of ASNS mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

argininosuccinate synthase 1

increases expression
multiple interactions

panobinostat results in increased expression of ASS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

astrotactin 1

decreases expression
multiple interactions

panobinostat results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440

G

astrotactin 2

increases expression
multiple interactions

panobinostat results in increased expression of ASTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273

G

activating transcription factor 3

increases expression

panobinostat results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

ATPase 13A4

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA

NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933

G

ATP23 metallopeptidase and ATP synthase assembly factor homolog

increases expression
multiple interactions

panobinostat results in increased expression of ATP23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862

G

ATPase secretory pathway Ca2+ transporting 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA
panobinostat results in increased expression of ATP2C2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:47,754,120...47,811,369
Ensembl chr19:47,754,120...47,811,368

G

ATPase H+ transporting V0 subunit a2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA
panobinostat results in decreased expression of ATP6V0A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:31,947,220...31,979,875
Ensembl chr12:31,822,733...32,007,069

G

ATPase H+ transporting V0 subunit a4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA
panobinostat results in increased expression of ATP6V0A4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110

G

ATPase H+ transporting V0 subunit D2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA
panobinostat results in increased expression of ATP6V0D2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

ATPase phospholipid transporting 8B1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
panobinostat results in increased expression of ATP8B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

ATPase phospholipid transporting 8B3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA
panobinostat results in increased expression of ATP8B3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:9,175,544...9,195,449
Ensembl chr 7:9,175,391...9,195,442

G

ATPase phospholipid transporting 9A (putative)

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA
panobinostat results in decreased expression of ATP9A mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818

G

axin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA
panobinostat results in increased expression of AXIN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA
panobinostat results in increased expression of B3GNT7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170

G

beta-secretase 2

increases expression
multiple interactions

panobinostat results in increased expression of BACE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546

G

BAG cochaperone 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
panobinostat results in increased expression of BAG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721

G

BAG cochaperone 5

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA

NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970

G

BMP and activin membrane-bound inhibitor

increases expression
multiple interactions

panobinostat results in increased expression of BAMBI mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA

PMID:26272509 PMID:27188386

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

basic leucine zipper ATF-like transcription factor 3

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA

NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139

G

BCL2 associated X, apoptosis regulator

multiple interactions

BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

bromodomain adjacent to zinc finger domain, 1A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA
panobinostat results in increased expression of BAZ1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:72,389,701...72,512,516
Ensembl chr 6:72,389,703...72,512,459

G

BCL11 transcription factor A

increases expression
multiple interactions

panobinostat results in increased expression of BCL11A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA

PMID:26272509 PMID:27188386

NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180

G

BCL2, apoptosis regulator

affects expression
decreases expression
multiple interactions

panobinostat affects the expression of BCL2 mRNA
panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA]

PMID:24435446 PMID:26272509 PMID:26733615 PMID:27188386

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

multiple interactions
increases expression
decreases expression

(+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein]
panobinostat results in increased expression of BCL2L11 protein
panobinostat results in decreased expression of BCL2L11 mRNA

PMID:24435446 PMID:26272509 PMID:27188386

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

brain-enriched guanylate kinase-associated

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA
panobinostat results in decreased expression of BEGAIN mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:127,943,651...127,979,876
Ensembl chr 6:127,943,651...127,979,841

G

bestrophin 4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA
panobinostat results in decreased expression of BEST4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:130,622,194...130,629,045
Ensembl chr 5:130,623,438...130,627,099

G

basic helix-loop-helix family, member e40

increases expression
multiple interactions

panobinostat results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

basic helix-loop-helix family, member e41

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA

NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468

G

baculoviral IAP repeat-containing 5

decreases expression

Panobinostat results in decreased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

basic helix-loop-helix ARNT like 2

multiple interactions

[Cisplatin co-treated with Panobinostat] affects the expression of BMAL2 mRNA

NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949

G

Bcl2 modifying factor

increases expression

Panobinostat results in increased expression of BMF mRNA

NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145

G

bone morphogenetic protein 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA
panobinostat results in increased expression of BMP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA
panobinostat results in increased expression of BMP4 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

bone morphogenetic protein 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
panobinostat results in increased expression of BMP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925

G

bone morphogenetic protein 7

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA
panobinostat results in increased expression of BMP7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

BMP-binding endothelial regulator

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA
panobinostat results in increased expression of BMPER mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256

G

bone morphogenetic protein receptor type 1B

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of BMPR1B mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BMPR1B mRNA]

NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368

G

basonuclin zinc finger protein 2

increases expression
multiple interactions

panobinostat results in increased expression of BNC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:98,687,410...99,079,426

G

BCL2 interacting protein like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA
panobinostat results in increased expression of BNIPL mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:182,818,593...182,830,421
Ensembl chr 2:182,818,595...182,828,588

G

BOC cell adhesion associated, oncogene regulated

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA
panobinostat results in increased expression of BOC mRNA

PMID:26272509 PMID:27188386

NCBI chr11:56,122,697...56,198,060
Ensembl chr11:56,122,750...56,198,059

G

Bri3 binding protein

increases expression

panobinostat results in increased expression of BRI3BP mRNA

NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572

G

BMP/retinoic acid inducible neural specific 1

increases expression
multiple interactions

panobinostat results in increased expression of BRINP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:82,348,501...82,550,506
Ensembl chr 5:82,348,930...82,493,150

G

BRCA1 interacting helicase 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA

NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324

G

B-box and SPRY domain containing

increases expression
multiple interactions

panobinostat results in increased expression of BSPRY mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583

G

similar to human chromosome 3 open reading frame 52

increases expression
multiple interactions

panobinostat results in increased expression of C3ORF52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:55,166,986...55,192,273
Ensembl chr11:55,166,678...55,192,292

G

similar to human chromosome 1 open reading frame 53

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA
panobinostat results in decreased expression of C1ORF53 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:50,413,785...50,418,974
Ensembl chr13:50,413,785...50,419,120

G

similar to human chromosome 4 open reading frame 19

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C4ORF19 mRNA

NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,387,393...44,478,041

G

similar to human chromosome 16 open reading frame 87

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA

NCBI chr19:21,626,390...21,653,869
Ensembl chr19:21,626,914...21,654,255

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA
panobinostat results in increased expression of C1GALT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831

G

similar to human chromosome 19 open reading frame 33

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA
Panobinostat results in increased expression of C19ORF33 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:84,549,830...84,550,666
Ensembl chr 1:84,549,831...84,550,664

G

C1q and TNF related 4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA
panobinostat results in decreased expression of C1QTNF4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:76,854,368...76,872,991
Ensembl chr 3:76,857,735...76,874,139

G

C2 calcium-dependent domain containing 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA
panobinostat results in decreased expression of C2CD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739

G

similar to human chromosome 3 open reading frame 33

decreases expression
multiple interactions

panobinostat results in decreased expression of C3ORF33 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:148,376,598...148,404,343
Ensembl chr 2:148,380,581...148,404,387

G

complement C3

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of C3 mRNA

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

similar to human chromosome 11 open reading frame 96

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA
panobinostat results in increased expression of C11ORF96 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:79,920,129...79,921,523

G

similar to human chromosome 2 open reading frame 68

decreases expression
multiple interactions

panobinostat results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:104,402,553...104,408,317
Ensembl chr 4:104,402,588...104,408,320

G

similar to human chromosome 8 open reading frame 34

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA
panobinostat results in increased expression of C8ORF34 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:7,237,968...7,777,119
Ensembl chr 5:7,238,853...7,776,769

G

similar to human chromosome 12 open reading frame 56

increases expression
multiple interactions

panobinostat results in increased expression of C12ORF56 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:57,170,406...57,220,930
Ensembl chr 7:57,170,992...57,220,925

G

similar to human chromosome 11 open reading frame 52

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA

NCBI chr 8:51,081,342...51,088,333
Ensembl chr 8:51,081,342...51,094,533

G

similar to human chromosome 6 open reading frame 141

decreases expression
multiple interactions

panobinostat results in decreased expression of C6ORF141 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:20,024,916...20,029,094
Ensembl chr 9:20,024,916...20,029,094

G

calcium voltage-gated channel auxiliary subunit alpha2delta 1

increases expression
multiple interactions

panobinostat results in increased expression of CACNA2D1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969

G

calcium voltage-gated channel auxiliary subunit beta 2

decreases expression
multiple interactions

panobinostat results in decreased expression of CACNB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106

G

cell adhesion molecule 4

decreases expression
multiple interactions

panobinostat results in decreased expression of CADM4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:80,075,163...80,097,423
Ensembl chr 1:80,075,202...80,097,423

G

calbindin 2

increases expression
multiple interactions

panobinostat results in increased expression of CALB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438

G

calcitonin-related polypeptide alpha

increases expression
multiple interactions

panobinostat results in increased expression of CALCA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calpain 6

decreases expression
multiple interactions

panobinostat results in decreased expression of CAPN6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:107,380,774...107,405,489
Ensembl chr X:107,380,774...107,405,489

G

carbonic anhydrase 12

increases expression
multiple interactions

panobinostat results in increased expression of CA12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440

G

carbonic anhydrase 13

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA

NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525

G

carbonic anhydrase 4

decreases expression
multiple interactions

panobinostat results in decreased expression of CA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501

G

carbonic anhydrase 8

increases expression
multiple interactions

panobinostat results in increased expression of CA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374

G

caspase 3

multiple interactions

[resveratrol co-treated with panobinostat] results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression

[Cisplatin co-treated with Panobinostat] affects the expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [Panobinostat co-treated with Vorinostat] results in increased cleavage of CASP8 protein; [Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein; CASP8 protein affects the susceptibility to [Resveratrol co-treated with Panobinostat]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein]
panobinostat results in increased expression of CASP8 mRNA

PMID:21791302 PMID:22923501 PMID:26272509 PMID:27188386

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

[resveratrol co-treated with panobinostat] results in increased cleavage of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

Cbl proto-oncogene C

increases expression
multiple interactions

panobinostat results in increased expression of CBLC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:79,439,975...79,456,755
Ensembl chr 1:79,439,977...79,456,755

G

coiled-coil and C2 domain containing 2A

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CC2D2A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CC2D2A mRNA]

NCBI chr14:67,349,004...67,435,883
Ensembl chr14:67,351,353...67,435,949

G

coiled-coil domain containing 136

decreases expression
multiple interactions

panobinostat results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:57,997,825...58,027,598
Ensembl chr 4:57,997,853...58,027,646

G

coiled-coil domain containing 177

decreases expression
multiple interactions

panobinostat results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:100,404,526...100,411,112
Ensembl chr 6:100,404,413...100,412,850

G

coiled-coil domain containing 69

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA
panobinostat results in increased expression of CCDC69 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:39,173,282...39,200,358
Ensembl chr10:39,173,282...39,199,878

G

cholecystokinin B receptor

decreases expression
multiple interactions

panobinostat results in decreased expression of CCKBR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881

G

C-C motif chemokine ligand 26

increases expression
multiple interactions

panobinostat results in increased expression of CCL26 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335

G

cellular communication network factor 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA

NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019

G

cyclin G2

decreases expression
multiple interactions

panobinostat results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830

G

cyclin T2

decreases expression
multiple interactions

panobinostat results in decreased expression of CCNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:39,251,573...39,293,172
Ensembl chr13:39,251,573...39,292,019

G

Cd200 molecule

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CD200 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CD200 mRNA]

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

CD24 molecule

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA
panobinostat results in increased expression of CD24 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CD274 molecule

increases expression

Panobinostat results in increased expression of CD274 protein

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD44 molecule

increases expression
multiple interactions

panobinostat results in increased expression of CD44 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CD52 molecule

increases expression
multiple interactions

panobinostat results in increased expression of CD52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348

G

CD55 molecule (Cromer blood group)

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA
panobinostat results in increased expression of CD55 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

CD74 molecule

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA
panobinostat results in increased expression of CD74 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

CD9 molecule

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
panobinostat results in increased expression of CD9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222

G

CDC42 effector protein 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA
panobinostat results in decreased expression of CDC42EP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721

G

CDC42 effector protein 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA
panobinostat results in increased expression of CDC42EP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:70,035,921...70,038,990

G

cadherin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
panobinostat results in increased expression of CDH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 10

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA
panobinostat results in increased expression of CDH10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995

G

cadherin 18

increases expression
multiple interactions

panobinostat results in increased expression of CDH18 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:72,818,076...73,820,144
Ensembl chr 2:73,345,005...73,820,138

G

cadherin 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA
panobinostat results in decreased expression of CDH2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cadherin 3

increases expression
multiple interactions

panobinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084

G

cadherin 8

decreases expression
multiple interactions

panobinostat results in decreased expression of CDH8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:5,494,038...5,901,810
Ensembl chr19:5,494,174...5,895,669

G

cyclin-dependent kinase 19

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA

NCBI chr20:43,770,409...43,910,629
Ensembl chr20:43,770,409...43,910,628

G

cyclin-dependent kinase 5 regulatory subunit 1

decreases expression

Panobinostat results in decreased expression of CDK5R1 mRNA

NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456

G

cyclin-dependent kinase 6

multiple interactions
increases expression

[(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of CDK6 protein; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA
panobinostat results in increased expression of CDK6 mRNA

PMID:24435446 PMID:26272509 PMID:27188386

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase inhibitor 1A

increases expression

panobinostat results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

panobinostat results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cell adhesion associated, oncogene regulated

increases expression
multiple interactions

panobinostat results in increased expression of CDON mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033

G

CCAAT/enhancer binding protein beta

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA
panobinostat results in increased expression of CEBPB mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein delta

increases expression
multiple interactions

panobinostat results in increased expression of CEBPD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA

PMID:26272509 PMID:27188386

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

CUGBP, Elav-like family member 5

decreases expression
multiple interactions

panobinostat results in decreased expression of CELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322

G

centrosomal protein 85-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
panobinostat results in increased expression of CEP85L mRNA

PMID:26272509 PMID:27188386

NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516

G

cilia and flagella associated protein 91

decreases expression
multiple interactions

Panobinostat results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:62,413,613...62,457,281
Ensembl chr11:62,413,602...62,457,293

G

cilia and flagella associated protein 95

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA

NCBI chr 1:221,123,786...221,242,963
Ensembl chr 1:221,131,813...221,242,963

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

cingulin-like 1

increases expression
multiple interactions

panobinostat results in increased expression of CGNL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:72,273,401...72,424,842
Ensembl chr 8:72,275,645...72,422,917

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

increases expression

panobinostat results in increased expression of CHAC1 mRNA

NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526

G

chromogranin A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA
panobinostat results in increased expression of CHGA mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398

G

chondrolectin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
panobinostat results in increased expression of CHODL mRNA

PMID:26272509 PMID:27188386

NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441

G

cholinergic receptor, muscarinic 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA
panobinostat results in increased expression of CHRM3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

carbohydrate sulfotransferase 15

increases expression
multiple interactions

panobinostat results in increased expression of CHST15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:187,028,970...187,107,707

G

carbohydrate sulfotransferase 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA
panobinostat results in increased expression of CHST4 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:37,993,471...38,002,123
Ensembl chr19:37,991,417...38,003,608

G

chondroitin sulfate synthase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA
panobinostat results in increased expression of CHSY1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:119,689,626...119,750,711
Ensembl chr 1:119,686,350...119,750,601

G

ciliary microtubule associated protein 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA

NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:193,475,782...193,493,139

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA
panobinostat results in increased expression of CITED2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

claudin 1

increases expression

panobinostat results in increased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 23

increases expression
multiple interactions

panobinostat results in increased expression of CLDN23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:56,413,677...56,415,401
Ensembl chr16:56,413,381...56,415,523

G

claudin 4

increases expression
multiple interactions

panobinostat results in increased expression of CLDN4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436

G

claudin 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA
panobinostat results in increased expression of CLDN6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:12,710,302...12,713,987
Ensembl chr10:12,709,960...12,715,973

G

claudin 7

increases expression
multiple interactions

panobinostat results in increased expression of CLDN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171

G

calmegin

decreases expression
multiple interactions

panobinostat results in decreased expression of CLGN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA

PMID:26272509 PMID:27188386

NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758

G

chloride intracellular channel 6

increases expression
multiple interactions

panobinostat results in increased expression of CLIC6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:31,737,813...31,780,360
Ensembl chr11:31,737,813...31,780,061

G

cleavage factor polyribonucleotide kinase subunit 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA

NCBI chr 3:69,806,774...69,818,633
Ensembl chr 3:69,806,778...69,810,421

G

calsyntenin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA
panobinostat results in increased expression of CLSTN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731

G

collectrin, amino acid transport regulator

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA
panobinostat results in decreased expression of CLTRN mRNA

PMID:26272509 PMID:27188386

NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349

G

clusterin

increases expression
multiple interactions

panobinostat results in increased expression of CLU mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA

PMID:26272509 PMID:27188386

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

connector enhancer of kinase suppressor of Ras 2

decreases expression
multiple interactions

panobinostat results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555

G

chondromodulin

increases expression
multiple interactions

panobinostat results in increased expression of CNMD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA

PMID:26272509 PMID:27188386

NCBI chr15:55,041,548...55,066,297
Ensembl chr15:55,041,561...55,066,297

G

CCR4-NOT transcription complex, subunit 4

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA

NCBI chr 4:63,712,770...63,814,355
Ensembl chr 4:63,712,770...63,814,360

G

cannabinoid receptor interacting protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA
panobinostat results in increased expression of CNRIP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:91,462,877...91,492,739
Ensembl chr14:91,462,647...91,492,735

G

contactin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA
panobinostat results in increased expression of CNTN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541

G

contactin 2

decreases expression
multiple interactions

panobinostat results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:43,942,868...43,975,973
Ensembl chr13:43,947,265...43,975,887

G

cordon-bleu WH2 repeat protein

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA
panobinostat results in increased expression of COBL mRNA

PMID:26272509 PMID:27188386

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800

G

cordon-bleu WH2 repeat protein-like 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA
panobinostat results in increased expression of COBLL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194

G

collagen type XI alpha 1 chain

increases expression

panobinostat results in increased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XIV alpha 1 chain

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA
panobinostat results in increased expression of COL14A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214

G

collagen type I alpha 1 chain

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
panobinostat results in increased expression of COL1A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type XXIII alpha 1 chain

increases expression
multiple interactions

panobinostat results in increased expression of COL23A1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314

G

collagen type V alpha 2 chain

increases expression

panobinostat results in increased expression of COL5A2 mRNA

NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154

G

collagen type V alpha 3 chain

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA
panobinostat results in increased expression of COL5A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853

G

collagen type VI alpha 1 chain

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA
panobinostat results in increased expression of COL6A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597

G

collagen type VI alpha 3 chain

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA
panobinostat results in increased expression of COL6A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471

G

collagen type IX alpha 3 chain

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA
panobinostat results in increased expression of COL9A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465

G

collectin sub-family member 12

increases expression
multiple interactions

panobinostat results in increased expression of COLEC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618

G

collagen beta(1-O)galactosyltransferase 2

decreases expression
multiple interactions

panobinostat results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:64,523,641...64,628,295
Ensembl chr13:64,523,658...64,627,549

G

catechol-O-methyltransferase domain containing 1

increases expression
multiple interactions

panobinostat results in increased expression of COMTD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:2,459,783...2,462,895
Ensembl chr15:2,459,783...2,462,895

G

coronin 2A

increases expression
multiple interactions

panobinostat results in increased expression of CORO2A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035

G

carboxypeptidase E

increases expression
multiple interactions

panobinostat results in increased expression of CPE mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA

PMID:26272509 PMID:27188386

NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233

G

cadherin-like and PC-esterase domain containing 1

increases expression
multiple interactions

panobinostat results in increased expression of CPED1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:50,516,712...50,789,651
Ensembl chr 4:50,516,819...50,788,674

G

copine 4

increases expression
multiple interactions

panobinostat results in increased expression of CPNE4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068

G

carboxypeptidase X (M14 family), member 2

increases expression
multiple interactions

panobinostat results in increased expression of CPXM2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:186,836,797...186,947,222
Ensembl chr 1:186,836,797...186,947,220

G

complement C3b/C4b receptor 1 like

increases expression
multiple interactions

panobinostat results in increased expression of CR1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA

PMID:26272509 PMID:27188386

NCBI chr13:106,606,952...106,660,442
Ensembl chr13:106,574,858...106,660,445

G

complement C3d receptor 2

increases expression
multiple interactions

panobinostat results in increased expression of CR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235

G

cellular retinoic acid binding protein 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA

NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360

G

cellular retinoic acid binding protein 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
panobinostat results in increased expression of CRABP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379

G

cysteine rich protein 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA

NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:132,226,746...132,234,620

G

cripto, EGF-CFC family member

increases expression

Panobinostat results in increased expression of CRIPTO mRNA

NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308

G

cysteine-rich secretory protein LCCL domain containing 1

increases expression
multiple interactions

panobinostat results in increased expression of CRISPLD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:1,267,347...1,314,926
Ensembl chr 5:1,274,647...1,314,926

G

crystallin, beta A1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA
panobinostat results in decreased expression of CRYBA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:62,608,373...62,614,726
Ensembl chr10:62,608,383...62,614,726

G

crystallin, beta A4

decreases expression
multiple interactions

panobinostat results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221

G

crystallin beta-gamma domain containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA
panobinostat results in increased expression of CRYBG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:47,425,030...47,496,918
Ensembl chr20:47,426,183...47,621,392

G

colony stimulating factor 2 receptor subunit alpha

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA

NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128

G

chondroitin sulfate proteoglycan 5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA
panobinostat results in decreased expression of CSPG5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758

G

cysteine and serine rich nuclear protein 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA

NCBI chr 3:50,498,379...50,695,598
Ensembl chr 3:50,498,633...50,685,950

G

collagen triple helix repeat containing 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA

NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756

G

catenin delta 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA
panobinostat results in decreased expression of CTNND2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:81,168,525...82,016,495
Ensembl chr 2:81,167,117...82,015,764

G

cullin 3

decreases expression
multiple interactions

panobinostat results in decreased expression of CUL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462

G

C-X3-C motif chemokine ligand 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA
panobinostat results in increased expression of CX3CL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833

G

C-X-C motif chemokine ligand 12

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA
panobinostat results in increased expression of CXCL12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 14

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA
panobinostat results in increased expression of CXCL14 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

C-X-C motif chemokine receptor 4

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

CXXC finger protein 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA
panobinostat results in increased expression of CXXC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:27,427,591...27,458,579
Ensembl chr18:27,427,230...27,458,673

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA
panobinostat results in increased expression of CYP1A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

panobinostat results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cell cycle regulator of NHEJ

decreases expression

panobinostat results in decreased expression of CYREN mRNA

NCBI chr 4:63,547,311...63,553,394
Ensembl chr 4:63,547,335...63,551,602

G

CYFIP related Rac1 interactor A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA
Panobinostat results in increased expression of CYRIA mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:35,045,208...35,150,669
Ensembl chr 6:35,045,208...35,150,668

G

DAB adaptor protein 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA
panobinostat results in decreased expression of DAB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552

G

dachshund family transcription factor 2

increases expression
multiple interactions

panobinostat results in increased expression of DACH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:78,718,963...79,018,023
Ensembl chr X:78,451,593...79,017,592

G

dishevelled-binding antagonist of beta-catenin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA
panobinostat results in increased expression of DACT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:89,790,676...89,818,254
Ensembl chr 6:89,790,644...89,817,906

G

deleted in azoospermia-like

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
panobinostat results in decreased expression of DAZL mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:10,695,593...10,712,330
Ensembl chr 9:10,695,592...10,712,323

G

DDB1 and CUL4 associated factor 12-like 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA
panobinostat results in decreased expression of DCAF12L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:123,293,761...123,296,550
Ensembl chr X:123,294,744...123,296,156

G

DDB1 and CUL4 associated factor 4

increases expression
multiple interactions

panobinostat results in increased expression of DCAF4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DCC netrin 1 receptor

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA
panobinostat results in increased expression of DCC mRNA

PMID:26272509 PMID:27188386

NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740

G

doublecortin-like kinase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA
panobinostat results in increased expression of DCLK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956

G

doublecortin-like kinase 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA
panobinostat results in decreased expression of DCLK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:172,202,733...172,338,411
Ensembl chr 2:172,208,706...172,338,250

G

defective in cullin neddylation 1 domain containing 4

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA

NCBI chr14:34,652,723...34,733,122
Ensembl chr14:34,652,723...34,733,207

G

DENN domain containing 1A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA
panobinostat results in decreased expression of DENND1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062

G

DENN domain containing 1B

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA
panobinostat results in decreased expression of DENND1B mRNA

PMID:26272509 PMID:27188386

NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601

G

DENN domain containing 2A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA
panobinostat results in decreased expression of DENND2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:68,233,016...68,332,235
Ensembl chr 4:68,233,958...68,332,105

G

DENN domain containing 4A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA
panobinostat results in increased expression of DENND4A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330

G

DEP domain containing 1B

decreases expression

panobinostat results in decreased expression of DEPDC1B mRNA

NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779

G

DEP domain containing 7

increases expression
multiple interactions

panobinostat results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:91,099,835...91,121,124

G

DEP domain containing MTOR-interacting protein

increases expression
multiple interactions

panobinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773

G

dehydrogenase/reductase 3

increases expression
multiple interactions

panobinostat results in increased expression of DHRS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417

G

diaphanous-related formin 2

increases expression
multiple interactions

panobinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:92,395,189...93,234,521
Ensembl chr X:92,395,251...93,229,869

G

divergent protein kinase domain 1C

decreases expression
multiple interactions

panobinostat results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA

PMID:26272509 PMID:27188386

NCBI chr18:78,087,972...78,109,910
Ensembl chr18:78,087,991...78,109,904

G

DLC1 Rho GTPase activating protein

increases expression
multiple interactions

panobinostat results in increased expression of DLC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439

G

delta like non-canonical Notch ligand 1

decreases expression
multiple interactions

panobinostat results in decreased expression of DLK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522

G

distal-less homeobox 3

increases expression
multiple interactions

panobinostat results in increased expression of DLX3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:80,064,489...80,069,891
Ensembl chr10:80,064,489...80,069,872

G

distal-less homeobox 6

decreases expression

panobinostat results in decreased expression of DLX6 mRNA

NCBI chr 4:34,984,264...34,989,926
Ensembl chr 4:34,984,232...34,991,343

G

DMRT-like family A2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA
panobinostat results in increased expression of DMRTA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:124,805,883...124,811,694
Ensembl chr 5:124,805,883...124,811,630

G

Dmx-like 1

increases expression

Panobinostat results in increased expression of DMXL1 mRNA

NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456

G

delta/notch-like EGF repeat containing

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA

NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637

G

dedicator of cytokinesis 5

increases expression
multiple interactions

panobinostat results in increased expression of DOCK5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:41,979,728...42,158,733
Ensembl chr15:41,979,729...42,158,649

G

dedicator of cytokinesis 9

increases expression
multiple interactions

panobinostat results in increased expression of DOCK9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:98,611,518...98,883,306
Ensembl chr15:98,618,084...98,883,153

G

docking protein 5

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA

NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:159,515,893...159,652,810

G

developmental pluripotency associated 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA
panobinostat results in increased expression of DPPA5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:79,215,341...79,217,282
Ensembl chr 8:79,215,362...79,216,570
Ensembl chr 7:79,215,362...79,216,570

G

desmocollin 2

increases expression
multiple interactions

panobinostat results in increased expression of DSC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392

G

dystonin

decreases expression
multiple interactions

panobinostat results in decreased expression of DST mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615

G

DTW domain containing 1

decreases expression

Panobinostat results in decreased expression of DTWD1 mRNA

NCBI chr 3:113,392,402...113,409,322
Ensembl chr 3:113,392,457...113,408,105

G

dual specificity phosphatase 10

increases expression
multiple interactions

panobinostat results in increased expression of DUSP10 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716

G

dual specificity phosphatase 23

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of DUSP23 mRNA

NCBI chr13:85,097,899...85,100,054
Ensembl chr13:85,097,899...85,100,093

G

dual specificity phosphatase 4

decreases expression
multiple interactions

panobinostat results in decreased expression of DUSP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

dual specificity phosphatase 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA
panobinostat results in increased expression of DUSP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

dynein cytoplasmic 1 intermediate chain 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA
panobinostat results in increased expression of DYNC1I1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149

G

dual specificity tyrosine phosphorylation regulated kinase 3

increases expression

Panobinostat results in increased expression of DYRK3 mRNA

NCBI chr13:42,594,120...42,604,898
Ensembl chr13:42,594,121...42,604,778

G

E2F transcription factor 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA
panobinostat results in decreased expression of E2F2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

ELL associated factor 2

increases expression

Panobinostat results in increased expression of EAF2 mRNA

NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610

G

EBF transcription factor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA
panobinostat results in increased expression of EBF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665

G

Epstein-Barr virus induced 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA

NCBI chr 9:774,252...787,544
Ensembl chr 9:783,617...787,544

G

Ecm29 proteasome adaptor and scaffold

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA
panobinostat results in decreased expression of ECPAS mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860

G

endothelin 1

increases expression
multiple interactions

panobinostat results in increased expression of EDN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

increases expression
multiple interactions

panobinostat results in increased expression of EDNRA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA

PMID:26272509 PMID:27188386

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

endothelin receptor type B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
panobinostat results in increased expression of EDNRB mRNA

PMID:26272509 PMID:27188386

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

ephrin A1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
panobinostat results in increased expression of EFNA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

ephrin A5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA
panobinostat results in decreased expression of EFNA5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:102,316,753...102,595,480
Ensembl chr 9:102,320,295...102,597,413

G

epidermal growth factor

decreases expression
multiple interactions

panobinostat results in decreased expression of EGF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

EGF-like-domain, multiple 8

increases expression

panobinostat results in increased expression of EGFL8 mRNA

NCBI chr20:4,132,930...4,136,024
Ensembl chr20:4,133,629...4,136,018

G

eukaryotic translation initiation factor 3, subunit M

decreases expression

panobinostat results in decreased expression of EIF3M mRNA

NCBI chr 3:91,424,754...91,442,358
Ensembl chr 3:91,416,325...91,442,392

G

eukaryotic translation initiation factor 4E family member 3

decreases expression
multiple interactions

panobinostat results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:132,258,502...132,301,808
Ensembl chr 4:132,258,502...132,301,808

G

E74 like ETS transcription factor 1

increases expression
multiple interactions

panobinostat results in increased expression of ELF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:54,890,644...54,986,721
Ensembl chr15:54,865,616...54,986,699

G

E74 like ETS transcription factor 3

increases expression
multiple interactions

panobinostat results in increased expression of ELF3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

E74 like ETS transcription factor 5

increases expression
multiple interactions

panobinostat results in increased expression of ELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973

G

ETS transcription factor ELK3

increases expression
multiple interactions

panobinostat results in increased expression of ELK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084

G

ELMO domain containing 1

increases expression
multiple interactions

panobinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140

G

ELOVL fatty acid elongase 2

decreases expression
multiple interactions

panobinostat results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848

G

elongator acetyltransferase complex subunit 4

decreases expression
multiple interactions

panobinostat results in decreased expression of ELP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:92,162,271...92,385,251
Ensembl chr 3:92,162,280...92,385,243

G

elastin microfibril interfacer 3

decreases expression
multiple interactions

panobinostat results in decreased expression of EMILIN3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:149,558,785...149,564,785
Ensembl chr 3:149,558,970...149,564,785

G

epithelial membrane protein 1

increases expression
multiple interactions

panobinostat results in increased expression of EMP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904

G

ecto-NOX disulfide-thiol exchanger 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA

NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA
panobinostat results in increased expression of ENPP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

EGF domain specific O-linked N-acetylglucosamine transferase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA
panobinostat results in increased expression of EOGT mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:129,718,897...129,756,558
Ensembl chr 4:129,718,901...129,756,445

G

endothelial PAS domain protein 1

increases expression
multiple interactions

panobinostat results in increased expression of EPAS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

erythrocyte membrane protein band 4.1-like 3

increases expression
multiple interactions

panobinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607

G

erythrocyte membrane protein band 4.1 like 5

increases expression
multiple interactions

panobinostat results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360

G

epithelial cell adhesion molecule

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA
panobinostat results in increased expression of EPCAM mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

Eph receptor A1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA

NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846

G

Eph receptor A3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA
panobinostat results in increased expression of EPHA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900

G

Eph receptor A4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA
panobinostat results in decreased expression of EPHA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139

G

Eph receptor A7

increases expression
multiple interactions

panobinostat results in increased expression of EPHA7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112

G

Eph receptor B2

decreases expression
multiple interactions

panobinostat results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059

G

epsin 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA

NCBI chr10:79,438,978...79,449,516
Ensembl chr10:79,438,978...79,447,356

G

EPS8-like 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA

NCBI chr 1:196,446,260...196,471,544
Ensembl chr 1:196,446,287...196,471,541

G

epithelial stromal interaction 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA
panobinostat results in increased expression of EPSTI1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191

G

endoplasmic reticulum aminopeptidase 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA
panobinostat results in decreased expression of ERAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447

G

erb-b2 receptor tyrosine kinase 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
panobinostat results in increased expression of ERBB3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

endoplasmic reticulum protein 27

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA
panobinostat results in increased expression of ERP27 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:169,804,656...169,821,660
Ensembl chr 4:169,804,658...169,821,660

G

epithelial splicing regulatory protein 1

increases expression
multiple interactions

panobinostat results in increased expression of ESRP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062

G

epithelial splicing regulatory protein 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA
panobinostat results in increased expression of ESRP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:34,034,559...34,041,726
Ensembl chr19:34,034,559...34,041,726

G

ethanolamine kinase 1

increases expression
multiple interactions

panobinostat results in increased expression of ETNK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770

G

ETS proto-oncogene 1, transcription factor

increases expression
multiple interactions

panobinostat results in increased expression of ETS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

ETS variant transcription factor 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA
panobinostat results in decreased expression of ETV1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775

G

exostosin glycosyltransferase 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA
panobinostat results in decreased expression of EXT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357

G

ezrin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA
panobinostat results in increased expression of EZR mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505

G

F2R like trypsin receptor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA
panobinostat results in increased expression of F2RL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

coagulation factor II (thrombin) receptor-like 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA
panobinostat results in decreased expression of F2RL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098

G

fatty acid binding protein 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA
panobinostat results in increased expression of FABP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

family with sequence similarity 110, member B

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA

NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828

G

family with sequence similarity 124 member A

decreases expression
multiple interactions

panobinostat results in decreased expression of FAM124A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA

PMID:26272509 PMID:27188386

NCBI chr15:36,799,836...36,855,062
Ensembl chr15:36,799,877...36,853,683

G

family with sequence similarity 13, member C

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA
panobinostat results in increased expression of FAM13C mRNA

PMID:26272509 PMID:27188386

NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592

G

family with sequence similarity 149, member A

decreases expression
multiple interactions

panobinostat results in decreased expression of FAM149A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA

PMID:26272509 PMID:27188386

NCBI chr16:46,855,377...46,914,553
Ensembl chr16:46,854,635...46,912,066

G

family with sequence similarity 163, member A

affects expression
multiple interactions

panobinostat affects the expression of FAM163A mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAM163A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAM163A mRNA]

NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049

G

family with sequence similarity 168, member A

decreases expression
multiple interactions

panobinostat results in decreased expression of FAM168A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220

G

family with sequence similarity 241 member A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA

NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242

G

family with sequence similarity 43, member A

increases expression
multiple interactions

panobinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA

PMID:26272509 PMID:27188386

NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401

G

family with sequence similarity 89, member A

increases expression
multiple interactions

panobinostat results in increased expression of FAM89A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA

PMID:26272509 PMID:27188386

NCBI chr19:52,710,002...52,722,630
Ensembl chr19:52,710,019...52,722,631

G

fibronectin type III and ankyrin repeat domains 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA
panobinostat results in decreased expression of FANK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:188,577,512...188,685,501
Ensembl chr 1:188,577,575...188,685,504

G

FAT atypical cadherin 3

decreases expression
multiple interactions

panobinostat results in decreased expression of FAT3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:12,691,470...13,274,336
Ensembl chr 8:12,694,019...13,273,135

G

failed axon connections homolog, metaxin like GST domain containing

affects expression
multiple interactions

panobinostat affects the expression of FAXC mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAXC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAXC mRNA]

NCBI chr 5:35,480,137...35,539,741
Ensembl chr 5:35,480,402...35,544,446

G

fibulin 7

decreases expression
multiple interactions

panobinostat results in decreased expression of FBLN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:116,111,581...116,145,839
Ensembl chr 3:116,111,677...116,147,983

G

fibrillin 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA
panobinostat results in decreased expression of FBN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

F-box and leucine-rich repeat protein 13

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA

NCBI chr 4:13,414,880...13,607,079
Ensembl chr 4:13,414,926...13,641,494

G

F-box protein 2

increases expression
multiple interactions

panobinostat results in increased expression of FBXO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355

G

F-box protein 8

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FBXO8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FBXO8 mRNA]

NCBI chr16:33,665,305...33,711,215
Ensembl chr16:33,665,306...33,711,272

G

f-box protein 9

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA

NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949

G

FERM domain containing kindlin 1

increases expression
multiple interactions

panobinostat results in increased expression of FERMT1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:120,171,301...120,213,555
Ensembl chr 3:120,171,561...120,213,555

G

fasciculation and elongation protein zeta 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA
panobinostat results in decreased expression of FEZ1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683

G

Fez family zinc finger 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA
panobinostat results in decreased expression of FEZF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:12,768,614...12,777,554
Ensembl chr15:12,773,762...12,777,554

G

FYVE, RhoGEF and PH domain containing 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA
panobinostat results in increased expression of FGD5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:124,497,061...124,594,564
Ensembl chr 4:124,497,068...124,594,563

G

fibroblast growth factor 18

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA

NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818

G

fibroblast growth factor 19

increases expression
multiple interactions

panobinostat results in increased expression of FGF19 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

fibroblast growth factor 8

decreases expression
multiple interactions

panobinostat results in decreased expression of FGF8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359

G

fibroblast growth factor 9

decreases expression
multiple interactions

panobinostat results in decreased expression of FGF9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

fibroblast growth factor binding protein 3

increases expression
multiple interactions

panobinostat results in increased expression of FGFBP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:234,644,023...234,646,028
Ensembl chr 1:234,644,019...234,646,547

G

fibroblast growth factor receptor 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA
panobinostat results in increased expression of FGFR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

formin homology 2 domain containing 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA
panobinostat results in decreased expression of FHOD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:15,993,079...16,425,796
Ensembl chr18:15,993,324...16,425,796

G

fidgetin, microtubule severing factor

affects expression
multiple interactions

panobinostat affects the expression of FIGN mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FIGN mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FIGN mRNA]

NCBI chr 3:48,637,510...48,760,772
Ensembl chr 3:48,642,496...48,760,787

G

four-jointed box kinase 1

decreases expression

panobinostat results in decreased expression of FJX1 mRNA

NCBI chr 3:88,774,220...88,776,321
Ensembl chr 3:88,774,220...88,776,321

G

filamin B

increases expression

panobinostat results in increased expression of FLNB mRNA

NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006

G

fibronectin leucine rich transmembrane protein 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA
panobinostat results in decreased expression of FLRT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785

G

Fms related receptor tyrosine kinase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
panobinostat results in increased expression of FLT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

fibronectin type III domain containing 5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA
panobinostat results in decreased expression of FNDC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731

G

forkhead box C1

increases expression
multiple interactions

panobinostat results in increased expression of FOXC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803

G

forkhead box C2

increases expression
multiple interactions

panobinostat results in increased expression of FOXC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737

G

forkhead box D3

increases expression
multiple interactions

panobinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:114,335,084...114,337,450
Ensembl chr 5:114,335,408...114,336,817

G

forkhead box H1

increases expression
multiple interactions

panobinostat results in increased expression of FOXH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:108,387,969...108,391,566
Ensembl chr 7:108,387,969...108,390,049

G

forkhead box O1

increases expression
multiple interactions

panobinostat results in increased expression of FOXO1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

Fraser extracellular matrix complex subunit 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of FRAS1 mRNA

NCBI chr14:12,791,407...13,200,862
Ensembl chr14:12,793,599...13,200,726

G

Fras1 related extracellular matrix 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA
panobinostat results in increased expression of FREM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:97,321,266...97,469,523
Ensembl chr 5:97,322,538...97,469,543

G

ferric-chelate reductase 1-like

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA
panobinostat results in decreased expression of FRRS1L mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:71,655,911...71,690,132
Ensembl chr 5:71,659,284...71,690,108

G

frizzled-related protein

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA
panobinostat results in decreased expression of FRZB mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208

G

fucosyltransferase 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA
panobinostat results in increased expression of FUT4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682

G

fucosyltransferase 9

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA
panobinostat results in decreased expression of FUT9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:39,351,815...39,565,256
Ensembl chr 5:39,351,819...39,565,130

G

frizzled class receptor 10

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA
panobinostat results in increased expression of FZD10 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566

G

frizzled class receptor 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA
panobinostat results in decreased expression of FZD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334

G

frizzled class receptor 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA
panobinostat results in decreased expression of FZD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:39,421,366...39,488,369
Ensembl chr15:39,421,355...39,488,369

G

frizzled class receptor 5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA
panobinostat results in decreased expression of FZD5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457

G

frizzled class receptor 7

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA
panobinostat results in increased expression of FZD7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781

G

frizzled class receptor 8

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA

NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA
panobinostat results in increased expression of GABRB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit beta 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
panobinostat results in increased expression of GABRB3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961

G

gamma-aminobutyric acid type A receptor subunit pi

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA

NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516

G

glutamate decarboxylase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA
panobinostat results in increased expression of GAD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; Panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45A mRNA]; SRT2183 promotes the reaction [Panobinostat results in increased expression of GADD45A mRNA]
panobinostat results in increased expression of GADD45A mRNA

PMID:23681230 PMID:26272509 PMID:27188386

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

increases expression
multiple interactions

panobinostat results in increased expression of GADD45B mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

multiple interactions
increases expression

GADD45G protein affects the susceptibility to [SRT2183 co-treated with panobinostat]; panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [resveratrol results in increased expression of GADD45G mRNA]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45G mRNA]; resveratrol promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]; SRT2183 promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

polypeptide N-acetylgalactosaminyltransferase 18

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA
panobinostat results in increased expression of GALNT18 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:165,593,180...165,904,268
Ensembl chr 1:165,593,187...165,904,268

G

polypeptide N-acetylgalactosaminyltransferase 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
panobinostat results in increased expression of GALNT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268

G

growth associated protein 43

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA
panobinostat results in increased expression of GAP43 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

golgi associated RAB2 interactor 1B

decreases expression

Panobinostat results in decreased expression of GARIN1B mRNA

NCBI chr 4:57,915,184...57,938,593
Ensembl chr 4:57,920,790...57,938,591

G

growth arrest specific 7

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA
panobinostat results in increased expression of GAS7 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276

G

GATA binding protein 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA
panobinostat results in increased expression of GATA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

GATA binding protein 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
panobinostat results in increased expression of GATA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

GATA binding protein 4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA
panobinostat results in decreased expression of GATA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636

G

GATA binding protein 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA

NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532

G

gastrulation brain homeobox 2

increases expression
multiple interactions

panobinostat results in increased expression of GBX2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:90,509,633...90,512,212
Ensembl chr 9:90,509,633...90,512,212

G

GTP cyclohydrolase I feedback regulator

increases expression
multiple interactions

panobinostat results in increased expression of GCHFR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080

G

growth differentiation factor 10

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA

NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343

G

gap junction protein, alpha 3

increases expression
multiple interactions

panobinostat results in increased expression of GJA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:31,181,360...31,206,820
Ensembl chr15:31,181,369...31,206,810

G

gap junction protein, beta 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA

NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177

G

gap junction protein, epsilon 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of GJE1 mRNA

NCBI chr 1:9,085,789...9,088,204
Ensembl chr 1:9,086,348...9,088,138

G

G kinase anchoring protein 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA
panobinostat results in decreased expression of GKAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:6,383,963...6,423,684
Ensembl chr17:6,383,963...6,423,679

G

galactosidase, beta 1-like

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of GLB1L mRNA

NCBI chr 9:76,693,325...76,705,548
Ensembl chr 9:76,695,173...76,705,510

G

glucocorticoid induced 1

decreases expression
multiple interactions

panobinostat results in decreased expression of GLCCI1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:36,307,956...36,635,614
Ensembl chr 4:36,307,903...36,635,612

G

GLIS family zinc finger 3

decreases expression
multiple interactions

panobinostat results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:225,976,029...226,395,849
Ensembl chr 1:225,976,326...226,395,899

G

glutaredoxin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA
panobinostat results in increased expression of GLRX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:55,481,875...55,504,737
Ensembl chr13:55,482,694...55,492,831

G

glutaminase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA
panobinostat results in increased expression of GLS mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

GNAS complex locus

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA
panobinostat results in increased expression of GNAS mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

G protein subunit gamma 11

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA
panobinostat results in increased expression of GNG11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,023,003...32,028,442

G

G protein subunit gamma 8

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA
panobinostat results in decreased expression of GNG8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371

G

G protein nucleolar 3 like

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA

NCBI chr X:19,961,277...19,994,454
Ensembl chr X:19,958,603...19,994,508

G

glypican 3

decreases expression
multiple interactions

panobinostat results in decreased expression of GPC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798

G

glypican 4

decreases expression
multiple interactions

panobinostat results in decreased expression of GPC4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:131,644,711...131,755,349
Ensembl chr X:131,644,704...131,755,284

G

glypican 6

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA
panobinostat results in decreased expression of GPC6 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:94,030,218...95,027,883
Ensembl chr15:94,029,884...95,024,006

G

glycerol-3-phosphate dehydrogenase 1 like

increases expression
multiple interactions

panobinostat results in increased expression of GPD1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723

G

G-protein coupled receptor 173

decreases expression
multiple interactions

panobinostat results in decreased expression of GPR173 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:21,446,261...21,471,119
Ensembl chr X:21,447,361...21,471,498

G

G protein-coupled receptor 183

decreases expression

Panobinostat results in decreased expression of GPR183 mRNA

NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559

G

G protein-coupled receptor 27

decreases expression
multiple interactions

panobinostat results in decreased expression of GPR27 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497

G

G protein-coupled receptor 37

increases expression
multiple interactions

panobinostat results in increased expression of GPR37 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001

G

gremlin 1, DAN family BMP antagonist

increases expression
multiple interactions

panobinostat results in increased expression of GREM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082

G

grainyhead-like transcription factor 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA

NCBI chr 6:41,207,325...41,257,516
Ensembl chr 6:41,207,348...41,254,301

G

grainyhead-like transcription factor 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA

NCBI chr 7:68,400,287...68,530,269
Ensembl chr 7:68,400,477...68,530,258

G

grainyhead-like transcription factor 3

increases expression
multiple interactions

panobinostat results in increased expression of GRHL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:147,774,161...147,806,291
Ensembl chr 5:147,774,160...147,806,160

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 3

decreases expression
multiple interactions

panobinostat results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096

G

glutamate ionotropic receptor kainate type subunit 3

decreases expression
multiple interactions

panobinostat results in decreased expression of GRIK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307

G

glutamate ionotropic receptor NMDA type subunit 2A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutamate metabotropic receptor 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA
panobinostat results in decreased expression of GRM3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:24,364,854...24,643,972
Ensembl chr 4:24,365,115...24,609,804

G

glutathione S-transferase alpha 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 2

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 5

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

guanylate cyclase 1 soluble subunit alpha 1

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of GUCY1A1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of GUCY1A1 mRNA]

NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671

G

glycophorin C

increases expression
multiple interactions

panobinostat results in increased expression of GYPC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA

PMID:26272509 PMID:27188386

NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204

G

H2A.X variant histone

multiple interactions
increases expression

manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]]; Panobinostat promotes the reaction [SRT2183 results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]

PMID:22923501 PMID:23681230

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B clustered histone 12

decreases expression
multiple interactions

Panobinostat results in decreased expression of H2BC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:42,485,699...42,486,162

G

H3.4 histone, cluster member

increases acetylation

Panobinostat results in increased acetylation of H3-4 protein

NCBI chr10:43,740,702...43,741,262

G

3-hydroxyacyl-CoA dehydratase 1

increases expression
multiple interactions

panobinostat results in increased expression of HACD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:77,081,508...77,106,114
Ensembl chr17:77,083,740...77,106,073

G

heart and neural crest derivatives expressed 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA

NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213

G

hyaluronan and proteoglycan link protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
panobinostat results in increased expression of HAPLN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777

G

hyaluronan synthase 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA
panobinostat results in increased expression of HAS2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

HCK proto-oncogene, Src family tyrosine kinase

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

histone deacetylase 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA
panobinostat results in increased expression of HDAC8 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923

G

histone deacetylase 9

decreases expression

Panobinostat results in decreased expression of HDAC9 mRNA

NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333

G

heart development protein with EGF-like domains 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA
panobinostat results in decreased expression of HEG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051

G

hes family bHLH transcription factor 2

increases expression
multiple interactions

panobinostat results in increased expression of HES2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:162,667,190...162,668,235
Ensembl chr 5:162,667,190...162,668,235

G

hes family bHLH transcription factor 5

decreases expression
multiple interactions

panobinostat results in decreased expression of HES5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001

G

HESX homeobox 1

decreases expression
multiple interactions

panobinostat results in decreased expression of HESX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:2,191,852...2,193,957
Ensembl chr16:2,191,852...2,193,957

G

hes-related family bHLH transcription factor with YRPW motif 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
panobinostat results in increased expression of HEY2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218

G

Hedgehog-interacting protein

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA

NCBI chr19:27,863,684...27,952,528
Ensembl chr19:27,863,213...27,952,528

G

huntingtin interacting protein 1

increases expression

Panobinostat results in increased expression of HIP1 mRNA

NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725

G

hexokinase 1

increases expression
multiple interactions

panobinostat results in increased expression of HK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

5-hydroxymethylcytosine binding, ES cell specific

increases expression

Panobinostat results in increased expression of HMCES mRNA

NCBI chr 4:120,392,812...120,415,616
Ensembl chr 4:120,366,542...120,415,616

G

3-hydroxy-3-methylglutaryl-CoA lyase like 1

decreases expression
multiple interactions

panobinostat results in decreased expression of HMGCLL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:76,757,301...76,887,300
Ensembl chr 8:76,757,497...76,886,816

G

heme oxygenase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA
panobinostat results in increased expression of HMOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

H6 family homeobox 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA

NCBI chr 1:186,319,110...186,326,771
Ensembl chr 1:186,319,110...186,326,771

G

histamine N-methyltransferase

increases expression
multiple interactions

panobinostat results in increased expression of HNMT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012

G

heterogeneous nuclear ribonucleoprotein R

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA

NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867

G

homeobox and leucine zipper encoding

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA

NCBI chr15:28,321,633...28,339,486
Ensembl chr15:28,320,819...28,339,745

G

homeobox A1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA

NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504

G

4-hydroxyphenylpyruvate dioxygenase-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA
panobinostat results in increased expression of HPDL mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:130,286,627...130,288,233
Ensembl chr 5:130,286,631...130,288,233

G

15-hydroxyprostaglandin dehydrogenase

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA

NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228

G

HPS1, biogenesis of lysosomal organelles complex 3 subunit 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA
panobinostat results in increased expression of HPS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:241,551,180...241,577,292
Ensembl chr 1:241,551,175...241,577,268

G

harakiri, BCL2 interacting protein

increases expression
multiple interactions

panobinostat results in increased expression of HRK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA

PMID:26272509 PMID:27188386

NCBI chr12:38,387,484...38,409,652

G

heparan sulfate-glucosamine 3-sulfotransferase 3B1

decreases expression
multiple interactions

panobinostat results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970

G

heat shock protein family A (Hsp70) member 4 like

increases expression
multiple interactions

panobinostat results in increased expression of HSPA4L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084

G

intercellular adhesion molecule 1

increases expression
multiple interactions

panobinostat results in increased expression of ICAM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA
panobinostat results in increased expression of ID4 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470

G

isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
panobinostat results in increased expression of IDH3A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084

G

immediate early response 3

increases expression
multiple interactions

panobinostat results in increased expression of IER3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

IFI30, lysosomal thiol reductase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA
panobinostat results in increased expression of IFI30 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175

G

interferon induced transmembrane protein 1

increases expression
multiple interactions

Panobinostat results in increased expression of IFITM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169

G

interferon alpha and beta receptor subunit 2

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of IFNAR2 mRNA

NCBI chr11:30,613,576...30,645,958
Ensembl chr11:30,613,767...30,668,124

G

intraflagellar transport 25

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA
Panobinostat results in decreased expression of IFT25 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:122,035,588...122,062,421
Ensembl chr 5:122,035,581...122,062,421

G

immunoglobulin superfamily, DCC subclass, member 3

increases expression
multiple interactions

panobinostat results in increased expression of IGDCC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:65,661,165...65,707,961
Ensembl chr 8:65,661,196...65,707,959

G

insulin-like growth factor 2

increases expression

panobinostat results in increased expression of IGF2 mRNA

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

insulin-like growth factor binding protein 3

decreases expression

panobinostat results in decreased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

insulin-like growth factor binding protein 7

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA
panobinostat results in increased expression of IGFBP7 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314

G

immunoglobin superfamily, member 21

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA

NCBI chr 5:152,287,834...152,512,174
Ensembl chr 5:152,287,835...152,512,174

G

interleukin 17 receptor D

decreases expression
multiple interactions

panobinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA

PMID:26272509 PMID:27188386

NCBI chr16:2,228,438...2,295,122
Ensembl chr16:2,228,287...2,292,556

G

interleukin 1 receptor accessory protein-like 1

decreases expression
multiple interactions

panobinostat results in decreased expression of IL1RAPL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:51,371,969...52,876,726
Ensembl chr X:51,378,215...52,876,772

G

interleukin 20 receptor subunit beta

increases expression
multiple interactions

panobinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942

G

interleukin 27 receptor subunit alpha

increases expression
multiple interactions

panobinostat results in increased expression of IL27RA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA

PMID:26272509 PMID:27188386

NCBI chr19:24,109,963...24,121,977
Ensembl chr19:24,109,972...24,121,938

G

interleukin 3 receptor subunit alpha

multiple interactions
increases expression

[Cisplatin co-treated with panobinostat] affects the expression of IL3RA mRNA
Panobinostat results in increased expression of IL3RA mRNA

PMID:21791302 PMID:33770205

NCBI chr12:16,318,081...16,323,781
Ensembl chr12:16,318,081...16,323,484

G

inverted formin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA
panobinostat results in increased expression of INF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941

G

inhibin subunit beta E

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA
panobinostat results in increased expression of INHBE mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

inositol polyphosphate-4-phosphatase type II B

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA

NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634

G

inositol polyphosphate-5-phosphatase D

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA

NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746

G

inositol polyphosphate-5-phosphatase F

increases expression

Panobinostat results in increased expression of INPP5F mRNA

NCBI chr 1:183,190,480...183,270,276
Ensembl chr 1:183,190,480...183,270,276

G

INSC, spindle orientation adaptor protein

increases expression
multiple interactions

panobinostat results in increased expression of INSC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:168,993,032...169,100,438
Ensembl chr 1:168,993,032...169,100,433

G

IQ motif containing with AAA domain 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQCA1 mRNA
panobinostat results in increased expression of IQCA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:90,626,735...90,742,563
Ensembl chr 9:90,626,744...90,742,618

G

IQ motif containing GTPase activating protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA
panobinostat results in increased expression of IQGAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755

G

interferon regulatory factor 6

increases expression
multiple interactions

panobinostat results in increased expression of IRF6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:104,672,179...104,691,386
Ensembl chr13:104,672,179...104,691,386

G

iroquois homeobox 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA
panobinostat results in increased expression of IRX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:31,294,615...31,300,444
Ensembl chr 1:31,294,615...31,300,444

G

iroquois homeobox 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA
panobinostat results in increased expression of IRX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:30,660,960...30,666,378
Ensembl chr 1:30,660,960...30,666,378

G

iroquois homeobox 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA
panobinostat results in increased expression of IRX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:15,211,882...15,215,317
Ensembl chr19:15,211,878...15,215,317

G

ISL LIM homeobox 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA

NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584

G

integrin subunit alpha 8

increases expression
multiple interactions

panobinostat results in increased expression of ITGA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510

G

integrin subunit alpha 9

increases expression
multiple interactions

panobinostat results in increased expression of ITGA9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:118,307,424...118,615,527
Ensembl chr 8:118,307,381...118,613,754

G

integrin subunit beta 5

decreases expression
multiple interactions

panobinostat results in decreased expression of ITGB5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472

G

inter-alpha-trypsin inhibitor heavy chain 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA
Panobinostat results in increased expression of ITIH5 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207

G

integral membrane protein 2A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA

NCBI chr X:72,486,383...72,492,344
Ensembl chr X:72,486,381...72,492,363

G

inositol 1,4,5-trisphosphate receptor, type 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA
panobinostat results in increased expression of ITPR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164

G

jade family PHD finger 2

increases expression
multiple interactions

panobinostat results in increased expression of JADE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:36,075,239...36,124,210
Ensembl chr10:36,078,917...36,116,984

G

jumonji and AT-rich interaction domain containing 2

increases expression

Panobinostat results in increased expression of JARID2 mRNA

NCBI chr17:19,777,487...19,957,696
Ensembl chr17:19,777,266...19,955,690

G

JAZF zinc finger 1

increases expression
multiple interactions

panobinostat results in increased expression of JAZF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:81,879,501...82,183,237
Ensembl chr 4:81,881,061...82,183,100

G

junctional cadherin 5 associated

increases expression
multiple interactions

panobinostat results in increased expression of JCAD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA

PMID:26272509 PMID:27188386

NCBI chr17:53,089,382...53,130,996
Ensembl chr17:53,089,382...53,130,967

G

Jun dimerization protein 2

increases expression
multiple interactions

panobinostat results in increased expression of JDP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:105,261,619...105,302,386
Ensembl chr 6:105,261,373...105,301,485

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

panobinostat results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KN motif and ankyrin repeat domains 4

increases expression
multiple interactions

panobinostat results in increased expression of KANK4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555

G

lysine acetyltransferase 2B

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA
panobinostat results in decreased expression of KAT2B mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064

G

lysine acetyltransferase 6A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA

NCBI chr16:69,084,914...69,165,923
Ensembl chr16:69,084,914...69,163,606

G

lysine acetyltransferase 7

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA
panobinostat results in decreased expression of KAT7 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:80,221,519...80,255,590
Ensembl chr10:80,221,524...80,255,567

G

kelch repeat and BTB domain containing 11

decreases expression
multiple interactions

panobinostat results in decreased expression of KBTBD11 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:74,618,291...74,638,010
Ensembl chr16:74,615,792...74,637,736

G

potassium voltage-gated channel subfamily A member 7

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of KCNA7 mRNA

NCBI chr 1:95,886,073...95,891,565
Ensembl chr 1:95,886,073...95,891,565

G

potassium voltage-gated channel subfamily C member 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA
panobinostat results in decreased expression of KCNC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:96,902,953...96,944,744
Ensembl chr 1:96,902,953...96,944,744

G

potassium voltage-gated channel subfamily D member 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
panobinostat results in decreased expression of KCND2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728

G

potassium voltage-gated channel modifier subfamily G member 1

increases expression
multiple interactions

panobinostat results in increased expression of KCNG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635

G

potassium voltage-gated channel subfamily H member 5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA
panobinostat results in decreased expression of KCNH5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:93,615,174...93,908,107
Ensembl chr 6:93,624,529...93,908,107

G

potassium inwardly-rectifying channel, subfamily J, member 13

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA
panobinostat results in decreased expression of KCNJ13 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:88,063,003...88,071,112

G

potassium inwardly-rectifying channel, subfamily J, member 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124

G

potassium two pore domain channel subfamily K member 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA

NCBI chr19:53,959,411...53,997,726
Ensembl chr19:53,959,657...53,997,724

G

potassium two pore domain channel subfamily K member 10

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA
panobinostat results in decreased expression of KCNK10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695

G

potassium calcium-activated channel subfamily M regulatory beta subunit 4

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of KCNMB4 mRNA

NCBI chr 7:52,066,145...52,119,098
Ensembl chr 7:52,066,136...52,119,278

G

potassium calcium-activated channel subfamily N member 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA
panobinostat results in decreased expression of KCNN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:174,929,846...175,088,910
Ensembl chr 2:174,936,629...175,081,145

G

potassium voltage-gated channel modifier subfamily V member 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA

NCBI chr 7:76,260,695...76,269,170
Ensembl chr 7:76,260,695...76,269,170

G

potassium channel tetramerization domain containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA
panobinostat results in increased expression of KCTD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:6,122,390...6,316,434
Ensembl chr18:6,122,390...6,317,393

G

potassium channel tetramerization domain containing 12

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA
panobinostat results in increased expression of KCTD12 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282

G

kinase insert domain receptor

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

KIAA0040 ortholog

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA
panobinostat results in increased expression of KIAA0040 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:72,274,519...72,312,103
Ensembl chr13:72,274,552...72,312,103

G

KIAA1549 homolog

decreases expression
multiple interactions

panobinostat results in decreased expression of KIAA1549 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:66,840,674...66,968,407
Ensembl chr 4:66,760,162...66,968,436

G

KIAA1755 ortholog

increases expression
multiple interactions

panobinostat results in increased expression of KIAA1755 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:146,850,558...146,884,238
Ensembl chr 3:146,850,557...146,884,871

G

kinesin family member 13A

decreases expression

panobinostat results in decreased expression of KIF13A mRNA

NCBI chr17:17,766,597...17,948,517
Ensembl chr17:17,766,597...17,943,615

G

kinesin family member 28, pseudogene

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA

NCBI chr13:91,427,527...91,482,297
Ensembl chr13:91,427,736...91,482,237

G

kinesin family member 5C

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of KIF5C mRNA

NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413

G

kinesin-associated protein 3

increases expression
multiple interactions

panobinostat results in increased expression of KIFAP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:76,127,702...76,264,654
Ensembl chr13:76,127,696...76,264,650

G

KISS1 receptor

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA

NCBI chr 7:9,785,135...9,790,283
Ensembl chr 7:9,785,135...9,788,793

G

KIT proto-oncogene receptor tyrosine kinase

increases expression
multiple interactions

panobinostat results in increased expression of KIT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA

PMID:26272509 PMID:27188386

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KIT ligand

increases expression
multiple interactions

panobinostat results in increased expression of KITLG mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

kizuna centrosomal protein

decreases expression
multiple interactions

panobinostat results in decreased expression of KIZ mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:134,277,631...134,385,260
Ensembl chr 3:134,277,687...134,385,190

G

KLF transcription factor 15

increases expression
multiple interactions

panobinostat results in increased expression of KLF15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374

G

KLF transcription factor 4

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

KLF transcription factor 5

increases expression
multiple interactions

panobinostat results in increased expression of KLF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA
panobinostat results in increased expression of KLF6 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kelch-like family member 14

increases expression

panobinostat results in increased expression of KLHL14 mRNA

NCBI chr18:12,804,253...12,917,828
Ensembl chr18:12,804,253...12,917,828

G

kallikrein related-peptidase 10

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA

NCBI chr 1:94,234,536...94,239,369
Ensembl chr 1:94,235,096...94,239,376

G

kallikrein related-peptidase 8

multiple interactions
increases expression

[Cisplatin co-treated with Panobinostat] affects the expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA
panobinostat results in increased expression of KLK8 mRNA

PMID:21791302 PMID:26272509 PMID:27188386

NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646

G

killer cell lectin like receptor G2

increases expression
multiple interactions

panobinostat results in increased expression of KLRG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:67,360,216...67,374,867
Ensembl chr 4:67,363,919...67,374,147

G

kringle containing transmembrane protein 1

increases expression
multiple interactions

panobinostat results in increased expression of KREMEN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:80,081,870...80,147,489
Ensembl chr14:80,084,403...80,147,516

G

keratin 18

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
panobinostat results in increased expression of KRT18 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166

G

keratin 19

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA

NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799

G

keratin 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA
panobinostat results in increased expression of KRT8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728

G

L1 cell adhesion molecule

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA
panobinostat results in increased expression of L1CAM mRNA

PMID:26272509 PMID:27188386

NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857

G

LINE-1 type transposase domain containing 1

increases expression

panobinostat results in increased expression of L1TD1 mRNA

NCBI chr 5:113,373,193...113,386,088
Ensembl chr 5:113,379,870...113,385,730

G

laccase domain containing 1

increases expression
multiple interactions

panobinostat results in increased expression of LACC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:52,390,267...52,407,630
Ensembl chr15:52,395,183...52,407,545

G

lactamase, beta

increases expression
multiple interactions

panobinostat results in increased expression of LACTB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:67,571,500...67,587,539

G

laminin subunit alpha 2

increases expression
multiple interactions

panobinostat results in increased expression of LAMA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530

G

laminin subunit alpha 4

increases expression
multiple interactions

panobinostat results in increased expression of LAMA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347

G

laminin subunit gamma 2

increases expression
multiple interactions

panobinostat results in increased expression of LAMC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

lysosomal-associated membrane protein 2

increases expression
multiple interactions

panobinostat results in increased expression of LAMP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

layilin

increases expression
multiple interactions

panobinostat results in increased expression of LAYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:51,363,928...51,384,748
Ensembl chr 8:51,367,091...51,384,330

G

lactase-like

decreases expression
multiple interactions

panobinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:64,618,356...64,654,851
Ensembl chr 8:64,618,350...64,639,357

G

lactate dehydrogenase D

increases expression
multiple interactions

panobinostat results in increased expression of LDHD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA

PMID:26272509 PMID:27188386

NCBI chr19:39,583,529...39,588,397
Ensembl chr19:39,573,621...39,595,575

G

LEM domain containing 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA

NCBI chr13:43,631,705...43,697,765
Ensembl chr13:43,665,926...43,697,948

G

galectin 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

galectin 3

increases expression
multiple interactions

panobinostat results in increased expression of LGALS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

LHFPL tetraspan subfamily member 6

increases expression
multiple interactions

panobinostat results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443

G

LIM homeobox 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA
panobinostat results in decreased expression of LHX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908

G

LIM homeobox 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA
panobinostat results in increased expression of LHX8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:243,244,958...243,269,624
Ensembl chr 2:243,244,961...243,269,416

G

LIF receptor subunit alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA
panobinostat results in increased expression of LIFR mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699

G

lens intrinsic membrane protein 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA

NCBI chr 1:93,837,597...93,843,769
Ensembl chr 1:93,837,597...93,843,769

G

LIM and calponin homology domains 1

decreases expression
multiple interactions

panobinostat results in decreased expression of LIMCH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191

G

lin-28 homolog B

multiple interactions
decreases expression
affects expression

(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LIN28B mRNA]; (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of LIN28B protein]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LIN28B mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of LIN28B protein]
panobinostat results in decreased expression of LIN28B protein
panobinostat affects the expression of LIN28B mRNA

NCBI chr20:48,865,329...48,964,769
Ensembl chr20:48,869,485...48,955,077

G

leucine rich repeat and Ig domain containing 2

increases expression
multiple interactions

panobinostat results in increased expression of LINGO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:50,370,744...51,687,252
Ensembl chr 5:50,367,101...50,516,956

G

limb and CNS expressed 1

decreases expression
multiple interactions

panobinostat results in decreased expression of LIX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:58,128,961...58,187,554
Ensembl chr 1:58,128,961...58,185,964

G

lectin, mannose-binding, 1

decreases expression
multiple interactions

panobinostat results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851

G

lipase maturation factor 1

increases expression

panobinostat results in increased expression of LMF1 mRNA

NCBI chr10:14,597,726...14,684,071
Ensembl chr10:14,597,594...14,684,119

G

LIM domain only 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA
panobinostat results in decreased expression of LMO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:90,355,234...90,377,970
Ensembl chr 3:90,365,883...90,377,953

G

LIM domain only 3

decreases expression
multiple interactions

panobinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222

G

LIM domain 7

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA

NCBI chr15:78,566,999...78,769,833
Ensembl chr15:78,567,023...78,769,783

G

ligand of numb-protein X 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA
panobinostat results in increased expression of LNX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:33,514,429...33,617,086
Ensembl chr14:33,514,436...33,617,086

G

protein BEX1-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA
panobinostat results in increased expression of BEX5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:110,047,861...110,051,812

G

lysophosphatidic acid receptor 6

increases expression
multiple interactions

panobinostat results in increased expression of LPAR6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331

G

leucine-rich repeats and immunoglobulin-like domains 1

decreases expression
multiple interactions

panobinostat results in decreased expression of LRIG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513

G

LDL receptor related protein 12

decreases expression
multiple interactions

panobinostat results in decreased expression of LRP12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:70,941,068...71,012,409
Ensembl chr 7:70,941,068...71,012,441

G

LDL receptor related protein 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA
panobinostat results in decreased expression of LRP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708

G

LDL receptor related protein 8

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA

NCBI chr 5:122,563,468...122,635,434
Ensembl chr 5:122,563,453...122,631,352

G

leucine rich repeat containing 17

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA
panobinostat results in increased expression of LRRC17 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:13,501,436...13,531,845

G

leucine rich repeat containing 3B

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA
panobinostat results in decreased expression of LRRC3B mRNA

PMID:26272509 PMID:27188386

NCBI chr15:9,973,580...10,050,891
Ensembl chr15:9,969,983...10,051,066

G

leucine rich repeat containing 55

decreases expression
multiple interactions

panobinostat results in decreased expression of LRRC55 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:70,269,908...70,280,651
Ensembl chr 3:70,265,936...70,278,639

G

leucine rich repeat containing 8 VRAC subunit B

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA
panobinostat results in decreased expression of LRRC8B mRNA

PMID:26272509 PMID:27188386

NCBI chr14:4,350,462...4,416,336
Ensembl chr14:4,354,508...4,416,311

G

leucine rich repeat containing 8 VRAC subunit E

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA
panobinostat results in increased expression of LRRC8E mRNA

PMID:26272509 PMID:27188386

NCBI chr12:2,578,240...2,589,407
Ensembl chr12:2,578,315...2,589,412

G

LRR binding FLII interacting protein 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA

NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250

G

leucine rich repeat neuronal 3

multiple interactions
increases expression
affects expression

(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRN3 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRN3 mRNA]
panobinostat results in increased expression of LRRN3 mRNA
panobinostat affects the expression of LRRN3 mRNA

PMID:26272509 PMID:26733615 PMID:27188386

NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330

G

leucine rich repeat neuronal 4

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA

NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831

G

leucine rich repeat transmembrane neuronal 1

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRTM1 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRTM1 mRNA]
panobinostat affects the expression of LRRTM1 mRNA

PMID:26733615 PMID:27188386

NCBI chr 4:109,701,815...109,718,924
Ensembl chr 4:109,701,815...109,717,184

G

lymphocyte antigen 75

increases expression
multiple interactions

panobinostat results in increased expression of LY75 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:44,764,702...44,852,219
Ensembl chr 3:44,765,122...44,852,374

G

LYN proto-oncogene, Src family tyrosine kinase

increases expression
multiple interactions

panobinostat results in increased expression of LYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868

G

Ly6/Plaur domain containing 3

increases expression
multiple interactions

panobinostat results in increased expression of LYPD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:80,226,449...80,230,901
Ensembl chr 1:80,226,449...80,230,901

G

LysM domain containing 2

increases expression
multiple interactions

panobinostat results in increased expression of LYSMD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:76,378,984...76,394,396
Ensembl chr 8:76,379,219...76,394,654

G

lysozyme-like 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA
panobinostat results in increased expression of LYZL6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:88,544,342...88,549,177
Ensembl chr10:88,544,342...88,549,177

G

leucine zipper tumor suppressor 1

increases expression
multiple interactions

panobinostat results in increased expression of LZTS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

mab-21 like 2

decreases expression
multiple interactions

panobinostat results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:171,946,573...171,949,655
Ensembl chr 2:171,946,573...171,949,655

G

MET transcriptional regulator MACC1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
panobinostat results in increased expression of MACC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:140,352,755...140,430,255

G

mono-ADP ribosylhydrolase 2

decreases expression
multiple interactions

panobinostat results in decreased expression of MACROD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:127,720,066...129,737,511
Ensembl chr 3:127,720,181...129,734,492

G

macroH2A.1 histone

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
Panobinostat results in decreased expression of MACROH2A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072

G

MAF bZIP transcription factor B

increases expression

panobinostat results in increased expression of MAFB mRNA

NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031

G

membrane associated guanylate kinase, WW and PDZ domain containing 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA
panobinostat results in increased expression of MAGI2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240

G

male germ cell-associated kinase

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA
panobinostat results in decreased expression of MAK mRNA

PMID:26272509 PMID:27188386

NCBI chr17:23,683,753...23,731,125
Ensembl chr17:23,693,878...23,730,001

G

mannosidase, alpha, class 1A, member 1

increases expression
multiple interactions

panobinostat results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824

G

mannosidase, endo-alpha-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA
panobinostat results in increased expression of MANEAL mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:137,115,154...137,122,299
Ensembl chr 5:137,115,632...137,122,353

G

microtubule-associated protein 2

increases expression
multiple interactions

panobinostat results in increased expression of MAP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen-activated protein kinase kinase 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

microtubule-associated protein 6

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA
panobinostat results in decreased expression of MAP6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414

G

MAP7 domain containing 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA

NCBI chr X:35,372,453...35,488,073
Ensembl chr X:35,372,700...35,488,091

G

mitogen activated protein kinase 1

multiple interactions

[Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 10

decreases expression
multiple interactions

panobinostat results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201

G

mitogen activated protein kinase 13

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA
panobinostat results in increased expression of MAPK13 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:6,835,277...6,845,500
Ensembl chr20:6,835,320...6,844,222

G

mitogen activated protein kinase 3

multiple interactions

[Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

methionine adenosyltransferase 1A

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of MAT1A mRNA

NCBI chr16:16,983,084...17,001,284
Ensembl chr16:16,983,022...17,001,274

G

muscleblind-like splicing regulator 3

increases expression
multiple interactions

panobinostat results in increased expression of MBNL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:130,641,942...130,737,179
Ensembl chr X:130,648,538...130,737,056

G

membrane bound O-acyltransferase domain containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA
panobinostat results in increased expression of MBOAT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:34,331,413...34,445,088
Ensembl chr17:34,331,422...34,445,088

G

MCC regulator of WNT signaling pathway

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA
panobinostat results in increased expression of MCC mRNA

PMID:26272509 PMID:27188386

NCBI chr18:36,794,206...37,266,237
Ensembl chr18:36,798,372...37,266,819

G

mucolipin TRP cation channel 3

increases expression
multiple interactions

panobinostat results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:235,008,716...235,042,885
Ensembl chr 2:234,966,010...235,043,047

G

mitochondrial calcium uniporter dominant negative subunit beta

decreases expression
multiple interactions

panobinostat results in decreased expression of MCUB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:218,479,301...218,549,594
Ensembl chr 2:218,479,301...218,549,593

G

MyoD family inhibitor domain containing

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA
panobinostat results in increased expression of MDFIC mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:43,972,310...44,052,162
Ensembl chr 4:43,972,507...44,052,161

G

malic enzyme 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA
panobinostat results in decreased expression of ME3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:143,534,024...143,735,551
Ensembl chr 1:143,534,139...143,733,132

G

MDS1 and EVI1 complex locus

decreases expression

panobinostat results in decreased expression of MECOM mRNA

NCBI chr 2:112,909,353...113,464,583
Ensembl chr 2:112,909,321...113,464,590

G

mediator complex subunit 13L

increases expression
multiple interactions

panobinostat results in increased expression of MED13L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA

PMID:26272509 PMID:27188386

NCBI chr12:37,807,596...38,004,886
Ensembl chr12:37,808,285...38,004,473

G

myocyte enhancer factor 2C

increases expression
multiple interactions

panobinostat results in increased expression of MEF2C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

Meis homeobox 2

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MEIS2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MEIS2 mRNA]

NCBI chr 3:102,742,904...102,944,833
Ensembl chr 3:102,742,900...102,949,696

G

mesenchyme homeobox 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA
panobinostat results in increased expression of MEOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660

G

meteorin-like, glial cell differentiation regulator

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA
panobinostat results in increased expression of METRNL mRNA

PMID:26272509 PMID:27188386

NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869

G

methyltransferase 21A, HSPA lysine

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA

NCBI chr 9:65,934,253...65,999,964
Ensembl chr 9:65,978,051...65,987,550

G

microfibril associated protein 3 like

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA
panobinostat results in decreased expression of MFAP3L mRNA

PMID:26272509 PMID:27188386

NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863

G

MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA
panobinostat results in decreased expression of MFNG mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653

G

beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of MGAT3 mRNA

NCBI chr 7:111,708,353...111,761,825
Ensembl chr 7:111,675,730...111,762,026

G

MIA SH3 domain containing

increases expression
multiple interactions

panobinostat results in increased expression of MIA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:82,473,677...82,476,378
Ensembl chr 1:82,473,678...82,475,370

G

myocardial infarction associated transcript

decreases expression
multiple interactions

panobinostat results in decreased expression of MIAT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA

PMID:26272509 PMID:27188386

NCBI chr12:44,414,620...44,429,852

G

MICAL-like 1

increases expression
multiple interactions

panobinostat results in increased expression of MICALL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:110,676,706...110,707,171
Ensembl chr 7:110,676,775...110,707,177

G

MHC class I polypeptide-related sequence B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA
Panobinostat results in increased expression of MICB mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827

G

MID1 interacting protein 1

increases expression
multiple interactions

panobinostat results in increased expression of MID1IP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:12,060,993...12,063,318
Ensembl chr X:12,060,883...12,065,774

G

matrix metallopeptidase 14

increases expression
multiple interactions

panobinostat results in increased expression of MMP14 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

motor neuron and pancreas homeobox 1

increases expression
multiple interactions

panobinostat results in increased expression of MNX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:5,866,506...5,871,465
Ensembl chr 4:5,866,506...5,871,465

G

metallophosphoesterase domain containing 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA
panobinostat results in decreased expression of MPPED2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:93,180,895...93,355,605
Ensembl chr 3:93,181,167...93,355,618

G

myelin protein zero

increases expression
multiple interactions

panobinostat results in increased expression of MPZ mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA

PMID:26272509 PMID:27188386

NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679

G

MSL complex subunit 1

affects expression
decreases expression
multiple interactions

panobinostat affects the expression of MSL1 mRNA
Panobinostat results in decreased expression of MSL1 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MSL1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MSL1 mRNA]

PMID:26733615 PMID:33770205

NCBI chr10:83,755,380...83,767,147
Ensembl chr10:83,755,720...83,765,726

G

msh homeobox 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA
panobinostat results in increased expression of MSX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:72,961,036...72,964,970
Ensembl chr14:72,961,148...72,964,966

G

msh homeobox 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA
panobinostat results in increased expression of MSX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879

G

mitochondrial amidoxime reducing component 2

increases expression
multiple interactions

Panobinostat results in increased expression of MTARC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:96,362,810...96,397,284

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like

increases expression
multiple interactions

panobinostat results in increased expression of MTHFD2L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA

PMID:26272509 PMID:27188386

NCBI chr14:17,089,947...17,170,036
Ensembl chr14:17,089,952...17,170,112

G

mucin 15, cell surface associated

increases expression
multiple interactions

panobinostat results in increased expression of MUC15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:97,294,728...97,308,641
Ensembl chr 3:97,294,783...97,307,090

G

mucin 3A, cell surface associated

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA

NCBI chr12:19,450,679...19,454,753

G

mucin 4, cell surface associated

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA
panobinostat results in increased expression of MUC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:68,008,245...68,053,242

G

musculoskeletal, embryonic nuclear protein 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA

NCBI chr16:6,072,908...6,075,161
Ensembl chr16:6,072,833...6,075,161

G

multivesicular body subunit 12A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA
panobinostat results in decreased expression of MVB12A mRNA

PMID:26272509 PMID:27188386

NCBI chr16:18,252,227...18,257,111
Ensembl chr16:18,252,222...18,257,539

G

matrix remodeling associated 7

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA
panobinostat results in decreased expression of MXRA7 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:102,003,034...102,031,428
Ensembl chr10:102,003,319...102,031,409

G

MYB proto-oncogene like 1

increases expression

Panobinostat results in increased expression of MYBL1 mRNA

NCBI chr 5:9,582,905...9,618,179
Ensembl chr 5:9,582,934...9,618,183

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression

(+)-JQ1 compound promotes the reaction [panobinostat results in decreased expression of MYC protein]; [panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of MYC protein; panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]; panobinostat promotes the reaction [SRT2183 results in decreased expression of MYC protein]

PMID:23681230 PMID:24435446

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions
increases expression
decreases expression

(+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of MYCN protein]; [(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; Panobinostat inhibits the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein]
panobinostat results in increased expression of MYCN mRNA
panobinostat results in decreased expression of MYCN protein

PMID:26272509 PMID:26733615 PMID:27188386

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

myc target 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA

NCBI chr 1:42,018,137...42,029,410
Ensembl chr 1:42,018,137...42,029,410

G

myogenic factor 5

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA

NCBI chr 7:42,802,946...42,806,177
Ensembl chr 7:42,802,946...42,806,177

G

myosin regulatory light chain interacting protein

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA
panobinostat results in increased expression of MYLIP mRNA

PMID:26272509 PMID:27188386

NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295

G

myosin light chain kinase

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA
panobinostat results in decreased expression of MYLK mRNA

PMID:26272509 PMID:27188386

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

myosin ID

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA
panobinostat results in increased expression of MYO1D mRNA

PMID:26272509 PMID:27188386

NCBI chr10:65,489,153...65,765,812
Ensembl chr10:65,489,154...65,766,349

G

myosin IE

increases expression

Panobinostat results in increased expression of MYO1E mRNA

NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169

G

myosin Vb

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA

NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745

G

myocardin

increases expression
multiple interactions

panobinostat results in increased expression of MYOCD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA

PMID:26272509 PMID:27188386

NCBI chr10:49,833,219...49,928,806
Ensembl chr10:49,836,641...49,927,627

G

myoferlin

increases expression
multiple interactions

panobinostat results in increased expression of MYOF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334

G

nucleic acid binding protein 1

increases expression
multiple interactions

panobinostat results in increased expression of NABP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107

G

NALCN channel auxiliary factor 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA
Panobinostat results in decreased expression of NALF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:79,713,577...80,236,295
Ensembl chr16:79,713,724...80,235,120

G

Nanog homeobox

increases expression
multiple interactions

panobinostat results in increased expression of NANOG mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

G

nanos C2HC-type zinc finger 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA
panobinostat results in decreased expression of NANOS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:259,897,663...259,901,561
Ensembl chr 1:259,897,939...259,898,730

G

N-acetylneuraminate synthase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA
panobinostat results in increased expression of NANS mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:60,780,441...60,797,583
Ensembl chr 5:60,780,392...60,814,950

G

neuron navigator 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA
panobinostat results in decreased expression of NAV1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449

G

neuron navigator 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA
panobinostat results in increased expression of NAV3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:45,052,206...45,840,471
Ensembl chr 7:45,054,296...45,840,698

G

neurocalcin delta

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA
panobinostat results in decreased expression of NCALD mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496

G

nuclear receptor coactivator 7

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA
panobinostat results in decreased expression of NCOA7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871

G

norrin cystine knot growth factor NDP

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA
panobinostat results in decreased expression of NDP mRNA

PMID:26272509 PMID:27188386

NCBI chr X:5,796,487...5,820,934
Ensembl chr X:5,796,487...5,820,934

G

NADH:ubiquinone oxidoreductase subunit B1

decreases expression
multiple interactions

panobinostat results in decreased expression of NDUFB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:121,115,649...121,124,055

G

neurofilament light chain

increases expression
multiple interactions

panobinostat results in increased expression of NEFL mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA

PMID:26272509 PMID:27188386

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

neurofilament medium chain

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA
panobinostat results in increased expression of NEFM mRNA

PMID:26272509 PMID:27188386

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

neuronal growth regulator 1

increases expression

panobinostat results in increased expression of NEGR1 mRNA

NCBI chr 2:245,624,460...246,359,605
Ensembl chr 2:245,624,435...246,356,730

G

neural EGFL like 1

increases expression
multiple interactions

panobinostat results in increased expression of NELL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860

G

neural EGFL like 2

decreases expression
multiple interactions

panobinostat results in decreased expression of NELL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:126,343,089...126,662,903
Ensembl chr 7:126,198,851...126,733,503

G

neuraminidase 1

increases expression

Panobinostat results in increased expression of NEU1 mRNA

NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745

G

neuralized E3 ubiquitin protein ligase 3

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of LINCR mRNA

NCBI chr 9:38,494,486...38,503,352
Ensembl chr 9:38,494,489...38,502,649

G

neurite extension and migration factor

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA
panobinostat results in decreased expression of NEXMIF mRNA

PMID:26272509 PMID:27188386

NCBI chr X:69,088,076...69,219,253
Ensembl chr X:69,088,076...69,112,930

G

neurofibromin 1

decreases expression
multiple interactions

panobinostat results in decreased expression of NF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658

G

neurofascin

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA
panobinostat results in decreased expression of NFASC mRNA

PMID:26272509 PMID:27188386

NCBI chr13:43,997,223...44,183,863
Ensembl chr13:43,997,224...44,183,880

G

nuclear factor of activated T-cells 4

decreases expression
multiple interactions

panobinostat results in decreased expression of NFATC4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions

panobinostat results in increased expression of NFE2L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor I/B

increases expression
multiple interactions

panobinostat results in increased expression of NFIB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479

G

nuclear factor I/C

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NFIC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NFIC mRNA]

NCBI chr 7:8,278,210...8,309,936
Ensembl chr 7:8,253,361...8,309,936

G

neuronal guanine nucleotide exchange factor

increases expression
multiple interactions

panobinostat results in increased expression of NGEF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914

G

nerve growth factor receptor

increases expression
multiple interactions

panobinostat results in increased expression of NGFR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA

PMID:26272509 PMID:27188386

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

NHS-like 2

affects expression
multiple interactions

panobinostat affects the expression of NHSL2 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NHSL2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NHSL2 mRNA]

NCBI chr X:66,969,953...67,209,464
Ensembl chr X:66,970,151...67,200,911

G

NIPA-like domain containing 2

increases expression
multiple interactions

panobinostat results in increased expression of NIPAL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:65,774,477...65,884,807
Ensembl chr 7:65,774,477...65,884,807

G

Sodium/potassium transporting ATPase interacting 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA
Panobinostat results in decreased expression of NKAIN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:33,613,720...34,310,090
Ensembl chr 5:33,623,713...34,309,381

G

NKD inhibitor of WNT signaling pathway 1

increases expression
multiple interactions

panobinostat results in increased expression of NKD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:18,476,344...18,549,380
Ensembl chr19:18,476,344...18,549,380

G

neuroligin 1

decreases expression
multiple interactions

panobinostat results in decreased expression of NLGN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:108,256,236...109,181,530
Ensembl chr 2:108,257,824...109,002,464

G

NLR family, pyrin domain containing 1A

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of NLRP1 mRNA

NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180

G

NME/NM23 family member 8

increases expression
multiple interactions

panobinostat results in increased expression of NME8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:45,237,022...45,304,948
Ensembl chr17:45,238,120...45,304,948

G

N-myc (and STAT) interactor

increases expression
multiple interactions

panobinostat results in increased expression of NMI mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498

G

nicotinamide nucleotide adenylyltransferase 2

multiple interactions
increases expression

[Cisplatin co-treated with Panobinostat] affects the expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA
panobinostat results in increased expression of NMNAT2 mRNA

PMID:21791302 PMID:26272509 PMID:27188386

NCBI chr13:65,105,950...65,277,350
Ensembl chr13:65,105,950...65,278,484

G

nocturnin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA
panobinostat results in increased expression of NOCT mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400

G

noggin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPY19L2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERLEC1P1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM200B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM226B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BW4P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00515 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503-AS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF785 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF93 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN16-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOBEC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C4ORF19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVMER61-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQCA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00472 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01405 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1LC3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF165 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF600 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA
panobinostat results in increased expression of NOG mRNA

PMID:26272509 PMID:27188386

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

nucleolar protein 4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA
panobinostat results in decreased expression of NOL4 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:13,932,499...14,294,873
Ensembl chr18:13,932,510...14,296,286

G

neuropeptide FF receptor 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA
panobinostat results in increased expression of NPFFR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:18,513,120...18,558,074
Ensembl chr14:18,513,277...18,521,919

G

nephronectin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA
panobinostat results in increased expression of NPNT mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401

G

natriuretic peptide receptor 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA
panobinostat results in increased expression of NPR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

neuropeptide Y

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA
panobinostat results in increased expression of NPY mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

neuropeptide Y receptor Y1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA
panobinostat results in decreased expression of NPY1R mRNA

PMID:26272509 PMID:27188386

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

neuropeptide Y receptor Y2

multiple interactions
decreases expression
affects expression

(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of NPY2R mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NPY2R mRNA]
panobinostat results in decreased expression of NPY2R mRNA
panobinostat affects the expression of NPY2R mRNA

PMID:26272509 PMID:26733615 PMID:27188386

NCBI chr 2:167,901,999...167,912,165
Ensembl chr 2:167,903,879...167,905,024

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA
panobinostat results in increased expression of NQO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA
panobinostat results in increased expression of NQO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 2, group F, member 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA
panobinostat results in increased expression of NR2F1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123

G

nuclear receptor subfamily 2, group F, member 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA
panobinostat results in decreased expression of NR2F2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031

G

neuregulin 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA
panobinostat results in decreased expression of NRG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

nuclear receptor interacting protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA
panobinostat results in increased expression of NRIP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761

G

nuclear receptor interacting protein 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA
panobinostat results in decreased expression of NRIP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600

G

Nik related kinase

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA

NCBI chr X:102,365,765...102,462,957
Ensembl chr X:102,365,765...102,459,657

G

neuropilin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA
panobinostat results in increased expression of NRP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633

G

neuropilin 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA

NCBI chr 9:64,122,815...64,238,007
Ensembl chr 9:64,123,132...64,237,958

G

negative regulator of reactive oxygen species

decreases expression

Panobinostat results in decreased expression of NRROS mRNA

NCBI chr11:68,628,641...68,646,152
Ensembl chr11:68,628,712...68,646,142

G

neurexin 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA

NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297

G

nuclear receptor binding SET domain protein 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA
panobinostat results in decreased expression of NSD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:76,833,179...76,911,304
Ensembl chr14:76,835,637...76,913,641

G

neutral sphingomyelinase activation associated factor

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NSMAF mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NSMAF mRNA]

NCBI chr 5:19,517,795...19,578,773
Ensembl chr 5:19,518,348...19,577,627

G

netrin 4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA
panobinostat results in decreased expression of NTN4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:28,186,611...28,300,390
Ensembl chr 7:28,186,611...28,300,390

G

NUAK family kinase 2

decreases expression

panobinostat results in decreased expression of NUAK2 mRNA

NCBI chr13:43,753,454...43,770,604
Ensembl chr13:43,753,832...43,770,604

G

nudix hydrolase 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA
panobinostat results in increased expression of NUDT4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:30,188,100...30,204,615
Ensembl chr 7:30,188,100...30,204,615

G

NACHT and WD repeat domain containing 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA
panobinostat results in increased expression of NWD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:44,480,049...44,671,417
Ensembl chr14:44,482,287...44,670,299

G

ornithine aminotransferase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA
panobinostat results in increased expression of OAT mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682

G

Obg-like ATPase 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA
panobinostat results in decreased expression of OLA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:57,966,896...58,085,955
Ensembl chr 3:57,966,896...58,084,480

G

olfactomedin 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA
panobinostat results in increased expression of OLFM3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:202,729,610...202,952,120
Ensembl chr 2:202,729,936...202,952,112

G

olfactomedin-like 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA
panobinostat results in increased expression of OLFML3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:191,244,221...191,247,050

G

oligodendrocyte transcription factor 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA

NCBI chr 1:14,081,259...14,083,336
Ensembl chr 1:14,081,328...14,082,149

G

one cut homeobox 2

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of ONECUT2 mRNA

NCBI chr18:57,831,647...57,890,884
Ensembl chr18:57,832,111...57,879,629

G

opioid binding protein/cell adhesion molecule-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA
panobinostat results in increased expression of OPCML mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:26,788,988...27,304,551
Ensembl chr 8:26,192,841...27,300,620

G

opioid receptor, kappa 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA
panobinostat results in decreased expression of OPRK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

orosomucoid 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA
panobinostat results in decreased expression of ORM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

oxysterol binding protein-like 10

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA
panobinostat results in increased expression of OSBPL10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:114,661,050...114,918,664
Ensembl chr 8:114,660,743...114,918,625

G

orthodenticle homeobox 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA

NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416

G

ovo like transcriptional repressor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA
panobinostat results in increased expression of OVOL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:202,855,261...202,868,858
Ensembl chr 1:202,855,265...202,866,831

G

ovo-like zinc finger 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA

NCBI chr 3:131,677,391...131,707,123
Ensembl chr 3:131,677,391...131,708,359

G

poly(A) binding protein, cytoplasmic 4-like

increases expression
multiple interactions

panobinostat results in increased expression of PABPC4L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:129,807,755...129,809,745
Ensembl chr 2:129,807,755...129,809,745

G

poly A binding protein, cytoplasmic 5

increases expression

panobinostat results in increased expression of PABPC5 mRNA

NCBI chr X:85,637,763...85,641,235
Ensembl chr X:85,638,574...85,639,722

G

p21 (RAC1) activated kinase 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA
panobinostat results in decreased expression of PAK3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314

G

peptidase domain containing associated with muscle regeneration 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA
panobinostat results in decreased expression of PAMR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:88,889,061...88,988,615
Ensembl chr 3:88,889,046...88,988,606

G

poly (ADP-ribose) polymerase 1

multiple interactions

[resveratrol co-treated with panobinostat] results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

PATJ, crumbs cell polarity complex component

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA

NCBI chr 5:113,061,985...113,364,807
Ensembl chr 5:113,062,118...113,364,807

G

paired box 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA
panobinostat results in increased expression of PAX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:243,616,509...243,697,454
Ensembl chr 1:243,616,606...243,695,321

G

paired box 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA
panobinostat results in increased expression of PAX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042

G

paired box 6

decreases expression
multiple interactions

panobinostat results in decreased expression of PAX6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

paired box 7

increases expression
multiple interactions

panobinostat results in increased expression of PAX7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:151,996,368...152,098,023
Ensembl chr 5:151,999,092...152,097,979

G

PBX homeobox 2

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of PBX2 mRNA

NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,151,500...4,156,425

G

protocadherin 10

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA
panobinostat results in increased expression of PCDH10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:128,617,174...128,677,190

G

protocadherin 20

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA
panobinostat results in increased expression of PCDH20 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:64,425,534...64,431,790
Ensembl chr15:64,425,534...64,431,790

G

protocadherin 7

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA
panobinostat results in increased expression of PCDH7 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051
Ensembl chr14:52,475,610...52,902,051

G

protocadherin 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA
panobinostat results in increased expression of PCDH8 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:55,198,470...55,203,039
Ensembl chr15:55,198,459...55,205,872

G

protocadherin beta 20

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA
panobinostat results in decreased expression of PCDHB14 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:29,211,878...29,215,272
Ensembl chr18:29,211,883...29,215,258

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

pericentriolar material 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA

NCBI chr16:51,008,315...51,105,261
Ensembl chr16:51,008,315...51,105,091

G

protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA

NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899

G

procollagen C-endopeptidase enhancer

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA

NCBI chr12:19,084,191...19,090,508
Ensembl chr12:19,084,210...19,090,508

G

procollagen C-endopeptidase enhancer 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA
panobinostat results in increased expression of PCOLCE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:96,193,461...96,251,116
Ensembl chr 8:96,193,461...96,251,114

G

Purkinje cell protein 4-like 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA

NCBI chr13:83,588,992...83,612,631
Ensembl chr13:83,588,992...83,609,966

G

phosphodiesterase 10A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA
panobinostat results in decreased expression of PDE10A mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563

G

phosphodiesterase 11A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA

NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158

G

phosphodiesterase 3A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA
panobinostat results in increased expression of PDE3A mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:174,172,804...174,443,944
Ensembl chr 4:174,172,868...174,438,274

G

phosphodiesterase 4C

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of PDE4C mRNA

NCBI chr16:18,690,727...18,711,555
Ensembl chr16:18,691,700...18,710,640

G

phosphodiesterase 4D

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA
panobinostat results in increased expression of PDE4D mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884

G

phosphodiesterase 4D interacting protein

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA
panobinostat results in increased expression of PDE4DIP mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379

G

platelet derived growth factor subunit A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA
panobinostat results in increased expression of PDGFA mRNA

PMID:26272509 PMID:27188386

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

platelet derived growth factor C

increases expression
multiple interactions

panobinostat results in increased expression of PDGFC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:166,316,870...166,493,449
Ensembl chr 2:166,316,803...166,493,433

G

platelet derived growth factor receptor alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA
panobinostat results in increased expression of PDGFRA mRNA

PMID:26272509 PMID:27188386

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

protein disulfide isomerase family A, member 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA
panobinostat results in increased expression of PDIA5 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:65,272,152...65,359,087
Ensembl chr11:65,272,155...65,359,084

G

PDZ and LIM domain 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA
panobinostat results in increased expression of PDLIM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076

G

podoplanin

increases expression
multiple interactions

panobinostat results in increased expression of PDPN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656

G

prodynorphin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA
panobinostat results in increased expression of PDYN mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

phosphofructokinase, platelet

increases expression
multiple interactions

panobinostat results in increased expression of PFKP mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA

PMID:26272509 PMID:27188386

NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018

G

phosphoglucomutase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA
panobinostat results in increased expression of PGM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

pleckstrin homology domain interacting protein

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA
panobinostat results in decreased expression of PHIP mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:83,776,802...83,891,192
Ensembl chr 8:83,781,465...83,894,283

G

pleckstrin homology-like domain, family A, member 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA
panobinostat results in increased expression of PHLDA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861

G

pleckstrin homology-like domain, family A, member 2

increases expression
multiple interactions

panobinostat results in increased expression of PHLDA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836

G

putative homeodomain transcription factor 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA

NCBI chr 4:14,215,190...14,330,549
Ensembl chr 4:14,215,263...14,330,513

G

phosphotyrosine interaction domain containing 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

piezo-type mechanosensitive ion channel component 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA

NCBI chr18:56,468,449...56,844,984
Ensembl chr18:56,469,680...56,844,216

G

Pim-1 proto-oncogene, serine/threonine kinase

increases expression
multiple interactions

panobinostat results in increased expression of PIM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174

G

pipecolic acid and sarcosine oxidase

increases expression
multiple interactions

panobinostat results in increased expression of PIPOX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA

PMID:26272509 PMID:27188386

NCBI chr10:62,769,874...62,783,484
Ensembl chr10:62,769,900...62,782,370

G

paired-like homeodomain 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA
panobinostat results in increased expression of PITX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293

G

protein kinase domain containing, cytoplasmic

increases expression
multiple interactions

panobinostat results in increased expression of PKDCC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:11,455,686...11,465,002
Ensembl chr 6:11,455,686...11,465,556

G

pyruvate kinase M1/2

increases expression
multiple interactions

panobinostat results in increased expression of PKM mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

PBX/knotted 1 homeobox 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA
panobinostat results in increased expression of PKNOX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:36,600,633...36,863,131
Ensembl chr 8:36,600,636...36,790,940

G

phospholipase A2 group IIA

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA
panobinostat results in increased expression of PLA2G2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014

G

phospholipase A2 group 4A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA
panobinostat results in increased expression of PLA2G4A mRNA

PMID:26272509 PMID:27188386

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

phospholipase A2 group VII

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA
panobinostat results in increased expression of PLA2G7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476

G

phospholipase A and acyltransferase 5

increases expression
multiple interactions

Panobinostat results in increased expression of PLAAT5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:204,847,600...204,878,456
Ensembl chr 1:204,847,600...204,878,184

G

plasminogen activator, tissue type

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA
panobinostat results in increased expression of PLAT mRNA

PMID:26272509 PMID:27188386

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

plasminogen activator, urokinase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA
panobinostat results in increased expression of PLAU mRNA

PMID:26272509 PMID:27188386

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

phospholipase B domain containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA
panobinostat results in increased expression of PLBD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:169,472,983...169,529,277
Ensembl chr 4:169,472,983...169,529,277

G

phospholipase C, epsilon 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA
panobinostat results in increased expression of PLCE1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438

G

pleckstrin homology domain containing A2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA

NCBI chr16:66,938,684...67,000,661
Ensembl chr16:66,939,109...66,999,395

G

pleckstrin homology domain containing M3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA

NCBI chr 9:66,166,233...66,325,332
Ensembl chr 9:66,166,321...66,325,294

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA
panobinostat results in increased expression of PLOD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255

G

proteolipid protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA
panobinostat results in increased expression of PLP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032

G

phospholipid scramblase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA
panobinostat results in increased expression of PLSCR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:92,784,279...92,804,698
Ensembl chr 8:92,784,356...92,804,692

G

plexin A2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA
panobinostat results in increased expression of PLXNA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979

G

plexin C1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA
panobinostat results in decreased expression of PLXNC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779

G

prostate transmembrane protein, androgen induced 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA
panobinostat results in increased expression of PMEPA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:162,011,884...162,060,343
Ensembl chr 3:162,012,751...162,060,454

G

phenylethanolamine-N-methyltransferase

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of PNMT mRNA

NCBI chr10:83,383,019...83,386,557
Ensembl chr10:83,384,923...83,386,556

G

purine nucleoside phosphorylase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA
panobinostat results in increased expression of PNP mRNA

PMID:26272509 PMID:27188386

NCBI chr15:24,170,607...24,178,269
Ensembl chr15:24,170,602...24,203,986

G

podocalyxin-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA
panobinostat results in increased expression of PODXL mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899

G

DNA polymerase iota

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA
panobinostat results in decreased expression of POLI mRNA

PMID:26272509 PMID:27188386

NCBI chr18:64,116,774...64,134,373
Ensembl chr18:64,116,774...64,163,418

G

RNA polymerase II subunit A

multiple interactions
decreases phosphorylation

(+)-JQ1 compound promotes the reaction [Panobinostat results in decreased phosphorylation of POLR2A protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of POLR2A protein]
panobinostat results in decreased phosphorylation of POLR2A protein

NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455

G

RNA polymerase III subunit E

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of POLR3E mRNA

NCBI chr 1:175,466,091...175,494,679
Ensembl chr 1:175,466,127...175,494,667

G

RNA polymerase III subunit G

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA
panobinostat results in increased expression of POLR3G mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:11,945,215...11,986,125
Ensembl chr 2:11,945,217...11,986,125

G

paraoxonase 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA
panobinostat results in decreased expression of PON1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

popeye domain containing 2

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of POPDC2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of POPDC2 mRNA]

NCBI chr11:62,351,843...62,398,688
Ensembl chr11:62,374,759...62,390,756

G

popeye domain containing 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA
panobinostat results in decreased expression of POPDC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:48,772,397...48,800,677
Ensembl chr20:48,772,462...48,800,593

G

POU class 3 homeobox 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA
panobinostat results in decreased expression of POU3F1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:136,910,391...136,913,371
Ensembl chr 5:136,910,391...136,913,371

G

POU class 3 homeobox 3

increases expression

panobinostat results in increased expression of POU3F3 mRNA

NCBI chr 9:44,945,872...44,948,998
Ensembl chr 9:44,945,872...44,948,992

G

POU class 5 homeobox 1

increases expression

panobinostat results in increased expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

PPARG coactivator 1 beta

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA
panobinostat results in increased expression of PPARGC1B mRNA

PMID:26272509 PMID:27188386

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

peptidylprolyl isomerase B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA
panobinostat results in increased expression of PPIB mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:66,603,877...66,609,734
Ensembl chr 8:66,603,861...66,630,428

G

peptidylprolyl isomerase C

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA
panobinostat results in increased expression of PPIC mRNA

PMID:26272509 PMID:27188386

NCBI chr18:46,842,410...46,855,016
Ensembl chr18:46,842,409...46,855,017

G

periplakin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA
panobinostat results in increased expression of PPL mRNA

PMID:26272509 PMID:27188386

NCBI chr10:10,450,919...10,496,575
Ensembl chr10:10,450,919...10,496,575

G

protein phosphatase, Mg2+/Mn2+ dependent, 1A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA

NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697

G

protein phosphatase, Mg2+/Mn2+ dependent, 1J

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA
panobinostat results in increased expression of PPM1J mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:192,278,597...192,283,883
Ensembl chr 2:192,278,517...192,283,882

G

protein phosphatase, Mg2+/Mn2+ dependent, 1K

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA
panobinostat results in increased expression of PPM1K mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:87,612,198...87,638,993
Ensembl chr 4:87,612,204...87,636,152

G

protoporphyrinogen oxidase

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA
panobinostat results in decreased expression of PPOX mRNA

PMID:26272509 PMID:27188386

NCBI chr13:83,697,661...83,701,998
Ensembl chr13:83,664,891...83,701,805

G

protein phosphatase 1, regulatory subunit 13 like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA
panobinostat results in increased expression of PPP1R13L mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:79,010,997...79,030,714
Ensembl chr 1:79,011,745...79,030,712

G

protein phosphatase 1, regulatory (inhibitor) subunit 1A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA
panobinostat results in increased expression of PPP1R1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:134,654,578...134,662,236
Ensembl chr 7:134,654,579...134,662,230

G

protein phosphatase 1, regulatory subunit 3B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA
panobinostat results in increased expression of PPP1R3B mRNA

PMID:26272509 PMID:27188386

NCBI chr16:56,830,011...56,842,395
Ensembl chr16:56,829,660...56,842,406

G

protein phosphatase 1, regulatory subunit 3D

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA
panobinostat results in increased expression of PPP1R3D mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:165,502,384...165,505,455
Ensembl chr 3:165,502,384...165,505,455

G

protein phosphatase 1, regulatory subunit 9A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA
panobinostat results in decreased expression of PPP1R9A mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907

G

protein phosphatase 2, regulatory subunit B, beta

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA
panobinostat results in decreased expression of PPP2R2B mRNA

PMID:26272509 PMID:27188386

NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025

G

PEAK1 related kinase activating pseudokinase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA
panobinostat results in increased expression of PRAG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:56,087,885...56,141,153
Ensembl chr16:56,087,885...56,141,153

G

PR/SET domain 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA
panobinostat results in increased expression of PRDM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488

G

PR/SET domain 14

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA
panobinostat results in increased expression of PRDM14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:6,082,163...6,092,712
Ensembl chr 5:6,082,442...6,092,712

G

PR/SET domain 16

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA

NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601

G

proline and arginine rich end leucine rich repeat protein

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA

NCBI chr13:45,368,407...45,391,480
Ensembl chr13:45,370,533...45,380,270

G

phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA
panobinostat results in increased expression of PREX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:155,306,950...155,456,688
Ensembl chr 3:155,306,950...155,456,688

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA
panobinostat results in increased expression of PRKACA mRNA

PMID:26272509 PMID:27188386

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

protein kinase C, alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA
panobinostat results in increased expression of PRKCA mRNA

PMID:26272509 PMID:27188386

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, beta

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA
panobinostat results in increased expression of PRKCB mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536

G

protein kinase C, eta

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA
panobinostat results in increased expression of PRKCH mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:92,292,000...92,490,663
Ensembl chr 6:92,292,000...92,490,654

G

prion protein

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA
panobinostat results in increased expression of PRNP mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

proline dehydrogenase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA
panobinostat results in increased expression of PRODH mRNA

PMID:26272509 PMID:27188386

NCBI chr11:82,910,043...82,927,305
Ensembl chr11:82,910,137...82,927,305

G

prokineticin 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA
panobinostat results in decreased expression of PROK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:132,346,681...132,361,754
Ensembl chr 4:132,347,103...132,361,385

G

proline rich 15

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA
panobinostat results in increased expression of PRR15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436

G

proline rich 16

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA
panobinostat results in increased expression of PRR16 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:44,424,348...44,764,796
Ensembl chr18:44,424,616...44,632,329

G

proline rich and Gla domain 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA
panobinostat results in increased expression of PRRG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:42,494,256...42,606,612
Ensembl chr X:42,494,256...42,606,588

G

paired related homeobox 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA
panobinostat results in increased expression of PRRX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866

G

serine protease 12

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA
panobinostat results in increased expression of PRSS12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126

G

serine protease 23

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA
panobinostat results in decreased expression of PRSS23 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

serine protease 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA
panobinostat results in increased expression of PRSS8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815

G

prune homolog 2 with BCH domain

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA
panobinostat results in decreased expression of PRUNE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:214,352,586...214,624,848
Ensembl chr 1:214,352,955...214,622,650

G

patched domain containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA
panobinostat results in increased expression of PTCHD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:39,681,910...39,733,416
Ensembl chr X:39,681,910...39,733,519

G

prostaglandin E receptor 4

increases expression

panobinostat results in increased expression of PTGER4 mRNA

NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670

G

prostaglandin-endoperoxide synthase 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA
panobinostat results in decreased expression of PTGS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

protein tyrosine phosphatase, non-receptor type 5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA
panobinostat results in decreased expression of PTPN5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882

G

protein tyrosine phosphatase, non-receptor type 9

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of PTPN9 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of PTPN9 mRNA]

NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952

G

protein tyrosine phosphatase, receptor type, F

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of PTPRF mRNA

NCBI chr 5:131,741,959...131,824,000
Ensembl chr 5:131,742,754...131,810,023

G

protein tyrosine phosphatase, receptor type N2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA
panobinostat results in decreased expression of PTPRN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575

G

protein tyrosine phosphatase, receptor type, O

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA
panobinostat results in decreased expression of PTPRO mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:170,164,071...170,374,790
Ensembl chr 4:170,164,431...170,374,771

G

purine-rich element binding protein G

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA
panobinostat results in decreased expression of PURG mRNA

PMID:26272509 PMID:27188386

NCBI chr16:58,732,327...58,763,356
Ensembl chr16:58,720,335...58,763,359

G

PWWP domain containing 2B

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA

NCBI chr 1:194,040,395...194,059,979
Ensembl chr 1:194,041,341...194,059,958

G

PX domain containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA
panobinostat results in increased expression of PXDC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:30,275,998...30,304,971
Ensembl chr17:30,276,377...30,304,973

G

PYD and CARD domain containing

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA
panobinostat results in increased expression of PYCARD mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

PYM homolog 1, exon junction complex associated factor

decreases expression

Panobinostat results in decreased expression of PYM1 mRNA

NCBI chr 7:1,177,746...1,200,899
Ensembl chr 7:1,178,008...1,198,937

G

RAB11 family interacting protein 1

increases expression

Panobinostat results in increased expression of RAB11FIP1 mRNA

NCBI chr16:64,886,902...64,917,491
Ensembl chr16:64,884,676...64,917,491

G

RAB11 family interacting protein 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA
panobinostat results in increased expression of RAB11FIP4 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:64,550,109...64,658,123
Ensembl chr10:64,550,177...64,654,759

G

RAB17, member RAS oncogene family

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA
panobinostat results in increased expression of RAB17 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:91,552,924...91,566,759
Ensembl chr 9:91,553,464...91,566,451

G

RAB20, member RAS oncogene family

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA
panobinostat results in increased expression of RAB20 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:78,019,337...78,043,529
Ensembl chr16:78,019,337...78,043,529

G

RAB31, member RAS oncogene family

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA
panobinostat results in increased expression of RAB31 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253

G

RAB33A, member RAS oncogene family

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA
panobinostat results in decreased expression of RAB33A mRNA

PMID:26272509 PMID:27188386

NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378

G

RAB3C, member RAS oncogene family

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA
panobinostat results in increased expression of RAB3C mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:41,627,720...41,843,541
Ensembl chr 2:41,627,720...41,843,749

G

RAB3A interacting protein

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA
panobinostat results in decreased expression of RAB3IP mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:52,531,461...52,575,295
Ensembl chr 7:52,532,401...52,561,043

G

Rab7b, member RAS oncogene family

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA
panobinostat results in increased expression of RAB7B mRNA

PMID:26272509 PMID:27188386

NCBI chr13:43,121,168...43,147,581
Ensembl chr13:43,121,226...43,147,581

G

RAB GTPase activating protein 1-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA
panobinostat results in increased expression of RABGAP1L mRNA

PMID:26272509 PMID:27188386

NCBI chr13:72,464,114...73,059,845
Ensembl chr13:72,468,110...73,059,984

G

Rac family small GTPase 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA
panobinostat results in increased expression of RAC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

[Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

ral guanine nucleotide dissociation stimulator like 1

increases expression

Panobinostat results in increased expression of RGL1 mRNA

NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191

G

retinoic acid receptor, beta

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA
panobinostat results in increased expression of RARB mRNA

PMID:26272509 PMID:27188386

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

retinoic acid receptor responder 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA
panobinostat results in increased expression of RARRES2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556

G

RAS p21 protein activator 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA
panobinostat results in decreased expression of RASA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:97,119,983...97,236,687
Ensembl chr 8:97,118,802...97,236,671

G

RAS and EF hand domain containing

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA
panobinostat results in increased expression of RASEF mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:87,548,908...87,619,286
Ensembl chr 5:87,548,908...87,619,031

G

RAS guanyl releasing protein 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA

NCBI chr 1:203,705,777...203,722,993
Ensembl chr 1:203,707,481...203,722,993

G

Ras association domain family member 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of RASSF1 mRNA

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

G

Ras association domain family member 10

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA
panobinostat results in decreased expression of RASSF10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:167,058,277...167,063,591
Ensembl chr 1:167,058,099...167,063,572

G

Ras association domain family member 3

increases expression

panobinostat results in increased expression of RASSF3 mRNA

NCBI chr 7:56,935,888...57,000,554
Ensembl chr 7:56,935,973...57,000,553

G

Ras association domain family member 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA

NCBI chr14:17,433,328...17,473,565
Ensembl chr14:17,442,789...17,473,330

G

retina and anterior neural fold homeobox

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA
panobinostat results in decreased expression of RAX mRNA

PMID:26272509 PMID:27188386

NCBI chr18:59,463,347...59,467,469
Ensembl chr18:59,463,737...59,467,431

G

RNA binding fox-1 homolog 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA
panobinostat results in increased expression of RBFOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:8,152,198...10,248,120
Ensembl chr10:8,152,198...9,686,659

G

RNA binding fox-1 homolog 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA
panobinostat results in decreased expression of RBFOX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935

G

RNA binding motif protein 22

decreases expression

Panobinostat results in decreased expression of RBM22 mRNA

NCBI chr18:54,013,374...54,024,182
Ensembl chr18:54,013,351...54,024,569

G

RNA binding motif protein 24

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA
panobinostat results in decreased expression of RBM24 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:18,275,681...18,288,231
Ensembl chr17:18,275,688...18,288,102

G

RNA binding motif protein 43

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA
panobinostat results in increased expression of RBM43 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:36,394,431...36,404,757
Ensembl chr 3:36,395,346...36,404,816

G

RNA binding motif protein 47

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA

NCBI chr14:42,053,290...42,191,572
Ensembl chr14:42,154,142...42,189,431

G

RNA binding motif, single stranded interacting protein 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA

NCBI chr 8:116,305,227...117,625,730
Ensembl chr 8:116,309,882...117,625,423

G

retinol binding protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA
panobinostat results in increased expression of RBP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743

G

RNA binding protein, mRNA processing factor 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA
panobinostat results in increased expression of RBPMS2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:66,153,169...66,184,278
Ensembl chr 8:66,153,593...66,184,268

G

regulator of calcineurin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA
panobinostat results in increased expression of RCAN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045

G

RAD52 motif containing 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA

NCBI chr10:86,562,871...86,573,034
Ensembl chr10:86,539,553...86,573,034

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

panobinostat results in increased activity of and results in decreased acetylation of RELA protein; resveratrol inhibits the reaction [panobinostat results in increased activity of and results in decreased acetylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

reelin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA
panobinostat results in increased expression of RELN mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211

G

RE1-silencing transcription factor

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA
panobinostat results in increased expression of REST mRNA

PMID:26272509 PMID:27188386

NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354

G

raftlin family member 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA
panobinostat results in increased expression of RFTN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:56,651,617...56,707,830
Ensembl chr 9:56,630,460...56,707,810

G

regulatory factor X3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA

NCBI chr 1:225,449,872...225,709,622
Ensembl chr 1:225,456,187...225,709,402

G

regulatory factor X4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA
panobinostat results in increased expression of RFX4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967

G

similar to RIKEN cDNA 3110043O21

decreases expression
multiple interactions

panobinostat results in decreased expression of C9ORF72 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:49,766,340...49,791,434
Ensembl chr 5:49,766,325...49,791,408

G

repulsive guidance molecule BMP co-receptor a

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA
panobinostat results in decreased expression of RGMA mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:127,128,934...127,172,918
Ensembl chr 1:127,128,934...127,172,918

G

regulator of G-protein signaling 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA
panobinostat results in increased expression of RGS5 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518

G

ras homolog family member B

increases expression
multiple interactions

panobinostat results in increased expression of RHOB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

Rho-related BTB domain containing 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA
panobinostat results in increased expression of RHOBTB3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041

G

ras homolog family member H

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA

NCBI chr14:42,341,135...42,371,971
Ensembl chr14:42,337,751...42,386,369

G

regulating synaptic membrane exocytosis 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA
panobinostat results in increased expression of RIMS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:24,696,959...25,196,404
Ensembl chr 9:24,698,854...25,196,631

G

receptor-interacting serine-threonine kinase 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA
panobinostat results in increased expression of RIPK4 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:37,122,555...37,144,799
Ensembl chr11:37,122,565...37,144,799

G

Rho family GTPase 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA
panobinostat results in increased expression of RND3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327

G

ring finger protein 144B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA
panobinostat results in increased expression of RNF144B mRNA

PMID:26272509 PMID:27188386

NCBI chr17:17,431,271...17,580,687
Ensembl chr17:17,432,786...17,562,760

G

ring finger protein 150

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA
panobinostat results in increased expression of RNF150 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:25,006,978...25,229,273
Ensembl chr19:25,006,611...25,228,678

G

ring finger protein 182

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA
panobinostat results in decreased expression of RNF182 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:21,026,110...21,081,760
Ensembl chr17:21,030,214...21,094,911

G

ring finger protein 217

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA
panobinostat results in increased expression of RNF217 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:26,016,668...26,108,736
Ensembl chr 1:26,015,728...26,108,736

G

ring finger protein 24

increases expression

Panobinostat results in increased expression of RNF24 mRNA

NCBI chr 3:118,520,459...118,575,213
Ensembl chr 3:118,525,349...118,541,080

G

ring finger protein 43

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA
panobinostat results in increased expression of RNF43 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:72,461,508...72,537,301
Ensembl chr10:72,464,348...72,536,977

G

roundabout guidance receptor 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA

NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536

G

receptor tyrosine kinase-like orphan receptor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA
panobinostat results in increased expression of ROR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:114,744,311...115,088,155
Ensembl chr 5:114,744,304...115,088,155

G

ribosomal protein L31

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA
panobinostat results in decreased expression of RPL31 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129

G

ribonuclease P and MRP subunit p25

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA
panobinostat results in increased expression of RPP25 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:57,907,352...57,908,732
Ensembl chr 8:57,907,352...57,908,732

G

reprimo, TP53 dependent G2 arrest mediator homolog

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA
panobinostat results in increased expression of RPRM mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:38,539,581...38,540,998
Ensembl chr 3:38,539,581...38,540,998

G

reprimo-like

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA
panobinostat results in increased expression of RPRML mRNA

PMID:26272509 PMID:27188386

NCBI chr10:88,560,248...88,561,252
Ensembl chr10:88,560,248...88,561,252

G

ribosomal protein S24

increases expression

panobinostat results in increased expression of RPS24 mRNA

NCBI chr16:89,538...94,267
Ensembl chr16:89,604...94,279

G

ribosomal protein S6 kinase A6

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA
panobinostat results in decreased expression of RPS6KA6 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:76,353,316...76,454,502
Ensembl chr X:76,353,760...76,454,484

G

Ras-related GTP binding D

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA
panobinostat results in decreased expression of RRAGD mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356

G

ras responsive element binding protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA
panobinostat results in increased expression of RREB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:26,876,687...27,002,554
Ensembl chr17:26,876,697...27,002,615

G

R-spondin 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA
panobinostat results in decreased expression of RSPO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:74,096,378...74,239,398
Ensembl chr 7:74,103,090...74,238,933

G

R-spondin 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA
panobinostat results in increased expression of RSPO3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:28,283,914...28,368,661
Ensembl chr 1:28,283,914...28,367,061

G

RT1 class II, locus Bb

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus DMa

multiple interactions
increases expression

[Cisplatin co-treated with Panobinostat] affects the expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA
panobinostat results in increased expression of HLA-DMA mRNA

PMID:21791302 PMID:26272509 PMID:27188386

NCBI chr20:4,707,028...4,710,432
Ensembl chr20:4,707,028...4,710,432

G

RT1 class II, locus DMb

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of HLA-DMB mRNA

NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340

G

RT1 class II, locus Ha

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of HLA-DPA1 mRNA

NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244

G

reticulon 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA
panobinostat results in decreased expression of RTN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436

G

receptor (chemosensory) transporter protein 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA

NCBI chr11:77,422,982...77,425,498
Ensembl chr11:77,422,982...77,425,498

G

RUNX1 partner transcriptional co-repressor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA
panobinostat results in increased expression of RUNX1T1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:27,187,551...27,335,592

G

RUNX family transcription factor 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

RUNX family transcription factor 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA
panobinostat results in increased expression of RUNX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156

G

ryanodine receptor 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA
panobinostat results in decreased expression of RYR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:99,431,755...99,979,125
Ensembl chr 3:99,432,505...99,704,961

G

S100 calcium binding protein A10

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA
panobinostat results in increased expression of S100A10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661

G

S100 calcium binding protein A11

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA
panobinostat results in increased expression of S100A11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

S100 calcium-binding protein A4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA
panobinostat results in increased expression of S100A4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

S100 calcium binding protein A6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA
panobinostat results in increased expression of S100A6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

S100 calcium binding protein B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA
panobinostat results in increased expression of S100B mRNA

PMID:26272509 PMID:27188386

NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743

G

sphingosine-1-phosphate receptor 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA
panobinostat results in decreased expression of S1PR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505

G

sphingosine-1-phosphate receptor 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA
panobinostat results in increased expression of S1PR5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:19,786,676...19,791,862
Ensembl chr 8:19,786,663...19,791,795

G

spalt-like transcription factor 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA
panobinostat results in decreased expression of SALL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:25,021,345...25,038,918
Ensembl chr15:25,021,345...25,038,918

G

spalt-like transcription factor 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA
panobinostat results in decreased expression of SALL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:74,406,066...74,425,974
Ensembl chr18:74,407,560...74,426,789

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA
panobinostat results in increased expression of SAT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813

G

SET binding factor 2

increases expression

panobinostat results in increased expression of SBF2 mRNA

NCBI chr 1:164,352,892...164,719,883
Ensembl chr 1:164,353,444...164,719,807

G

saccharopine dehydrogenase (putative)

decreases expression
multiple interactions

panobinostat results in decreased expression of SCCPDH mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA

PMID:26272509 PMID:27188386

NCBI chr13:91,400,120...91,421,875
Ensembl chr13:91,400,190...91,422,222

G

secretogranin III

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA
panobinostat results in increased expression of SCG3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015

G

secretoglobin, family 3A, member 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA
panobinostat results in increased expression of SCGB3A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:35,932,840...35,935,762
Ensembl chr18:35,932,840...35,935,762

G

secretagogin, EF-hand calcium binding protein

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA

NCBI chr17:41,106,681...41,148,656
Ensembl chr17:41,106,467...41,148,667

G

Scm polycomb group protein like 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA
panobinostat results in increased expression of SCML1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:32,893,100...32,912,686
Ensembl chr X:32,894,327...32,911,366

G

sodium voltage-gated channel beta subunit 2

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of SCN2B mRNA

NCBI chr 8:45,425,629...45,437,765
Ensembl chr 8:45,425,629...45,437,765

G

sodium voltage-gated channel beta subunit 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA
panobinostat results in increased expression of SCN4B mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:45,446,580...45,462,294
Ensembl chr 8:45,446,215...45,462,292

G

sodium voltage-gated channel alpha subunit 7

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA
panobinostat results in decreased expression of SCN7A mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:51,335,841...51,438,308
Ensembl chr 3:51,335,841...51,438,256

G

sodium channel epithelial 1 subunit alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA
panobinostat results in increased expression of SCNN1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181

G

sodium channel epithelial 1 subunit gamma

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA
panobinostat results in increased expression of SCNN1G mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816

G

stimulator of chondrogenesis 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA
panobinostat results in increased expression of SCRG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:32,760,028...32,788,299
Ensembl chr16:32,760,028...32,788,299

G

signal peptide, CUB domain and EGF like domain containing 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA
panobinostat results in decreased expression of SCUBE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:163,831,876...163,899,925
Ensembl chr 1:163,832,015...163,899,393

G

syndecan 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA
panobinostat results in increased expression of SDC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580

G

SEC24 homolog D, COPII coat complex component

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA
panobinostat results in increased expression of SEC24D mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:211,418,557...211,526,588
Ensembl chr 2:211,418,623...211,526,587

G

selenoprotein I

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA
panobinostat results in increased expression of SELENOI mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:26,073,127...26,111,326
Ensembl chr 6:26,072,648...26,111,314

G

selenoprotein P

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA
panobinostat results in increased expression of SELENOP mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852

G

semaphorin 3C

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA
panobinostat results in increased expression of SEMA3C mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534

G

semaphorin 3E

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA
panobinostat results in increased expression of SEMA3E mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:20,297,534...20,555,287
Ensembl chr 4:20,299,718...20,555,229

G

semaphorin 5A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA
panobinostat results in decreased expression of SEMA5A mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:83,309,843...83,741,084
Ensembl chr 2:83,309,843...83,741,084

G

semaphorin 6D

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA
panobinostat results in decreased expression of SEMA6D mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:111,883,415...111,941,100
Ensembl chr 3:111,883,872...111,941,094

G

SUMO specific peptidase 6

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of SENP6 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of SENP6 mRNA]

NCBI chr 8:80,988,675...81,071,606
Ensembl chr 8:80,989,052...81,067,170

G

septin 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA
Panobinostat results in increased expression of SEPTIN6 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:116,153,255...116,230,334
Ensembl chr X:116,153,255...116,230,115

G

serpin family B member 9

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA
panobinostat results in increased expression of SERPINB9 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230

G

serpin family F member 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA
panobinostat results in decreased expression of SERPINF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

G

SEC14 and spectrin domain containing 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA
panobinostat results in decreased expression of SESTD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:62,123,590...62,220,759
Ensembl chr 3:62,129,887...62,220,546

G

seizure related 6 homolog

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA
panobinostat results in increased expression of SEZ6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:62,818,931...62,868,686
Ensembl chr10:62,819,069...62,868,671

G

Scm-like with four mbt domains 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA
panobinostat results in decreased expression of SFMBT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:5,889,046...6,009,860
Ensembl chr16:5,890,782...6,006,605

G

Scm-like with four mbt domains 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA
panobinostat results in increased expression of SFMBT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:67,934,296...68,128,905
Ensembl chr17:67,935,904...68,128,781

G

stratifin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA
panobinostat results in increased expression of SFN mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

secreted frizzled-related protein 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA
panobinostat results in decreased expression of SFRP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286

G

secreted frizzled-related protein 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA
panobinostat results in decreased expression of SFRP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

serum/glucocorticoid regulated kinase family, member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA
panobinostat results in increased expression of SGK3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:9,345,761...9,472,243
Ensembl chr 5:9,346,040...9,415,476

G

sphingosine-1-phosphate phosphatase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA
panobinostat results in increased expression of SGPP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:94,425,339...94,446,534
Ensembl chr 6:94,425,339...94,446,534

G

sphingosine-1-phosphate phosphatase 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA
panobinostat results in increased expression of SGPP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:79,762,658...79,884,665
Ensembl chr 9:79,763,284...79,880,457

G

SH3 domain-containing kinase-binding protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA
panobinostat results in increased expression of SH3KBP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:34,877,862...35,223,013
Ensembl chr X:34,877,866...35,222,747

G

SH2 domain containing adaptor protein B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA
panobinostat results in increased expression of SHB mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:59,678,066...59,785,443
Ensembl chr 5:59,678,216...59,785,538

G

SHC adaptor protein 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA

NCBI chr17:13,652,247...13,772,710
Ensembl chr17:13,651,202...13,772,710

G

shisa family member 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA

NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013

G

shisa family member 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA

NCBI chr10:50,897,740...51,192,111
Ensembl chr10:50,903,333...51,192,063

G

salt-inducible kinase 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA

NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991

G

SIX homeobox 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA
panobinostat results in increased expression of SIX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:91,746,739...91,751,975
Ensembl chr 6:91,746,739...91,751,975

G

SIX homeobox 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA
panobinostat results in decreased expression of SIX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:9,039,017...9,043,336
Ensembl chr 6:9,036,434...9,053,301

G

SIX homeobox 6

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA
panobinostat results in decreased expression of SIX6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:91,634,568...91,639,548
Ensembl chr 6:91,634,568...91,639,548

G

Six6 opposite strand transcript 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA
panobinostat results in decreased expression of C14ORF39 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:91,579,185...91,615,183
Ensembl chr 6:91,579,325...91,615,148

G

src kinase associated phosphoprotein 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA
panobinostat results in increased expression of SKAP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891

G

solute carrier family 16 member 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA
panobinostat results in increased expression of SLC16A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 16, member 14

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA
panobinostat results in decreased expression of SLC16A14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:86,112,894...86,137,318

G

solute carrier family 16, member 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA
panobinostat results in increased expression of SLC16A4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:194,911,075...194,933,162
Ensembl chr 2:194,911,236...194,933,117

G

solute carrier family 17 member 5

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of SLC17A5 mRNA

NCBI chr 8:79,394,416...79,429,387

G

solute carrier family 18 member B1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA
panobinostat results in increased expression of SLC18B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:21,628,235...21,670,807
Ensembl chr 1:21,628,237...21,670,684

G

solute carrier family 19 member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA
panobinostat results in increased expression of SLC19A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:84,277,024...84,299,337

G

solute carrier family 1 member 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of SLC1A1 mRNA

NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402

G

solute carrier family 1 member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA
panobinostat results in increased expression of SLC1A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605

G

solute carrier family 24 member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA
panobinostat results in increased expression of SLC24A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:132,552,119...133,051,192
Ensembl chr 3:132,551,595...133,051,192

G

solute carrier family 25 member 12

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA
panobinostat results in increased expression of SLC25A12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:56,097,166...56,191,841
Ensembl chr 3:56,097,269...56,192,100

G

solute carrier family 25 member 16

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA
panobinostat results in increased expression of SLC25A16 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:25,691,474...25,717,558
Ensembl chr20:25,662,055...25,716,319

G

solute carrier family 25 member 25

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of SLC25A25 mRNA

NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216

G

solute carrier family 25, member 53

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA
panobinostat results in decreased expression of SLC25A53 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:100,306,917...100,319,662
Ensembl chr X:100,306,915...100,319,863

G

solute carrier family 27 member 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA

NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208

G

solute carrier family 2 member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA
panobinostat results in increased expression of SLC2A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

solute carrier family 30 member 4

increases expression

panobinostat results in increased expression of SLC30A4 mRNA

NCBI chr 3:109,753,270...109,775,306
Ensembl chr 3:109,753,273...109,775,306

G

solute carrier family 35, member D3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA

NCBI chr 1:14,565,482...14,573,581
Ensembl chr 1:14,569,687...14,573,159

G

solute carrier family 35, member F2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA
panobinostat results in increased expression of SLC35F2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:54,159,970...54,203,614
Ensembl chr 8:54,159,970...54,203,612

G

solute carrier family 35, member G2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA

NCBI chr 8:101,085,579...101,113,339
Ensembl chr 8:101,085,545...101,113,349

G

solute carrier family 38, member 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA

NCBI chr 6:91,987,652...92,076,416
Ensembl chr 6:91,987,672...92,049,935

G

solute carrier family 39 member 6

decreases expression

panobinostat results in decreased expression of SLC39A6 mRNA

NCBI chr18:15,864,874...15,885,417
Ensembl chr18:15,864,875...15,885,417

G

solute carrier family 39 member 7

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of SLC39A7 mRNA

NCBI chr20:4,823,166...4,826,538
Ensembl chr20:4,822,012...4,826,537

G

solute carrier family 39 member 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA
panobinostat results in increased expression of SLC39A8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:224,171,787...224,319,326
Ensembl chr 2:224,256,654...224,319,129

G

solute carrier family 40 member 1

multiple interactions
increases expression

[Cisplatin co-treated with Panobinostat] affects the expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA
panobinostat results in increased expression of SLC40A1 mRNA

PMID:21791302 PMID:26272509 PMID:27188386

NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481

G

solute carrier family 43 member 1

increases expression

panobinostat results in increased expression of SLC43A1 mRNA

NCBI chr 3:69,920,586...69,946,768
Ensembl chr 3:69,920,649...69,946,768

G

solute carrier family 52 member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA
panobinostat results in increased expression of SLC52A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:140,498,924...140,515,845
Ensembl chr 3:140,509,473...140,514,096

G

solute carrier family 6 member 8

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA
panobinostat results in decreased expression of SLC6A8 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979

G

solute carrier family 7 member 10

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA
panobinostat results in increased expression of SLC7A10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:87,829,084...87,845,073
Ensembl chr 1:87,829,175...87,845,071

G

solute carrier family 7 member 11

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA
panobinostat results in increased expression of SLC7A11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 7 member 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA
panobinostat results in increased expression of SLC7A5 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

solute carrier family 9 member B2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA
panobinostat results in decreased expression of SLC9B2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:223,726,982...223,761,234
Ensembl chr 2:223,736,354...223,761,225

G

solute carrier organic anion transporter family, member 4C1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA
panobinostat results in increased expression of SLCO4C1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715

G

schlafen family member 5

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA

NCBI chr10:67,881,068...67,895,013
Ensembl chr10:67,880,009...67,893,109

G

slit guidance ligand 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA
panobinostat results in increased expression of SLIT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127

G

slit guidance ligand 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA
panobinostat results in increased expression of SLIT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948

G

slit guidance ligand 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA
panobinostat results in increased expression of SLIT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634

G

SLIT and NTRK-like family, member 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA
panobinostat results in increased expression of SLITRK6 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:87,563,506...87,570,125
Ensembl chr15:87,563,322...87,570,393

G

SMAD family member 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA
panobinostat results in decreased expression of SMAD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA
panobinostat results in increased expression of SMARCA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:224,191,125...224,358,640
Ensembl chr 1:224,191,125...224,358,684

G

small integral membrane protein 14

increases expression

Panobinostat results in increased expression of SMIM14 mRNA

NCBI chr14:42,783,361...42,829,762
Ensembl chr14:42,783,332...42,829,760

G

SPARC related modular calcium binding 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA
panobinostat results in decreased expression of SMOC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:100,701,330...100,897,441
Ensembl chr 6:100,701,346...100,862,699

G

SPARC related modular calcium binding 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA

NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693

G

sphingomyelin phosphodiesterase, acid-like 3A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA

NCBI chr20:37,132,592...37,155,567
Ensembl chr20:37,132,592...37,155,567

G

SET and MYND domain containing 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA
panobinostat results in increased expression of SMYD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:101,425,270...101,466,576
Ensembl chr13:101,425,273...101,466,576

G

snail family transcriptional repressor 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA
panobinostat results in increased expression of SNAI2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

synaptosome associated protein 25

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA
panobinostat results in increased expression of SNAP25 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760

G

SNF related kinase

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of SNRK mRNA

NCBI chr 8:121,779,704...121,833,949
Ensembl chr 8:121,793,302...121,832,323

G

sorting nexin 25

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA
panobinostat results in decreased expression of SNX25 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:46,134,552...46,238,471
Ensembl chr16:46,125,804...46,238,440

G

suppressor of cytokine signaling 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA
panobinostat results in increased expression of SOCS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383

G

suppressor of cytokine signaling 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA
panobinostat results in increased expression of SOCS2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

suppressor of cytokine signaling 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA
panobinostat results in decreased expression of SOCS3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

sortilin-related VPS10 domain containing receptor 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA
panobinostat results in decreased expression of SORCS2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:74,371,089...74,735,943
Ensembl chr14:74,371,415...74,735,943

G

sorbitol dehydrogenase

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA
panobinostat results in decreased expression of SORD mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133

G

sclerostin

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA

NCBI chr10:86,912,517...86,915,561
Ensembl chr10:86,911,517...86,915,561

G

SRY-box transcription factor 10

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA
panobinostat results in increased expression of SOX10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544

G

SRY-box transcription factor 11

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA
panobinostat results in decreased expression of SOX11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:44,008,333...44,010,354
Ensembl chr 6:44,008,340...44,010,354

G

SRY-box transcription factor 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA
panobinostat results in decreased expression of SOX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

SRY-box transcription factor 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA
panobinostat results in decreased expression of SOX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:139,308,608...139,310,687
Ensembl chr X:139,309,329...139,310,678

G

SRY-box transcription factor 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA
panobinostat results in increased expression of SOX8 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818

G

SRY-box transcription factor 9

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA
panobinostat results in increased expression of SOX9 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

Sp5 transcription factor

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA
panobinostat results in increased expression of SP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:55,274,931...55,277,733
Ensembl chr 3:55,274,931...55,277,733

G

Sp6 transcription factor

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA
panobinostat results in increased expression of SP6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:82,005,518...82,009,699
Ensembl chr10:82,005,294...82,011,013

G

Sp8 transcription factor

decreases expression

panobinostat results in decreased expression of SP8 mRNA

NCBI chr 6:139,816,258...139,818,865
Ensembl chr 6:139,814,819...139,823,168
Ensembl chr 6:139,814,819...139,823,168

G

sperm associated antigen 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA

NCBI chr 7:67,361,474...67,421,369
Ensembl chr 7:67,361,477...67,421,368

G

sperm associated antigen 9

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA

NCBI chr10:78,943,439...79,077,797
Ensembl chr10:78,943,479...79,077,797

G

sphingosine kinase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA
panobinostat results in increased expression of SPHK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240

G

serine peptidase inhibitor, Kazal type 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA
panobinostat results in increased expression of SPINK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642

G

serine peptidase inhibitor, Kazal type 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA
panobinostat results in increased expression of SPINK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:30,967,682...30,974,326
Ensembl chr14:30,967,714...30,974,326

G

secreted phosphoprotein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA
panobinostat results in increased expression of SPP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sprouty RTK signaling antagonist 1

decreases expression

panobinostat results in decreased expression of SPRY1 mRNA

NCBI chr 2:120,557,256...120,561,917
Ensembl chr 2:120,556,706...120,566,189

G

splA/ryanodine receptor domain and SOCS box containing 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA
panobinostat results in increased expression of SPSB4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:97,536,519...97,609,757
Ensembl chr 8:97,536,520...97,609,787

G

sulfide quinone oxidoreductase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA
panobinostat results in increased expression of SQOR mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:109,841,225...109,886,724
Ensembl chr 3:109,841,250...109,960,778

G

SRC kinase signaling inhibitor 1

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA
panobinostat results in decreased expression of SRCIN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:82,502,911...82,569,882
Ensembl chr10:82,504,393...82,571,040

G

single-stranded DNA binding protein 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA
panobinostat results in decreased expression of SSBP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:22,650,488...22,938,669
Ensembl chr 2:22,651,258...22,933,696

G

somatostatin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA
panobinostat results in increased expression of SST mRNA

PMID:26272509 PMID:27188386

NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173

G

ST14 transmembrane serine protease matriptase

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA

NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA
panobinostat results in increased expression of ST3GAL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 5

increases expression

Panobinostat results in increased expression of ST3GAL5 mRNA

NCBI chr 4:104,134,613...104,192,558
Ensembl chr 4:104,134,613...104,192,558

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA

NCBI chr10:101,910,220...101,928,412
Ensembl chr10:101,909,971...101,915,008
Ensembl chr10:101,909,971...101,915,008

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA
panobinostat results in decreased expression of ST6GALNAC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:241,741,933...241,911,214
Ensembl chr 2:241,742,688...241,911,208

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ST8SIA2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA2 mRNA]

NCBI chr 1:127,762,573...127,838,017
Ensembl chr 1:127,762,573...127,838,091

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of ST8SIA3 mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA3 mRNA]
panobinostat affects the expression of ST8SIA3 mRNA

NCBI chr18:57,754,349...57,760,839
Ensembl chr18:57,754,347...57,760,839

G

signal transducing adaptor molecule 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA

NCBI chr 3:37,186,145...37,234,810
Ensembl chr 3:37,186,145...37,234,812

G

signal transducer and activator of transcription 3

multiple interactions
increases acetylation

Panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; Panobinostat promotes the reaction [Resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; Panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]
Panobinostat results in increased acetylation of STAT3 protein

PMID:23681230 PMID:26775640

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA
panobinostat results in increased expression of STAT6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495

G

stanniocalcin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA
panobinostat results in increased expression of STC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264

G

STEAP family member 1

multiple interactions

[Cisplatin co-treated with Panobinostat] affects the expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA

PMID:21791302 PMID:27188386

NCBI chr 4:28,276,972...28,287,484
Ensembl chr 4:28,276,909...28,287,479

G

STEAP3 metalloreductase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA
panobinostat results in increased expression of STEAP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:31,351,954...31,397,344
Ensembl chr13:31,351,954...31,396,519

G

STIM activating enhancer

increases expression

Panobinostat results in increased expression of STIMATE-MUSTN1 mRNA

NCBI chr16:6,013,392...6,070,829
Ensembl chr16:6,013,369...6,071,816

G

serine/threonine kinase 32A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA
panobinostat results in decreased expression of STK32A mRNA

PMID:26272509 PMID:27188386

NCBI chr18:35,258,865...35,374,985
Ensembl chr18:35,259,052...35,369,451

G

stathmin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA
panobinostat results in increased expression of STMN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011

G

stomatin

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA

NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:18,644,378...18,667,354

G

stonin 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of STON1 mRNA

NCBI chr 6:5,843,186...5,892,557
Ensembl chr 6:5,843,185...5,892,449

G

storkhead box 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA

NCBI chr20:30,598,284...30,666,371
Ensembl chr20:30,598,168...30,666,939

G

signaling receptor and transporter of retinol STRA6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA
panobinostat results in increased expression of STRA6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:58,548,899...58,568,861
Ensembl chr 8:58,549,736...58,568,860

G

serine/threonine/tyrosine kinase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA
panobinostat results in increased expression of STYK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:165,047,613...165,097,890
Ensembl chr 4:165,048,440...165,096,440

G

sulfatase 2

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of SULF2 mRNA

NCBI chr 3:154,822,079...154,904,566
Ensembl chr 3:154,822,085...154,904,415

G

sulfotransferase family 1A member 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

sulfotransferase family 1C member 2A

increases expression
multiple interactions

panobinostat results in increased expression of SULT1C2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734

G

sushi domain containing 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA
panobinostat results in increased expression of SUSD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903

G

sushi domain containing 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA
panobinostat results in increased expression of SUSD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:15,400,845...15,417,851
Ensembl chr17:15,400,845...15,417,044

G

synaptic vesicle glycoprotein 2c

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA
panobinostat results in increased expression of SV2C mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:27,232,933...27,428,479
Ensembl chr 2:27,232,933...27,428,477

G

spleen associated tyrosine kinase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA
panobinostat results in increased expression of SYK mRNA

PMID:26272509 PMID:27188386

NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410

G

synaptotagmin binding, cytoplasmic RNA interacting protein

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA

NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515

G

spectrin repeat containing nuclear envelope protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA
panobinostat results in increased expression of SYNE1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:41,512,146...41,983,382
Ensembl chr 1:41,512,030...41,983,322

G

spectrin repeat containing, nuclear envelope family member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA
panobinostat results in increased expression of SYNE3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:123,872,895...123,964,773
Ensembl chr 6:123,873,174...123,953,409

G

synaptogyrin 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA
panobinostat results in increased expression of SYNGR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:111,635,911...111,659,341
Ensembl chr 7:111,635,918...111,659,341

G

synaptoporin

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA
panobinostat results in increased expression of SYNPR mRNA

PMID:26272509 PMID:27188386

NCBI chr15:11,573,373...11,900,255
Ensembl chr15:11,574,231...11,900,243

G

synaptotagmin 11

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA
panobinostat results in decreased expression of SYT11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964

G

synaptotagmin 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA
panobinostat results in increased expression of SYT4 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:23,036,973...23,046,380
Ensembl chr18:23,038,378...23,046,332

G

synaptotagmin 7

increases expression
multiple interactions

panobinostat results in increased expression of SYT7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:207,031,359...207,093,787
Ensembl chr 1:207,031,592...207,089,026

G

synaptotagmin-like 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA

NCBI chr 1:144,272,870...144,379,310
Ensembl chr 1:144,273,360...144,379,222

G

synaptotagmin-like 4

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA

NCBI chr X:97,135,496...97,185,867
Ensembl chr X:97,135,500...97,185,854

G

tachykinin, precursor 1

increases expression

panobinostat results in increased expression of TAC1 mRNA

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

transforming, acidic coiled-coil containing protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA
panobinostat results in increased expression of TACC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:66,812,232...66,895,736
Ensembl chr16:66,812,295...66,895,733

G

tumor-associated calcium signal transducer 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
panobinostat results in increased expression of TACSTD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:96,707,950...96,709,650
Ensembl chr 4:96,707,951...96,709,650

G

transgelin 2

increases expression
multiple interactions

panobinostat results in increased expression of TAGLN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA
panobinostat results in increased expression of TANC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:44,099,387...44,335,478
Ensembl chr 3:44,134,016...44,331,627

G

threonyl-tRNA synthetase 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA
Panobinostat results in increased expression of TARS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:60,368,893...60,387,715
Ensembl chr 2:60,367,796...60,387,717

G

TBC1 domain family, member 16

increases expression

Panobinostat results in increased expression of TBC1D16 mRNA

NCBI chr10:104,400,963...104,486,698
Ensembl chr10:104,402,398...104,486,670

G

TBC1 domain family, member 30

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA
panobinostat results in decreased expression of TBC1D30 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:56,779,570...56,869,092
Ensembl chr 7:56,782,165...56,870,515

G

TBC1 domain family, member 8

decreases expression

panobinostat results in decreased expression of TBC1D8 mRNA

NCBI chr 9:41,651,394...41,761,432
Ensembl chr 9:41,651,395...41,761,409

G

TBL1X/Y related 1

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBL1XR1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBL1XR1 mRNA]

NCBI chr 2:104,788,950...104,929,055
Ensembl chr 2:104,801,721...104,929,055

G

T-box transcription factor 3

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBX3 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBX3 mRNA]

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

tandem C2 domains, nuclear

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA

NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326

G

tudor and KH domain containing

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA
panobinostat results in decreased expression of TDRKH mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:182,049,175...182,071,516
Ensembl chr 2:182,049,215...182,070,755

G

testis development related protein

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA
panobinostat results in increased expression of TDRP mRNA

PMID:26272509 PMID:27188386

NCBI chr16:75,624,047...75,652,635
Ensembl chr16:75,624,907...75,652,420

G

teneurin transmembrane protein 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA
panobinostat results in increased expression of TENM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:20,480,662...21,706,415
Ensembl chr10:20,481,854...21,705,597

G

terminal nucleotidyltransferase 5B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA
panobinostat results in increased expression of TENT5B mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:145,695,358...145,702,668
Ensembl chr 5:145,695,362...145,706,073

G

telomerase associated protein 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of TEP1 mRNA

NCBI chr15:24,045,876...24,093,526
Ensembl chr15:24,045,878...24,093,526

G

testin LIM domain protein

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA
panobinostat results in increased expression of TES mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:45,365,304...45,403,829
Ensembl chr 4:45,365,285...45,403,829

G

transcription factor AP-2 alpha

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA
panobinostat results in increased expression of TFAP2A mRNA

PMID:26272509 PMID:27188386

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

transcription factor AP-2 beta

multiple interactions
increases expression
affects expression

(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of TFAP2B mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TFAP2B mRNA]
panobinostat results in increased expression of TFAP2B mRNA
panobinostat affects the expression of TFAP2B mRNA

PMID:26272509 PMID:26733615 PMID:27188386

NCBI chr 9:21,786,251...21,816,054
Ensembl chr 9:21,786,258...21,814,520

G

transcription factor AP-2 gamma

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA
panobinostat results in increased expression of TFAP2C mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:161,315,114...161,322,998
Ensembl chr 3:161,315,031...161,322,995

G

transcription factor CP2-like 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA
panobinostat results in increased expression of TFCP2L1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:29,733,813...29,793,870
Ensembl chr13:29,733,840...29,793,870

G

tissue factor pathway inhibitor

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA
panobinostat results in increased expression of TFPI mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

tissue factor pathway inhibitor 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA
panobinostat results in increased expression of TFPI2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600

G

transforming growth factor beta 1 induced transcript 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA
panobinostat results in increased expression of TGFB1I1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:182,828,544...182,837,080

G

transforming growth factor, beta induced

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA

NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240

G

transforming growth factor, beta receptor associated protein 1

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TGFBRAP1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TGFBRAP1 mRNA]

NCBI chr 9:45,320,975...45,371,329
Ensembl chr 9:45,320,930...45,371,311

G

THAP domain containing 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA

NCBI chr 7:50,992,912...51,007,582
Ensembl chr 7:50,995,793...51,008,061

G

thrombospondin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA
panobinostat results in increased expression of THBS2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:55,670,394...55,699,789
Ensembl chr 1:55,670,394...55,699,789

G

thyroid hormone receptor beta

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA
panobinostat results in increased expression of THRB mRNA

PMID:26272509 PMID:27188386

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

transketolase-like 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA

NCBI chr X:151,954,261...151,987,208
Ensembl chr X:151,954,175...151,987,208

G

TLE family member 4, transcriptional corepressor

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA
panobinostat results in decreased expression of TLE4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:211,661,738...211,798,458
Ensembl chr 1:211,661,746...211,797,862

G

transmembrane channel-like 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA
panobinostat results in increased expression of TMC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:172,914,915...172,999,478
Ensembl chr 1:172,914,457...172,999,474

G

transmembrane and coiled-coil domain family 2

increases expression

Panobinostat results in increased expression of TMCC2 mRNA

NCBI chr13:43,794,029...43,831,716
Ensembl chr13:43,794,029...43,831,716

G

transmembrane p24 trafficking protein 5

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA
panobinostat results in increased expression of TMED5 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:1,607,895...1,619,028
Ensembl chr14:1,607,819...1,628,426

G

transmembrane protein 125

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA
panobinostat results in increased expression of TMEM125 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:132,063,162...132,064,566
Ensembl chr 5:132,059,554...132,079,297
Ensembl chr 5:132,059,554...132,079,297

G

transmembrane protein 144

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA
panobinostat results in increased expression of TMEM144 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:164,960,649...164,993,562
Ensembl chr 2:164,961,247...164,992,368

G

transmembrane protein 154

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA
panobinostat results in increased expression of TMEM154 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:170,015,247...170,054,903
Ensembl chr 2:170,015,184...170,052,481

G

transmembrane protein 163

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA
panobinostat results in decreased expression of TMEM163 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:38,967,913...39,141,664
Ensembl chr13:38,968,101...39,141,452

G

transmembrane protein 169

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA
panobinostat results in decreased expression of TMEM169 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:73,926,553...73,950,679
Ensembl chr 9:73,926,568...73,950,576

G

transmembrane protein 170B

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA
panobinostat results in decreased expression of TMEM170B mRNA

PMID:26272509 PMID:27188386

NCBI chr17:23,131,151...23,169,946
Ensembl chr17:23,131,456...23,170,248

G

transmembrane protein 178A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA
panobinostat results in decreased expression of TMEM178A mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:14,004,629...14,063,677
Ensembl chr 6:14,004,630...14,063,549

G

transmembrane protein 18

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA
panobinostat results in decreased expression of TMEM18 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:47,206,845...47,214,294
Ensembl chr 6:47,206,845...47,214,294

G

transmembrane protein 218

decreases expression

panobinostat results in decreased expression of TMEM218 mRNA

NCBI chr 8:36,924,553...36,940,564
Ensembl chr 8:36,924,585...36,939,927

G

transmembrane protein 30B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA
panobinostat results in increased expression of TMEM30B mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:92,251,626...92,254,702
Ensembl chr 6:92,249,790...92,254,842

G

transmembrane protein 64

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA
panobinostat results in increased expression of TMEM64 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:28,698,947...28,745,384
Ensembl chr 5:28,698,918...28,745,330

G

transmembrane protein 74

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA
panobinostat results in decreased expression of TMEM74 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:74,929,290...74,937,929
Ensembl chr 7:74,931,694...74,937,934

G

transmembrane protein 88

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA
panobinostat results in decreased expression of TMEM88 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:54,118,752...54,120,447
Ensembl chr10:54,118,752...54,120,447

G

tropomodulin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA
panobinostat results in increased expression of TMOD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:76,316,736...76,366,003
Ensembl chr 8:76,325,667...76,365,720

G

transmembrane serine protease 11E

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA

NCBI chr14:21,283,587...21,328,203
Ensembl chr14:21,282,823...21,327,184

G

thiol methyltransferase 1A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA

NCBI chr 7:131,452,099...131,460,154
Ensembl chr 7:131,451,641...131,460,154

G

TNF alpha induced protein 3

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 11B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA
panobinostat results in increased expression of TNFRSF11B mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF receptor superfamily member 12A

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA
panobinostat results in increased expression of TNFRSF12A mRNA

PMID:26272509 PMID:27188386

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 19

increases expression

Panobinostat results in increased expression of TNFRSF19 mRNA

NCBI chr15:35,092,206...35,158,472
Ensembl chr15:35,092,206...35,180,795

G

TNF superfamily member 10

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA
panobinostat results in increased expression of TNFSF11 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

TNF superfamily member 9

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA

NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345

G

TRAF2 and NCK interacting kinase

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA
panobinostat results in increased expression of TNIK mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:111,184,352...111,587,993
Ensembl chr 2:111,184,387...111,580,750

G

tenascin N

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA
panobinostat results in increased expression of TNN mRNA

PMID:26272509 PMID:27188386

NCBI chr13:72,319,160...72,386,362
Ensembl chr13:72,319,155...72,408,156

G

trinucleotide repeat containing adaptor 6B

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of TNRC6B mRNA

NCBI chr 7:112,252,351...112,469,829
Ensembl chr 7:112,252,359...112,461,790

G

thymocyte selection-associated high mobility group box

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA
panobinostat results in increased expression of TOX mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:19,874,994...20,171,272
Ensembl chr 5:19,874,467...20,171,272

G

TOX high mobility group box family member 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA
panobinostat results in decreased expression of TOX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:151,853,294...151,980,086
Ensembl chr 3:151,853,294...151,980,749

G

TOX high mobility group box family member 3

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA
panobinostat results in decreased expression of TOX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:16,648,338...16,757,151
Ensembl chr19:16,648,342...16,757,148

G

tumor protein p53

multiple interactions
increases acetylation

[panobinostat co-treated with SRT2183] results in increased acetylation of TP53 protein
panobinostat results in increased acetylation of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p63

increases expression

panobinostat results in increased expression of TP63 protein alternative form

NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398

G

trophoblast glycoprotein

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA

NCBI chr 8:86,793,953...86,797,324
Ensembl chr 8:86,793,749...86,797,741

G

TPD52 like 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA
panobinostat results in increased expression of TPD52L1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109

G

TraB domain containing 2B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA
panobinostat results in increased expression of TRABD2B mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:127,941,198...128,158,946
Ensembl chr 5:127,941,114...128,143,747

G

tripartite motif-containing 14

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA
panobinostat results in increased expression of TRIM14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:60,800,568...60,824,858
Ensembl chr 5:60,800,032...60,824,858

G

tripartite motif containing 38

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA
panobinostat results in increased expression of TRIM38 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:41,351,857...41,365,021

G

tripartite motif containing 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA
panobinostat results in increased expression of TRIM6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:158,683,746...158,696,936
Ensembl chr 1:158,683,746...158,696,914

G

tripartite motif-containing 69

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA
panobinostat results in increased expression of TRIM69 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:109,111,468...109,135,255
Ensembl chr 3:109,111,468...109,132,037

G

tripartite motif-containing 8

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TRIM8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TRIM8 mRNA]

NCBI chr 1:245,369,632...245,384,513
Ensembl chr 1:245,369,632...245,384,513

G

tripartite motif-containing 9

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA
panobinostat results in increased expression of TRIM9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:88,756,824...88,856,588
Ensembl chr 6:88,757,303...88,856,542

G

TMF1-regulated nuclear protein 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA
panobinostat results in increased expression of TRNP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:145,706,427...145,713,279
Ensembl chr 5:145,706,094...145,713,272

G

transient receptor potential cation channel subfamily C member 2

multiple interactions

[Cisplatin co-treated with Panobinostat] affects the expression of TRPC2 mRNA

NCBI chr 1:156,460,009...156,473,039
Ensembl chr 1:156,440,305...156,473,073

G

transient receptor potential cation channel, subfamily C, member 4

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA
panobinostat results in decreased expression of TRPC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:138,307,676...138,476,856
Ensembl chr 2:138,308,084...138,476,768

G

transient receptor potential cation channel, subfamily C, member 6

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA
panobinostat results in increased expression of TRPC6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092

G

transcriptional repressor GATA binding 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA
panobinostat results in increased expression of TRPS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:81,916,668...82,142,733
Ensembl chr 7:81,921,601...82,141,905

G

teashirt zinc finger homeobox 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA

NCBI chr 3:158,405,469...158,666,915
Ensembl chr 3:158,405,423...158,850,128

G

translocator protein

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA
panobinostat results in increased expression of TSPO mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450

G

TSPO associated protein 1

decreases expression
multiple interactions

panobinostat results in decreased expression of TSPOAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:72,554,220...72,586,402
Ensembl chr10:72,560,980...72,586,412

G

tetratricopeptide repeat domain 29

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA
panobinostat results in increased expression of TTC29 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:29,531,707...29,750,635
Ensembl chr19:29,532,663...29,750,615

G

tubulin tyrosine ligase like 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA

NCBI chr10:81,081,985...81,118,009
Ensembl chr10:81,091,975...81,127,234

G

tubulin, alpha 1A

decreases expression

panobinostat results in decreased expression of TUBA1A mRNA

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, beta 2A class IIa

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA
panobinostat results in increased expression of TUBB2A mRNA

PMID:26272509 PMID:27188386

NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714

G

TUB like protein 4

increases expression

Panobinostat results in increased expression of TULP4 mRNA

NCBI chr 1:46,682,416...46,813,167
Ensembl chr 1:46,682,863...46,809,688

G

trans-golgi network vesicle protein 23 homolog A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA

NCBI chr10:5,227,198...5,263,185
Ensembl chr10:5,227,220...5,263,180

G

twist family bHLH transcription factor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA
panobinostat results in increased expression of TWIST1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

UDP glucuronosyltransferase 2 family, polypeptide B34 like 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA

NCBI chr14:21,146,140...21,167,706
Ensembl chr14:21,145,827...21,167,704

G

UDP glycosyltransferase family 3 member A1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA

NCBI chr 2:58,327,058...58,350,186
Ensembl chr 2:58,334,603...58,350,186

G

UDP glycosyltransferase 8

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA
panobinostat results in increased expression of UGT8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:214,264,483...214,332,769
Ensembl chr 2:214,264,483...214,332,660

G

unc-5 netrin receptor A

decreases expression
multiple interactions

panobinostat results in decreased expression of UNC5A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA

PMID:26272509 PMID:27188386

NCBI chr17:9,614,841...9,670,558
Ensembl chr17:9,614,838...9,670,526

G

unc-5 netrin receptor C

multiple interactions
increases expression
affects expression

(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of UNC5C mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of UNC5C mRNA]
panobinostat results in increased expression of UNC5C mRNA
panobinostat affects the expression of UNC5C mRNA

PMID:26272509 PMID:26733615 PMID:27188386

NCBI chr 2:230,180,353...230,535,219
Ensembl chr 2:230,180,951...230,535,217

G

ubiquinol-cytochrome c reductase complex assembly factor 2

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA
panobinostat results in decreased expression of UQCC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:5,202,837...5,214,541
Ensembl chr20:5,202,837...5,214,164

G

ubiquitin specific peptidase 28

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA
panobinostat results in increased expression of USP28 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:49,325,766...49,386,229
Ensembl chr 8:49,325,867...49,386,229

G

ubiquitin specific peptidase 43

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA

NCBI chr10:52,549,200...52,611,168
Ensembl chr10:52,548,963...52,611,533

G

ubiquitin specific peptidase 49

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA
panobinostat results in decreased expression of USP49 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:13,305,640...13,366,132
Ensembl chr 9:13,308,178...13,366,132

G

uronyl-2-sulfotransferase

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of UST mRNA

NCBI chr 1:2,666,983...2,962,276
Ensembl chr 1:2,669,592...2,962,044

G

undifferentiated embryonic cell transcription factor 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA
panobinostat results in increased expression of UTF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:194,740,339...194,741,465
Ensembl chr 1:194,740,339...194,741,465

G

vesicle-associated membrane protein 7

increases expression
multiple interactions

panobinostat results in increased expression of VAMP7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:16,728,486...16,764,261
Ensembl chr12:16,728,524...16,764,097

G

vesicle-associated membrane protein 8

increases expression
multiple interactions

panobinostat results in increased expression of VAMP8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:104,442,383...104,452,884
Ensembl chr 4:104,442,393...104,452,897

G

VAMP associated protein A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA
panobinostat results in decreased expression of VAPA mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:105,177,904...105,208,400
Ensembl chr 9:105,177,907...105,207,847

G

vasohibin 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA
panobinostat results in increased expression of VASH2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:102,529,718...102,561,204
Ensembl chr13:102,529,719...102,560,391

G

VENT homeobox

increases expression
multiple interactions

Panobinostat results in increased expression of VENTX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA

PMID:26272509 PMID:27188386

NCBI chr X:86,483,893...86,484,900
Ensembl chr X:86,483,893...86,484,954

G

ventricular zone expressed PH domain-containing 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA
panobinostat results in increased expression of VEPH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:150,291,379...150,537,491
Ensembl chr 2:150,296,573...150,537,266

G

vestigial-like family member 1

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA
panobinostat results in increased expression of VGLL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:134,979,657...134,996,007

G

vestigial-like family member 3

increases expression
multiple interactions

panobinostat results in increased expression of VGLL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:3,642,993...3,692,590
Ensembl chr11:3,643,069...3,689,140

G

WD repeat domain 72

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA
panobinostat results in increased expression of WDR72 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:74,838,338...75,020,938
Ensembl chr 8:74,838,318...75,018,229

G

WAP four-disulfide core domain 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA
panobinostat results in increased expression of WFDC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:153,286,946...153,314,832
Ensembl chr 3:153,286,131...153,292,807

G

Wnt ligand secretion mediator

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA

NCBI chr 2:248,931,885...249,047,248
Ensembl chr 2:248,931,903...249,048,298

G

Wnt family member 10B

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA
panobinostat results in increased expression of WNT10B mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892

G

Wnt family member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA
Panobinostat results in increased expression of WNT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099

G

Wnt family member 4

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA
panobinostat results in increased expression of WNT4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859

G

Wnt family member 5A

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA
panobinostat results in decreased expression of WNT5A mRNA

PMID:26272509 PMID:27188386

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

Wnt family member 5B

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA
panobinostat results in decreased expression of WNT5B mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:152,609,566...152,733,790
Ensembl chr 4:152,609,569...152,733,407

G

Wnt family member 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA

NCBI chr 9:76,329,882...76,343,523
Ensembl chr 9:76,329,882...76,343,523

G

Wnt family member 8A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA

NCBI chr18:26,137,690...26,143,283
Ensembl chr18:26,137,690...26,143,283

G

WW and C2 domain containing 1

increases expression
multiple interactions

panobinostat results in increased expression of WWC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:20,300,735...20,454,393
Ensembl chr10:20,300,833...20,454,497

G

X-C motif chemokine ligand 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of XCL1 mRNA

NCBI chr13:77,248,687...77,252,343
Ensembl chr13:77,248,717...77,252,329

G

XK related 4

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA

NCBI chr 5:15,896,818...16,297,733
Ensembl chr 5:15,895,863...16,282,962

G

XK related, X-linked

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA

NCBI chr X:97,341,158...97,353,175
Ensembl chr X:97,341,152...97,354,759

G

Yes1 associated transcriptional regulator

increases expression
multiple interactions

panobinostat results in increased expression of YAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

G

yippee-like 1

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA

NCBI chr11:83,921,799...83,936,409

G

zinc finger and BTB domain containing 1

decreases expression

Panobinostat results in decreased expression of ZBTB1 mRNA

NCBI chr 6:95,096,838...95,125,811
Ensembl chr 6:95,096,387...95,118,996

G

zinc finger and BTB domain containing 16

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA
panobinostat results in decreased expression of ZBTB16 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011

G

zinc finger CCCH type containing 12C

decreases expression
multiple interactions

panobinostat results in decreased expression of ZC3H12C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:52,443,791...52,508,643
Ensembl chr 8:52,448,320...52,504,315

G

zinc finger CCCH type containing 6

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA

NCBI chr 3:116,203,466...116,254,186
Ensembl chr 3:116,204,197...116,253,282

G

zinc finger E-box binding homeobox 1

decreases expression
multiple interactions

panobinostat results in decreased expression of ZEB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

G

ZFP14 zinc finger protein

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA
panobinostat results in decreased expression of ZFP14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:85,268,649...85,286,125
Ensembl chr 1:85,268,643...85,285,759

G

zinc finger protein 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA

NCBI chr10:35,209,187...35,228,849
Ensembl chr10:35,207,260...35,228,853

G

zinc finger protein 280C

increases expression

Panobinostat results in increased expression of ZNF280C mRNA

NCBI chr X:127,716,403...127,807,600
Ensembl chr X:127,717,983...127,779,825

G

zinc finger protein 287

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA

NCBI chr10:47,395,650...47,415,610
Ensembl chr10:47,397,285...47,439,755

G

zinc finger protein 36, C3H type-like 2

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA
panobinostat results in increased expression of ZFP36L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064

G

zinc finger protein 385B

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA
panobinostat results in decreased expression of ZNF385B mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:62,355,182...62,640,417
Ensembl chr 3:62,355,196...62,640,510

G

zinc finger protein 385D

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA
panobinostat results in decreased expression of ZNF385D mRNA

PMID:26272509 PMID:27188386

NCBI chr15:5,040,182...5,849,975
Ensembl chr15:5,042,572...5,423,367

G

zinc finger protein 386 (Kruppel-like)

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA
panobinostat results in decreased expression of ZNF519 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:136,966,547...136,984,013
Ensembl chr 6:136,966,586...136,983,441

G

zinc finger protein 42

increases expression
multiple interactions

panobinostat results in increased expression of ZFP42 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:48,836,463...48,845,443
Ensembl chr16:48,836,648...48,845,401

G

zinc finger protein 46

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA
panobinostat results in decreased expression of ZNF436 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:148,519,398...148,529,903
Ensembl chr 5:148,520,855...148,529,459

G

zinc finger protein 462

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF462 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF462 mRNA]

NCBI chr 5:69,670,085...69,810,729
Ensembl chr 5:69,670,328...69,810,327

G

zinc finger protein 483

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA
panobinostat results in decreased expression of ZNF483 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:73,763,201...73,780,511
Ensembl chr 5:73,763,179...73,776,223

G

zinc finger protein 503

multiple interactions
decreases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA
panobinostat results in decreased expression of ZNF503 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:2,313,060...2,316,848
Ensembl chr15:2,313,060...2,316,848

G

zinc finger protein 521

decreases expression
multiple interactions

panobinostat results in decreased expression of ZNF521 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:4,775,952...5,068,592
Ensembl chr18:4,787,295...5,068,458

G

zinc finger protein 804A

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA

NCBI chr 3:67,033,481...67,267,769
Ensembl chr 3:67,034,170...67,263,607

G

zinc finger protein 827

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF827 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF827 mRNA]

NCBI chr19:28,720,568...28,887,381
Ensembl chr19:28,721,021...28,887,191

G

Zic family member 1

multiple interactions

[Cisplatin co-treated with panobinostat] affects the expression of ZIC1 mRNA

NCBI chr 8:91,908,548...91,918,020
Ensembl chr 8:91,908,576...91,912,731

G

Zic family member 3

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA
panobinostat results in increased expression of ZIC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:136,123,662...136,129,627
Ensembl chr X:136,124,026...136,134,746

G

zinc finger MYM-type containing 2

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA

NCBI chr15:31,035,835...31,108,945
Ensembl chr15:31,035,838...31,109,357

G

zinc finger, MYND-type containing 8

multiple interactions
affects expression

(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZMYND8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZMYND8 mRNA]

NCBI chr 3:154,528,917...154,629,532
Ensembl chr 3:154,529,043...154,628,463

G

zinc finger protein 750

multiple interactions
increases expression

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA
panobinostat results in increased expression of ZNF750 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:106,772,162...106,781,186
Ensembl chr10:106,772,669...106,781,200

G

zinc finger RANBP2-type containing 3

multiple interactions

[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA

NCBI chr13:39,440,653...39,595,782
Ensembl chr13:39,440,889...39,595,670

G

zyg-11 family member A, cell cycle regulator

increases expression
multiple interactions

panobinostat results in increased expression of ZYG11A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:122,935,439...122,973,766
Ensembl chr 5:122,937,136...122,973,649

pazopanib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

pazopanib results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101 PMID:28437613

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

decreases activity

pazopanib results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

aldo-keto reductase family 1 member B10

multiple interactions

pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

androgen receptor

multiple interactions

pazopanib binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

pazopanib results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

pazopanib results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

pazopanib results in increased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases expression

pazopanib results in increased expression of CYP2C8 mRNA

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

pazopanib results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

interleukin 1 beta

increases secretion

pazopanib results in increased secretion of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions

pazopanib results in decreased phosphorylation of MAPK1 protein
mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions

pazopanib results in decreased phosphorylation of MAPK3 protein
mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nuclear receptor coactivator 1

multiple interactions

pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]

NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pazopanib inhibits the reaction [T0901317 results in increased activity of NR1I2 protein]

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

progesterone receptor

multiple interactions

pazopanib binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

proteinase 3

increases expression

pazopanib results in increased expression of PRTN3 protein

NCBI chr 7:9,822,123...9,831,300
Ensembl chr 7:9,822,122...9,831,944

G

thyroid hormone receptor alpha

multiple interactions

pazopanib binds to and results in decreased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions

pazopanib binds to and results in decreased activity of THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

semaxanib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 2

increases expression

semaxanib (SUGEN) increases expression of IL2 mRNA in rat whole lung

RGD

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

kinase insert domain receptor

su5416, semaxanib, decreases phosphorylation of kdr (vegfr2) protein in rat lung

RGD

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

replication factor C subunit 1

multiple interactions

[Sugen-5416 co-treated with hypoxia] increases expression of Rfc1 protein in the heart right ventricle

RGD

NCBI chr14:42,966,279...43,041,372
Ensembl chr14:42,966,324...43,041,370

trabectedin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression

[ABCB1A protein mutant form co-treated with ABCB1B protein mutant form] results in increased susceptibility to trabectedin
trabectedin results in increased expression of ABCB1A mRNA

PMID:12154027 PMID:19238326

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

multiple interactions
increases expression

[ABCB1A protein mutant form co-treated with ABCB1B protein mutant form] results in increased susceptibility to trabectedin
trabectedin results in increased expression of ABCB1B mRNA

PMID:12154027 PMID:19238326

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

aconitase 1

increases expression

Trabectedin results in increased expression of ACO1 mRNA; Trabectedin results in increased expression of ACO1 protein

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

carbonic anhydrase 3

decreases expression

trabectedin results in decreased expression of CAR3 mRNA

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

cyclin A2

decreases expression

trabectedin results in decreased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

trabectedin results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

decreases expression

trabectedin results in decreased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin D1

increases expression

trabectedin results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

increases expression

trabectedin results in increased expression of CCNE1 mRNA

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin-dependent kinase 1

increases expression

trabectedin results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases expression

trabectedin results in decreased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity

trabectedin results in decreased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

trabectedin results in decreased activity of CYP3A2 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions

Trabectedin inhibits the reaction [2-Acetylaminofluorene results in increased expression of CYP3A23-3A1 mRNA]

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases expression

trabectedin results in decreased expression of CYP3A13 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

dihydrofolate reductase

decreases expression

trabectedin results in decreased expression of DHFR mRNA

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

E2F transcription factor 1

increases expression

trabectedin results in increased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

glutathione peroxidase 4

decreases expression

Trabectedin results in decreased expression of GPX4 mRNA; Trabectedin results in decreased expression of GPX4 protein

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

hypoxia inducible factor 1 subunit alpha

increases expression

Trabectedin results in increased expression of HIF1A mRNA; Trabectedin results in increased expression of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

Kelch-like ECH-associated protein 1

increases expression

Trabectedin results in increased expression of KEAP1 protein

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

marker of proliferation Ki-67

increases expression

trabectedin results in increased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mechanistic target of rapamycin kinase

multiple interactions
decreases response to substance

everolimus inhibits the reaction [MTOR results in decreased susceptibility to trabectedin]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFE2 like bZIP transcription factor 2

decreases expression

Trabectedin results in decreased expression of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear transcription factor Y subunit alpha

multiple interactions

trabectedin affects the activity of [NFYA protein binds to NFYB protein binds to NFYC protein]

NCBI chr 9:12,587,437...12,613,911
Ensembl chr 9:12,586,259...12,613,898

G

nuclear transcription factor Y subunit beta

multiple interactions

trabectedin affects the activity of [NFYA protein binds to NFYB protein binds to NFYC protein]

NCBI chr 7:20,964,988...20,980,569
Ensembl chr 7:20,964,993...20,980,565

G

nuclear transcription factor Y subunit gamma

multiple interactions

trabectedin affects the activity of [NFYA protein binds to NFYB protein binds to NFYC protein]

NCBI chr 5:134,336,802...134,405,372
Ensembl chr 5:134,336,808...134,405,377

G

transferrin receptor

increases expression

Trabectedin results in increased expression of TFRC mRNA; Trabectedin results in increased expression of TFRC protein

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

thymidine kinase 1

decreases expression

trabectedin results in decreased expression of TK1 mRNA

NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19808
role	19784
application	19627
pharmaceutical	19468
drug	19468
angiogenesis modulating agent	1788
(20S)-ginsenoside Rg3 +	103
15-hydroxy-tetracosa-6,9,12,16,18-pentaenoic acid	0
2-methoxy-17beta-estradiol +	55
2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxy-19-norvitamin D3	0
4-senecioyloxymethyl-6,7-dimethoxycoumarin	0
CIGB-300	0
Glu-Trp	0
SC560	0
asiatic acid +	23
carnosic acid	247
cortistatins +	0
cremastranone +	0
hydrazinocurcumin	0
morin	109
oltipraz	73
panobinostat	1295
panobinostat lactate	0
pazopanib	18
pazopanib hydrochloride	0
pro-angiogenic agent +	149
proanthocyanidin A2	0
semaxanib	3
trabectedin	28

paths to the root